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Abstract 
Development of novel biodegradable polymers from renewable 
resources has attracted attention due to the limitations 
associated with polymers obtained from petroleum resources. 
The objective of the work presented in this thesis was to 
develop various novel biodegradable amphiphilic block 
copolymers from commercially available sustainable 
feedstocks for drug delivery applications. Synthesis was 
performed using a reported method under mild reaction 
conditions.  
Renewable į-decalactone was chosen as a key monomer to 
synthesise novel amphiphilic block copolymers via ROP using 
PEG as initiator. A diblock (i.e. mPEG-b-PDL) and a triblock 
(i.e. PDL-b-PEG-b-PDL) copolymer of poly(decalactone) (PDL) 
was synthesised and purified successfully. Additionally, a 
novel triblock copolymer (i.e. mPEG-b-PDL-b-PPDL) was 
synthesised using ǔ-pentadecalactone as monomer and 
mPEG-b-PDL as initiator via ROP to generate a copolymer with 
different physical properties. Further, a di-block copolymer of 
İ-caprolactone (i.e. mPEG-b-PCL) was synthesised for 
comparative studies with novel block copolymers. Micelles of 
synthesised block copolymers were fabricated using a reported 
nanoprecipitation method. Micelles fabricated from these novel 
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block copolymers were of sizes <200nm and possessed low 
critical micelle concentration (CMC) values.  
Curcumin and Amphotericin B were successfully encapsulated 
in the novel block copolymer micelles via nanoprecipitation 
method. The results obtained from curcumin loading and 
release studies suggested that these novel PDL block 
copolymers could perform in similar fashion when compared 
with poly(caprolactone) (PCL) block copolymer micelles. 
However, in subsequent study micelle of mPEG-b-PDL gave 
high loading content compared to mPEG-b-PCL micelles when 
amphotericin B was used as a drug. Further, a preliminary in 
vitro degradation study of mPEG-b-PDL micelles was 
performed and the results proposed that the ester linkage of 
PDL chain were susceptible to hydrolytic degradation in 
physiological condition. Additionally, in vitro cytotoxicity 
studies performed on HCT-116 human colon cancer cells 
revealed that the novel mPEG-b-PDL micelles have similar 
toxicity profiles when compared to the well-established mPEG-
b-PCL micelles.  
Ligand mediated targeting efficiency of novel diblock 
copolymer micelles was also studied for potential future 
applications in cancer therapy. Amphiphilic block copolymers 
using PEG and PDL were synthesised via click chemistry to 
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generate functionalised block copolymers. Folic acid and 
rhodamine B were used as targeting ligand and tracker dye 
respectively. Mixed micelles fabricated from functionalised 
block copolymers (i.e. FA-PEG-b-PDL, RhB-PEG-b-PDL and 
mPEG-b-PDL) were tested on folate receptor positive (MCF-7 
FR+ve) and folate receptor negative (A549 FR-ve) human 
cancer cell lines for receptor mediated endocytosis. The 
acquired confocal images demonstrated the nonspecific uptake 
of the PEG-b-PDL micelles formulations (targeted and non-
targeted) in both cell lines selected in current study. 
The results obtained from this thesis study suggested that the 
synthesised novel PDL block copolymer micelles have potential 
to act as a novel drug delivery system. However, further 
studies have been proposed to explore the possible 
applications of these renewable block copolymers. 
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1.1 Introduction to Biodegradable Polymers in 
Drug Delivery 
Development of novel formulations is paramount to improve 
the bioavailability of active pharmaceutical ingredients (API). 
Improved bioavailability of an API may eventually lead to an 
increase in the pharmacological response, lower the dose size 
and therefore minimise the side effects of API. Bioavailability 
of a drug can be increased by enhancing its aqueous solubility, 
stabilising the drug in vivo, providing controlled release of 
drug over prolonged time and by the change of route of 
administration1, 2. With the aid of polymeric carriers, one or all 
of the above factors can be altered to improve bioavailability. 
Therefore, polymers play a vital role in the development of 
several novel drug-delivery systems. Specifically, 
biodegradable polymers have attracted special attention in 
drug delivery because they do not accumulate in the body3, 4. 
Biodegradable polymers are the materials, which can be 
broken down and excreted from the human body after they 
have served their function. These materials are typically 
excreted from the body by renal clearance after degradation 
into small molecules4, 5. Polymer degradation can take place 
mainly through the chain scission, which is stimulated by 
oxidation, thermal activation, radiolysis, photolysis, hydrolysis 
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and enzymes. However, degradation by hydrolysis and/or 
enzymes is of utmost importance because these mechanisms 
mostly involve degradation of polymers in the human body3-5.  
1.2 Classification of Biodegradable Polymers 
Biodegradable polymers have been divided into two classes 
based on the source of origin i.e. Natural and Synthetic. 
Naturally occurring polymers generally undergo enzymatic 
degradation whereas synthetic polymers can be degraded 
hydrolytically as well as enzymatically5. Enzymatically 
degradable polymers can be further defined as materials, 
which possess hydrolytically cleavable bonds but require 
catalyst to undergo significant degradation under physiological 
conditions. Normally the degradation rate of enzymatically 
degradable polymers is much lower due to the presence of 
either ether or amide bonds4, 5. 
1.2.1 Biodegradable Polymers from Natural Origin 
Polymers obtained from natural origin are available in ample 
quantity and fulfil most of the properties generally required for 
a biomaterial, to be used clinically. Natural polymers possess 
numerous inherent benefits such as natural remodeling, 
bioactivity, susceptibility to cell-triggered proteolytic 
degradation and the ability to present receptor-binding ligands 
to cells4. Several naturally occurring polymers have been 
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reported for drug delivery and tissue engineering applications. 
For instance, micro/nano-particles prepared from chitosan6, a 
modified natural carbohydrate polymer has been successfully 
used for the delivery of Insulin7, Cyclosporine A8, Doxorubicin9 
etc. Similarly, collagen and its derivatives have been widely 
used to produce the scaffolds for bone tissue engineering10.  
Since, natural polymers mimic the extracellular matrix (ECM), 
they have therefore been extensively utilised for tissue 
engineering applications11, 12. Several other polymers obtained 
from natural resources have been reported for various 
biomedical applications and were reviewed recently1, 4, 13-15.  
Despite their several advantages as biomaterial for drug 
and/or macromolecules delivery and tissue engineering, some 
restrictions are associated with the natural polymers. For 
instance, the rate of in vivo degradation of such polymers 
varies considerably with the site of implantation. Additionally, 
chemical modification can also affect their degradation rate4. 
Furthermore, the undesirable immunological response, 
difficulty in purification and processing, risk of transmitting 
pathogens (origin related) and batch-to-batch variability limits 
their applications4, 11, 16.   
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1.2.2 Biodegradable Polymers from Synthetic Origin 
Synthetic biodegradable polymers used for biomedical 
applications are able to offer certain advantages over naturally 
occurring polymers17, 18. These polymers provide the 
opportunity to synthesise tailor made material with desired 
properties. Furthermore, with synthetic polymers, it is possible 
to obtain material reproducibly with better quality control. 
Polymers with a desired property can be prepared by blending 
or copolymerising two or more different polymers4, 18, 19. In 
view of the above advantages, it can be concluded that 
synthetic polymers can possibly overcome the various 
disadvantages associated with natural polymers. 
Synthetic biodegradable polymer generally contain a 
hydrolytically cleavable bond such as esters, thioesters, 
amides, carbonates, ureas, urethanes, imides, anhydrides, 
acetals, phosphonates etc. (figure 1-1). However, poly(esters) 
are the earliest and most studied class of biodegradable 
polymers due to their easy method of synthesis from 
commercially available monomers5, 20. Therefore, in the 
current study, the literature review is limited to poly(ester) 
polymers. 
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Figure 1-1 Schematic representation of hydrolytic degradable functional 
groups with their degraded products. 
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The two general routes used to synthesise poly (esters) 
polymers are step growth polymerisation (i.e. 
polycondensation) and chain growth polymerisation, which 
includes ring opening polymerisation (figure 1-2).  
 Polycondensation Reaction 
Homo-polymerisation of a single monomer having two 
different end groups (for example: lactic acid) or 
copolymerisation of two monomers (for example: succinic acid 
and 1,4 butanediol) yield a polymer via polycondensation 
reaction. When two functional groups (acid and alcohol) join 
together during polyester synthesis, a small molecule 
(condensate) most often water is generally liberated as a by-
product 21.  
 
Figure 1-2 Graphical representation of polycondensation and ring opening 
polymerisation reaction 
 
 
 
Monomer 
Initiator 
Monomer 2 
Monomer 1 
Homopolymer Copolymer Polymer 
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Mechanism involved in Polycondensation Reaction: 
Fischer Esterification 
In Fischer esterification a carboxylic acid reacts with alcohol in 
the presence of Lewis or Bronsted acid to give esters by 
releasing a molecule of water22. The products and reactants 
are in equilibrium in this reaction (scheme 1-1). So, to drive 
equilibrium for the effective conversion of monomers to 
polymer, water is often removed continuously from the 
reaction medium. 
 
Scheme 1-1 Mechanism of acid catalysed Fischer esterification reaction.23 
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Trans-esterification Reaction  
It is a route where an ester is converted into another ester by 
reacting with an alcohol in the presence of acid/base 
catalyst24. To drive the equilibrium (to get the efficient 
conversion), either excess of reacting alcohol was used or the 
by-product (alcohol) was removed continuously from the 
reaction mixture (scheme 1-2).  
 
Scheme 1-2 Mechanism of acid catalysed trans-esterification reaction.24 
These reactions are reversible and therefore high conversion 
cannot be achieved without the removal of condensate 
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molecule. Additionally, in Fischer esterification reactions, high 
temperature is often required to generate the polyesters in 
acceptable yield. Therefore, a mild approach was developed in 
1978 by Wolfgang Steglich to synthesise esters25. Dicyclohexyl 
carbodiimide was used as a coupling reagent and 4-dimethyl 
aminopyridine acted as a catalyst. Dicyclohexylurea (DHU) is 
the by-product during the reaction, which can be removed 
easily by filtration (scheme 1-3). 
 
Scheme 1-3 Mechanism of Steglich esterification reaction25 
Ring Opening Polymerisation 
Ring opening polymerisation (ROP) is a widely investigated 
synthetic route to develop poly(esters). In this method, cyclic 
esters were used to synthesise long chain polyesters (figure 1-
1). The target molecular weight can be predefined, based on 
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the quantity of monomer used. ROP is advantageous over 
polycondensation route to synthesise polyesters in terms of 
reaction condition and time, absence of by-product and control 
over the molecular weight. ROP is a form of chain-growth 
polymerisation, where the terminal ends of the chain have a 
reactive functional group, which repeatedly reacts with cyclic 
monomer, opening the next available ring until all monomers 
are consumed. However, an initiator is always required to 
open the first ring of cyclic monomer26, 27. The three general 
mechanisms involved in ROP are cationic, anionic, and 
coordination-insertion. However, it has been reported that the 
high molecular weight polyesters can only be obtained by 
either anionic or coordination-insertion mechanism26. 
Anionic Mechanism of ROP 
In an anionic ROP, the reaction is started by the nucleophilic 
attack of negatively charged initiator on the carbonyl carbon 
or on the carbon atom present beside the acyl oxygen of the 
lactone ring, yielding polyester (scheme 1-4). The commonly 
used initiators for an anionic ROP are alkali metals, alkali 
metal oxides etc. The propagating species in this mechanism 
is negatively charged which can attack the next available 
ring26. In 4-membered rings such as ǃ-EXW\URODFWRQH ǃ-
propiolactone, either alkyl or acyl-oxygen cleavage has been 
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reported giving a carboxylate or alkoxide respectively28. 
However, in bigger size ring such as lactide, only acyl-oxygen 
scission has been involved giving an alkoxide as the 
propagating species26.  
 
Scheme 1-4 Anionic mechanism for ROP of lactone (I) acyl-oxygen scission 
(II) alkyl-oxygen scission26 
Coordination-Insertion Mechanism of ROP 
The coordination-insertion mechanism for ROP of lactones is 
shown in scheme 1-5.  
 
Scheme 1-5 Coordination-insertion mechanism for ROP of lactones26 
The initiators which open the lactone ring via this mechanism 
are aluminium and tin alkoxides and carboxylates26. These 
LQLWLDWRUV ZLWK YDFDQW ³G´ RUELWDOV UHDFW DV FRRUGLQDWLRQ
initiators and not as anionic initiators. Cleavage of the acyl 
oxygen bond leads to ring opening of the lactone. The 
propagation continues by coordination of the monomer to the 
active species and then insertion of the monomer into the 
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metal-oxygen bond. The coordination of metal with the 
exocyclic oxygen makes the carbonyl carbon more susceptible 
for nucleophilic attack (scheme 1-5). However, in this 
mechanism long reaction time or high temperature leads to 
both inter and intramolecular transesterification reactions26.  
Cationic Mechanism of ROP 
In this mechanism, a positively charged species of monomer is 
generated after reacting with a cationic catalyst. The 
subsequent attack by another monomer leads to ring opening 
via SN2 reaction (scheme 1-6)
27, 29, 30. 
 
Scheme 1-6 Cationic mechanism for ROP of lactones30 
1.3 Classification of Synthetic Poly(esters):  
Synthetic biodegradable poly(esters) can be further classified 
into two classes: 
1.3.1 Poly(esters) Synthesised from Non-Renewable 
Monomers 
Non-renewable monomers are those monomers whose supply 
is limited. These monomers are procured directly from fossil 
fuels, which exist within the earth. Fossil fuels are extracted 
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from organic matter; which are the remains of once living 
material. As generation of organic matters takes millions of 
years, the available fossil fuels are going to be finished in the 
near future31. Several polymers, synthesised from monomers 
derived from fossil fuels are currently in use for biomedical 
applications3, 32. However, the objective of the current study is 
to make biodegradable poly(esters) from renewable 
monomers and hence this section has not been exhaustively 
reviewed.  Some brief examples of such polymers with 
cleavable bonds (esters) are given below: 
Poly(caprolactone):  
 
Poly(caprolactone) (PCL) synthesised by ROP of İ-
caprolactone, is one of the most extensively studied 
biodegradable polymers. The key precursor used for the 
preparation of caprolactone is cyclohexanone whose starting 
material is benzene. The use of PCL in the drug delivery and 
tissue engineering applications has been reported by several 
researchers and reviewed recently (figure 1-3)3, 13, 33, 34. The 
complete hydrolytic degradation of PCL generally takes 2±3 
years33. 
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Figure 1-3 Structures made from PCL: Nanospheres (a,b). Nanofibres 
(c,d). Foams (e,f). Knitted textiles (g,h,i). Selective laser sintered scaffold 
(j-o). Fused deposition modeled scaffolds (p±u)33. 
³&apronor´ is the regulatory approved formulation of PCL used 
for the sustained subdermal delivery of contraceptive steroids 
(levonorgestrel)33, 35.  
Poly(p-dioxanone):  
 
Poly(p-dioxanone) (PPDO) has been synthesised by ring 
opening polymerisation of p-dioxanone (PDO). PDO was 
prepared by oxidative dehydrogenation of diethylene glycol 
over Cu(O) catalyst supported on silica particles36. Diethylene 
glycol is generally produced by the hydrolysis of ethylene 
oxide, an oxidised ethylene (hydrocarbon). PPDO has been 
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used for the preparation of sutures (FDA approved)37, in tissue 
engineering36 and its copolymers have also been studied for 
drug delivery applications38.   
Poly(anhydrides):  
 
For a long time, poly (anhydrides) have been used for the 
controlled release drug delivery applications39. For instance, 
microspheres of poly(adipic anhydride), synthesised by ROP of 
oxepan-2,7-dione has been used for ocular drug (Timolol 
maleate) delivery in controlled fashion40. The key monomer for 
the synthesis of oxepan-2,7-dione is adipic acid, which is 
prepared using cyclohexane (hydrocarbon), as starting 
material41.  
Poly(trimethylene carbonate) 
 
Poly (trimethylene carbonate) (PTMC) has been used in 
biomedical field because it degrades into biocompatible 1,3-
propanediol and carbonic acid42. PTMC is generally synthesised 
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by the ROP of trimethylene carbonate (TMC) which is 
commercially available. TMC is usually prepared from 1,3-
propanediol and ethyl chloroformate or from oxetane and 
carbon dioxide43. Nanoparticles44, microparticles45 and gels46 
have been prepared from PTMC but more often it has been 
copolymerised with PLA47 or PCL48 to improve its drug delivery 
potential. 
1.3.2 Poly(esters) Synthesised from Renewable 
Monomers 
Renewable resources can be GHILQHG DV ³DQ\ DQLPDO RU
vegetable species which is exploited without endangering its 
survival and which is renewed by biological (short term) 
instead of geochemical (very long term) activities´49. They are 
the most attractive feedstock to synthesise polymers of 
choice. Based on the concept ³DFWLQJUHVSRQVLEO\WRPHHWWKH
needs of the present without compromising the ability of 
future generations to meet their own needs´50, several 
renewable feedstocks have been discovered, which are 
obtained from either plant or animal source.  A biodegradable 
polymer obtained solely from renewable resources can be 
described as a ³green´ polymeric material51. A polymer 
synthesised using monomers obtained from natural resources 
might be a good alternative for natural and synthetic polymers 
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(non-renewables). Some examples of biodegradable polymers 
having ester bonds, synthesised from the natural monomers 
are described below: 
In the first section, renewable poly(esters) synthesised by 
polycondensation reaction have been reviewed, while in the 
second section, polyesters synthesised by ROP have been 
reported. 
(I) Renewable Poly (esters) via Polycondensation 
Reaction 
Ricinoleic acid (RA) (12-hydroxy-9-cis-octadecenoic acid) 
obtained from castor oil is the most important fatty acid based 
monomer, due to its bifunctionality50. RA is a C18 fatty acid 
containing a hydroxyl group in the chain.  RA can be used to 
V\QWKHVLVH Ǆ-Decalactone and İ-decalactone52. Undecenoic 
acid produced from ricinoleic acid was utilised to synthesise 
1,20-eicosanedioic acid and eicosane- 1,20-diol. 
Polycondensation reactions between the diacid and the diol, 
produced a high molecular weight polymer named ³polyester 
20,20´ (Tm-108°C)(scheme 1-7)53.  
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Scheme 1-7 Synthesis scheme of the 20,20-polyester by 
polycondensation53 
Ricinoleic acid has been also incorporated in different ratios 
into anhydride end-capped poly(sebacic acid) by 
transesterification reactions. Release of cisplatin from these 
degradable polymers was studied, which suggested that 
increases in the RA content decreased the release rate54. 
Similarly, RA has been copolymerised with lactic acid to 
decrease the degradation rate of resultant polymer and to 
slow down the release of incorporated drugs55. 
In another study, methyl 10-undecenoate, a castor oil derived 
product, was functionalised by thiol-ene chemistry to prepare 
renewable monomers (scheme 1-8). Aliphatic polyesters have 
been synthesized from the prepared monomer in the form of 
hyperbranched, dendritic, and linear chains56.  
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Scheme 1-8 Synthesis scheme of functional monomers by thiol-ene 
chemistry using renewable methyl 10-undecenoate56 
18-Hydroxy-9,10- epoxyoctadecanoic acid, 15-hydroxy-
hexadecanoic, 9(10),16-dihydroxyhexadecanoic acid are other 
examples of fatty acid-based monomers used in the 
preparation of polyesters50, 57, 58. 
Some other examples of renewable monomers used to 
generate polyesters are succinic acid, fumaric acid, citric acid, 
sebacic acid, suberic acid, itaconic acid and 2,5-
furandicarboxylic acid. Bio-based alcohols used for polyester 
synthesis include 1,3-propanediol, 1,4-butanediol, isosorbide 
and glycerol50.  
For instance, Goerz et. al. reported the synthesis of a series of 
polyesters using isosorbide, itaconic acid and succinic acid 
under microwave irradiation. The polyesters demonstrated 
glass transition temperature (Tg) values between 57°C to 
65°C and possessed one-way shape memory effect59. In 
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another work, synthesis of poly(propylene sebacate) has been 
reported using 1,3-propanediol, sebacic acid, and itaconic 
acid. Biodegradable poly(propylene sebacate) (PPS) was found 
to be non-toxic when tested on NIH3T3 cell lines. Additionally, 
it was also demonstrated that the shape memory behaviour of 
PPS was tunable by introducing diethylene glycol60. Co-
polymers of sebacic acid or fumaric acid with poly(ethylene 
glycol) (PEG) have also been prepared for the controlled drug 
delivery applications61. 
Poly(butylene succinate) (PBSu) synthesised by 
polycondensation reaction between succinic acid and 1,4-
butanediol is a commercially available polymer. However, 
PBSu has been less explored for drug delivery applications 
because of the poor degradability and functionality3, 62, 63. To 
address these problems, copolymers of PBSu are most often 
prepared to obtain the polymer with suitable properties. For 
instance, novel aliphatic poly(butylene succinate-co-cyclic 
carbonate) bearing various functionalisable carbonate building 
blocks have been reported63. In an another study, a 
copolymer of PBSu with ǔ-pentadecalactone i.e. poly(ǔ-
pentadecalactone-co-butylene -co-succinate) (PPDL-co-PBSu) 
has been synthesised in two steps for the effective delivery of 
Camptothecin (CPT). The PPDL-co-PBSu nanoparticles loaded 
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with CPT demonstrated high cellular uptake compared to free 
CPT against Lewis lung carcinoma cell lines in vitro (figure 1-
4)64.  
 
Figure 1-4 (1) Two-stage synthesis method for copolymerization of ǔ-
pentadecalactone, diethyl succinate, and 1,4-butanediol. (2) Confocal 
microscopic images of Lewis lung carcinoma cells after 2 h incubation with 
(A) free CPT and (B) CPT-loaded PPDL-co-PBSu nanoparticles. Cells and 
CPT are visualized in the red and blue channels, respectively64. 
Citric acid, due to its branched structure is generally used to 
prepare hyperbranched polyesters and dendrimers. For 
instance, Namazi et.al. reported the successful synthesis of a 
citric acid dendrimer using PEG as the core molecule. The 
1 
2 
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aqueous solubility of 5-amino salicylic acid, pyridine, 
mefenamic acid, and diclofenac have been improved using this 
water soluble dendrimer65. Recently synthesis of a 
hyperbranched polymer of citric acid and glycerol via a 
polycondensation route has been reported. This polymer has 
been used for the improved delivery of the cytotoxic drug, 
cisplatin66. In another study, a series of poly(diol citrates) has 
been synthesised by reacting citric acid with various diols via a 
polycondensation reaction.  
These novel poly(diol citrates) were tunable in terms of 
mechanical properties, degradation and surface characteristics 
by varying the diols and by manipulating the cross-link 
density. The synthesised poly(diol citrate)s were fabricated 
into various type of soft scaffold for tissue engineering 
applications (figure 1-5)67, 68.  
 
Figure 1-5 (A) Picture of poly(1,8-octanediol-co-citrate) (POC) scaffold, 
non-porous (left), sponge (middle) and porous (right). (B) SEM image of 
the porous POC scaffold cross section. Scale bar 50 µm67 
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Glycerol, a renewable monomer has attracted special attention 
to prepare polyesters due to its large amount of production as 
a by-product during biodiesel production. Recently, Dow 
announced the production of propylene glycol from glycerol57. 
Glycerol can also be converted into 1,3-propanediol using 
biotechnological methods69. Several useful monomers and 
polymers have been derived from glycerol including 
poly(esters) for various applications and were reviewed 
recently70, 71.  
 
Scheme 1-9 Synthesis scheme of Poly(glycerol-sebacate)72 
Langer and co-workers synthesised poly(glycerol sebacate) 
(PGS), a tough biodegradable elastomer using glycerol and 
sebacic acid for various tissue engineering applications 
(scheme 1-9)72, 73. The in vitro degradation of this elastomer 
was compared with poly(DL-lactide-co-glycolide) (PLGA) and it 
was found that unlike PLGA, PGS gave a linear degradation 
profile74. Biodegradable PGS implants loaded with 5-
fluorouracil (5-FU) showed control release of 5-FU for 7 days 
with superior antitumour activity in vitro75. Degradable 
polyesters of glycerol with adipic acid, citric acid, 1,18-cis-9-
octanedecenedioic acid have also been reported76. 
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 (II) Renewable Poly(esters) via Ring Opening 
Polymerisation 
Poly(esters) of Lactide and Glycolide  
 
 
 
Poly(lactide) (PLA) and poly(glycolide) (PGA) are generally 
prepared by ring opening polymerisation of renewable lactide 
and glycolide respectively. Although PLA and PGA can also be 
synthesise by polycondensation of lactic acid and glycolic acid, 
but due to the better control over molecular weight during 
ROP, cyclic monomers (lactide and glycolide) are generally 
preferred. Lactic acid is commercially produced by the 
fermentation of glucose and sucrose (from corn or sugar) by 
lactic acid bacteria. The lactic acid is then converted into its 
cyclic dimer, lactide with the help of an acid catalyst at high 
temperature. Similarly, glycolic acid can be isolated from 
natural sources, such as sugarcane, sugar beets, pineapple 
and unripe grapes and then converted into glycolide32. Several 
reviews have been published recently, summarising their 
potential for various biomedical applications5, 15, 19, 77-79. 
CHAPTER 1 
Page | 26  
 
Polymer 
Glass Transition 
Temperature (Tg) 
(°C) 
Degradation time 
(months) 
PGA 36 2-4 
PLA 60-67 18-24 
PDLLA 57-59 12-16 
50: 50  
Poly(DLLA-co-GA) 
46.1 2 
85: 15  
Poly(DLLA-co-GA) 
45 5 
Table 1-1 Glass transition temperature and degradation time of PLA, PGA 
and PLGA polymers80 
However, due to the high crystallinity, rapid degradation and 
poor solubility of PGA (in many common organic solvents), the 
use of PGA in drug delivery has been limited. On the other 
hand, PLA, specifically poly(L-lactic acid) (PLLA), poly(DL-
lactic acid) (PDLLA), has been widely investigated for drug 
delivery applications. PLLA is a semicrystalline polymer 
whereas PDLLA is an amorphous polymer due to the random 
positions of methyl groups in the polymer chain. The presence 
of methyl groups in PLA increased its hydrophobicity and 
hence reduced the degradation time5, 79. Therefore, 
copolymers of PLA and PGA have been synthesised to alter the 
degradation time of final polymer (table 1-1). 
Poly(lactide-co-glycolide) (PLGA), a random copolymer of PLA 
and PGA is the most investigated degradable polymer for 
biomedical applications. It has been used to prepare drug 
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delivery carriers, sutures, and tissue engineering scaffolds77, 
79. Due to the difference in the properties of PLA and PGA, it is 
possible to make PLGA of choice by careful selection of 
copolymer composition for intended applications (table 1-1).  
 
Figure 1-6 SEM pictures of (1) microsphere81, (3) nanofibers82 and TEM 
pictures of (2) nanoparticles83, (4) micelles84 prepared from PLGA  
PLGA has been fabricated into microspheres81, 85, 
nanoparticles86, nanofibers82, 87, micelles88 (figure 1-6), for 
controlled and improved delivery of vaccines89 cytotoxic 
drugs90, proteins91, antibiotics92, siRNA93 etc. PLGA and PLA 
KDYHDOUHDG\EHHQDSSURYHGE\ WKH ³8QLWHG6WDWHV )RRGDQG
'UXJ $GPLQLVWUDWLRQ´ US-FDA) and ³European Medicine 
Agency´ (EMA) for human use.  
 
 
 
 
1 2 
3 4 
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Poly(esters) Synthesised from Renewable Lactone Monomers 
 
 
The synthesis of high molecular weight (90 kg/mol) 
poly(menthide) (PM), an amorphous polymer (Tg §í&) via 
the ROP of menthide has been reported recently94. Menthide, 
a seven-membered lactone monomer was prepared by the 
simple Baeyer-Villiger oxidation reaction of menthone. 
Menthol, a natural product extracted from the plant Mentha 
Arvensis, (in ton scale) is the starting material to prepare 
menthone94. Later PM was used as initiator to synthesise a 
triblock copolymer of PLA. The obtained triblock copolymer 
(PLA-PM-PLA) possessed the properties similar to styrene 
based systems. Further, in vitro degradation of PLA-PM-PLA 
copolymers was assessed in phosphate buffer solution (pH 
7.4) at 37 qC. It was observed that the rate of degradation of 
triblock copolymers was in between that of PLA and PM 
homopolymers (figure 1-7). These copolymers maintained 
their mechanical properties for approximately 21 weeks, which 
was claimed to be better than any previously reported PLA-
containing block copolymers95, 96.  
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Figure 1-7 Hydrolytic degradation of PM and its copolymer in PBS at 37°C. 
(A) mass loss with time and (B) molecular weight loss (determined by 
SEC) with time95 
Carvone is another monomer investigated to prepare 
renewable lactone rings. Carvone is a natural product found in 
spearmint (Mentha spicata) and caraway oils (Carum carvi). 
Hydrogenation of carvone produced dihydrocarvone and 
carvomenthone, which can be easily converted into respective 
lactone i.e. dihydrocarvide and carvomenthide by Baeyer±
Villiger oxidation97. 
 
B A 
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In another study, the ROP of renewable į-decalactone using 
an organic catalyst 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) 
has been published to synthesise amorphous poly(į-
decalactone)98. The synthesis of high molecular weight triblock 
copolymer i.e. poly (lactide)-b-SRO\į-decalactone)-b-
poly(lactide) was also reported by sequential addition of 
monomers98. A very similar study was done with renewable İ̻
decalactone monomer to prepare a tough and thermo-
resistant copolymer99. 
 
Scheme 1-10 Synthesis scheme of poly(MBL-co-CL) via ring opening 
polymerisation.100 
Recently Tulipaline A or Į-methylene-Ȗ-butyrolactone (MBL), a 
natural product isolated from tulips has been explored to 
make polyester by ROP using lanthanide based catalysts100. It 
has been known that due to the high thermodynamic stability 
(or low strain energy) of five membered rings, the ROP of MBL 
is difficult26. Due to this reason, a copolymer with caprolactone 
(high strain energy) was prepared (scheme 1-10)100. The 
resultant unsaturated copolymer can be of great interest due 
to the presence of allyl functional group for post 
functionalization101. However, to date, no application has been 
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reported. Based on this approach, other renewable lactones 
with high ring strain might also be used to make copolymer 
with MBL in order to obtain a complete renewable polymer102.  
Macrolactones obtained from naturally occurring macrocyclic 
musks such as ǔ-pentadecalactone and Globalide (GI), have 
been also explored for the synthesis of poly(ester) by ROP 
using enzyme as catalyst103, 104.  
 
Figure 1-8 (A) SEM image of DOX-loaded nanoparticles prepared from 
poly(PDL-co-DO) copolymers and (B) change in number-average molecular 
weight with respect to time for blank poly(PDL-co-DO) nanoparticles 
having different concentration of PDL incubated in PBS solution (pH - 7.4) 
at 37°C105. 
The poly(ǔ-pentadecalactone) synthesised from ǔ-
pentadecalactone was found to be nontoxic as determined by 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay on 3T3 mouse fibroblast cell line. However, 
due to high crystallinity and highly hydrophobic nature of the 
polymer, no hydrolytic or enzymatic degradation was 
observed104. To address this problem, a copolymer with p-
B 
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dioxanone (DO) has been synthesised named pRO\ǔ-
pentadecalactone-co-p-dioxanone) (poly(PPDL-co-DO)) using 
different ratios of ǔ-pentadecalactone and DO. The 
nanoparticles fabricated using poly(PPDL-co-DO) showed 
hydrolytic degradation at 37 °C (figure 1-8).  
 
Figure 1-9 Structures of macrolactones synthesized from ricinoleic acid. 
Abbreviations for cyclic macrolactones:(? 1RM, monolactone; 2RM, 
dilactone, 3RM, trilactone; 4RM, tetralactone; 5RM, pentalactone; 6RM, 
hexalactone.106 
Doxorubicin (DOX) and siRNA were successfully encapsulated 
in the poly(PPDL-co-DO) nanoparticles with the maximum 
encapsulation efficiency of 42 and 33 % respectively. The 
loaded poly(PPDL-co-DO) nanoparticles demonstrated the 
controlled release of encapsulated molecules for up to 60 
days105. 
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In an interesting study, Domb et al. reported the synthesis of 
macrolactones using ricinoleic acid (figure 1-9). Several 
catalysts were explored to make the polyesters using these 
lactone rings by ROP but only low molecular weight 
homopolymers were obtained. The low reactivity towards ROP 
of these lactone monomers was suggested to be due to the 
low ring strain and steric hindrance of the ester bond by the 
fatty acid side chain106. However, TBD has been proven to be 
an efficient catalyst for the ROP of hindered lactones and 
might be helpful to synthesise high molecular weight 
polyesters using these lactones98, 107.    
 
In another study, a poly(ester) synthesised by the ROP of a D-
gluconolactone, a commercially available (and cheap) 
carbohydrate lactone has been reported108. Gluconic acid is 
the starting material to synthesis D-Gluconolactone and the 
former is generally produced from glucose. In a similar study, 
a renewable lactone monomer was prepared from a reduced 
galactose, D-dulcitol and copolymerised with caprolactone to 
generate high molecular weight polyester109.  
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Poly(carbonate) from Renewable Monomers 
A carbonate monomer was recently reported via a multistep 
synthesis beginning with a commercially available glucose 
derivative, methyl 4,6-O-benzylidene-Į-D-glucopyranoside. 
The monomer was successfully copolymerized using a water 
soluble polyphosphoester (PBYP) as initiator to prepare PBYP-
b-PDGC block copolymer (scheme 1-11 )110.  The PDGC is an 
amorphous polymer with Tg of 106±123°C111.  
 
Scheme 1-11 Synthesis scheme of D-glucose carbonate monomer and its 
copolymerisation with polyphosphoester to make amphiphilic copolymers110 
The preparation of spherical micelles was also reported using 
synthesised block copolymer after post functionalization which 
suggested its potential to be used as biomaterial110. 
Renewable poly(carbonate)s can also be prepared from 
glycerol70, 112, levulinic or itaconic acids113 as starting material. 
D-Glucose Carbonate 
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However, despite the unique properties of the above 
mentioned polyesters and their copolymers, very few of them 
has been investigated for drug delivery applications. 
Therefore, more research is required in this field to identify 
the potential renewable polymers for such applications. 
1.4 Polymeric Micelles in Drug Delivery and Cancer 
Therapy  
A surfactant is a molecule, which comprises both a water 
soluble and insoluble portion. Surfactants can form micelles 
after being dispersed in aqueous solutions by self-assembly 
above their critical micelle concentrations (CMC). The CMC is 
defined as the concentration of surfactant molecules above 
which they start forming micelles. However, small surfactant 
molecules such as sodium lauryl sulphate, polysorbates etc. 
usually have a very high CMC value thus can dissociate upon 
dilution in the bloodstream or other biological fluids in vivo. 
Due to this limitation, the use of these surfactants as drug 
delivery vehicles have been limited and therefore alternative 
amphiphilic block copolymers surfactants have been developed 
to address this problem114. Polymeric micelles prepared from 
amphiphilic block copolymers have recently attracted more 
attention due to their unique structure with low CMC values. 
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Figure 1-10 Pictorial presentation of self-assembly of an amphiphilic block 
copolymer into micelles when dispersed in water. 
Amphiphilic block copolymers can form micelles in aqueous 
solvent with a hydrophobic core sterically stabilized by a 
hydrophilic shell (figure 1-10). The hydrophobic core serves as 
a reservoir for drugs with low aqueous solubility while the 
hydrophilic shell prevents the adsorption of opsonins on the 
surface. Additionally the nano-scopic sized polymeric micelles 
(10 ± 200 nm in diameter) are sufficiently large to avoid renal 
excretion (>50 kDa) as well as small enough to bypass the 
filtration of inter-endothelial cells in the spleen. All these 
factors contribute towards the longer blood circulation time of 
micelles, which leads to improved accumulation at tissue sites 
with vascular abnormalities115-118. PEG is the polymer of choice 
to be used as the hydrophilic block whereas the hydrophobic 
block can be chosen based on the required application115-118.  
Some of the reasons, which makes PEG consistently a polymer 
of choice for fabricating amphiphilic block copolymers are: it is 
an inexpensive, non-toxic, and FDA approved polymer for the 
Hydrophilic Shell 
Hydrophobic Core 
Drug 
Drug 
Self-Assembly 
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use in drug products116. Additionally, in micelles structure, 
PEG forms a dense, brush-like shell which imparts steric 
stability to the formulation117.  Further, PEG is known to 
increase the circulatory time of carriers by impeding their 
uptake by the cells of the Reticuloendothelial System (RES)119. 
Moreover, PEG can be easily functionalised to attach the 
targeting ligands for targeted drug delivery applications120. 
Polymeric micelles have been widely utilised as solubilising 
tool for hydrophobic drugs116. The micelle structures are 
known to have an anisotropic distribution of water and 
therefore the core of the micelles is usually water free121. 
During the drug loading procedure, the hydrophobic drugs 
migrate towards the hydrophobic block (core) due to the 
hydrophobic interaction.  
Hydrophobic interaction is defined as the interaction between 
the non-polar substances in water. This interaction brings the 
non-polar (hydrophobic) molecules together in order to have 
minimal contact with water. This is a spontaneous process and 
is reasonably stronger than other weak intermolecular forces 
such as hydrogen bonding122. Therefore, during drug 
encapsulation procedure, hydrophobic core and drug come 
together to obtain drug loaded micelles. Furthermore, 
hydrophilic block provides the steric stability to micelles due to 
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which they remain well dispersed in aqueous solution without 
aggregation115, 117, 123. In terms of thermodynamics, the drug 
solubilisation in micelles core can be considered as a 
partitioning of the drug between polar and non-polar 
phases121. In addition to the solubilisation tool, micelles have 
also known to increase the bioavailability, reduce the toxicity 
and offer the control release of loaded drugs leading to patient 
compliance 117, 124.  
As shown in figure 1-10 and figure 1-11, drug molecules are 
generally localised within the hydrophobic core separated from 
the outside environment by hydrophilic shell. This unique 
feature prevents the direct interaction of encapsulated drugs 
with the physiological environment such as cells or body 
fluids.  This in turn, prevents any undesirable 
pharmacodynamics and pharmacokinetics reactions, which 
leads in improved bioavailability and reduction in toxicity of a 
drug.  
Using polymeric micelles as a drug delivery carrier is certainly 
beneficial because of various advantages it holds over other 
carrier systems like easier preparation method with tunable 
property, good loading capacity and better formulation 
stability116-118, 121, 124, 129-131. All these advantages are due to 
the unique structure (core-shell) of polymeric micelles as 
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discussed above. A number of micelles formulations are 
already in the clinical trials such as NK012, SP1049C, NC-
6004, NK911 etc., (figure 1-11) while FDA has approved 
Genexol-PM for the treatment of breast cancer116, 132. 
 
 
Figure 1-11 Schematic presentation of NK911125, NK012126, NC-6004127 
and Genexol-PM128 micelle formulation. 
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1.4.1 Methods of Fabrication of Drug Loaded Polymeric 
Micelles  
The four frequently used methods for the preparation of 
micelles and drug encapsulation are described below:  
Dialysis Method 
In this method, block copolymer and drug are dissolved in a 
water miscible non-volatile organic solvent (such as dimethyl 
sulfoxide and N,N-dimethyl formamide) followed by dialysis of 
the obtained solution against water (figure 1-12A).  
 
Figure 1-12 Pictorial presentation of methods used for micelle preparation 
and drug encapsulation133 
CHAPTER 1 
Page | 41  
 
During dialysis, water will gradually replace the organic 
solvent from the dialysis bag leading to the self-assembly of 
amphiphilic polymer in micelles with encapsulated hydrophobic 
drug. It was suggested that during dialysis any 
unencapsulated drug will be removed from micellar solution 
leaving behind the drug loaded micelles only133. However, it 
should be noted that the replacement of organic solvent with 
water is a slow process. Hence, diffusion of some amount of 
drug into external media (water) might be possible before 
self-assembly. To avoid this problem Allen et al. prepared the 
drug loaded micelles by adding the water directly to the drug-
polymer solution (in DMSO) followed by dialysis in order to 
remove the solvent134. 
Oil-in-Water Emulsion Method 
In this method, block copolymer and drug are dissolved in a 
water immiscible volatile organic solvent such as chloroform 
ethyl acetate and methylene chloride. The solution is then 
slowly added to the aqueous phase under stirring to make an 
oil-in-water emulsion (figure 1-12B). In some cases, additional 
surfactants are also used to make a stable emulsion. The 
organic solvent is then evaporated at room temperature to 
yield the drug loaded micelles131, 133. 
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Solvent Evaporation/Film Method 
In this method, block copolymer and drug are dissolved in a 
suitable volatile organic solvent and then the solvent is 
evaporated to make a thin polymer-drug film on the wall of a 
flask. The film is then reconstituted with the aid of aqueous 
solvent by vigorous shaking to produce the drug loaded 
polymeric micelles (figure 1-12C)131, 135. Large scale 
production is possible with the solvent evaporation method. 
However, the use of this method is not preferred to make 
micelles from block copolymers with high hydrophobic to 
hydrophilic ratio. Due to the high hydrophobicity, the complete 
reconstitution of such polymers by simple mixing is difficult133. 
Co-solvent evaporation/Nanoprecipitation Method 
In this method, block copolymer and drug are dissolved in a 
water miscible volatile organic solvent and then added drop 
wise to water under stirring. The diffusion of solvent in water 
with simultaneous evaporation triggered the self-assembly of 
copolymer, yielding the drug loaded polymeric micelles (figure 
1-12D)133, 136.  
1.4.2 Polymeric Micelles in Cancer Therapy 
Cancer therapy (chemotherapy) needs targeted delivery of 
cytotoxic drugs to tumours to avoid unwanted side-effects, 
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which are attributed to the distribution of drugs in normal 
tissues. Targeted delivery of drugs to the tumors (cancer cells) 
can be achieved with the aid of suitable drug delivery carriers 
based on active and passive targeting strategies (figure 1-
13)137-140.  
 
Figure 1-13 Schematic presentation of targeted therapy to tumors with the 
aid of nanoparticles (micelles) by active and passive mechanism140. 
Indeed, polymeric micelles as a drug delivery carrier for 
cytotoxic drugs offer numerous advantages in 
chemotherapy123, 130-132. For instance, the incorporation of 
cytotoxic drugs into micelles has been reported to increase the 
half-life of drug by circumventing its elimination by the liver 
and/or kidneys thus increasing the bioavailability132. 
Additionally, small size micelles have been reported to 
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passively target the tumors by the Enhanced Permeability and 
Retention (EPR) effect141, 142. Moreover, many anticancer 
drugs are hydrophobic in nature and hence encapsulating 
them within polymeric micelles can enhance their aqueous 
solubility (thus they can be more easily administrable in the 
body) and consequently bioavailability130-132. Furthermore, the 
controlled release of bio-actives for a longer duration at a 
tumor site can also increase the effectiveness of treatment130-
132. In addition to that, the shell of polymeric micelles can be 
modified for active targeting by attaching specific ligands. This 
modification enhanced the selectivity of polymeric micelles for 
tumor cells and consequently improved the intracellular drug 
delivery (figure 1-13)120, 132. Thus, the use of micelles for 
cancer therapy can be beneficial in order to improve the 
bioavailability and to reduce the side effects of anticancer 
drugs141, 142. 
Passively targeted micelles for Cancer Therapy 
Targeting solid tumors using long circulatory drug delivery 
carriers via the Enhanced Permeability and Retention (EPR) 
effect is considered as passive targeting. The EPR effect was 
first described by Maeda and co-worker143. Physiological and 
pathological studies of solid tumours suggested that the tumor 
vasculature possessed some unique characteristics such as 
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incomplete architecture and immature lymphatic capillaries. 
Tumor vasculature generally has poorly aligned and defective 
endothelial cells with broad fenestrations XS WR  ǋP DQG 
lacking smooth muscle layer (or innervations and functional 
lymphatics). Additionally, impaired receptor function for 
vasoactive mediators especially angiotensin II in tumor 
vascular has been observed (Figure 1-13 and 1-14) 137, 139.  
 
Figure 1-14 Differences between normal and tumor tissues, which explains 
the passive targeting of nanocarriers by the EPR effect. (A) normal tissues 
contain linear blood vessels maintained by pericytes. (B) tumor tissues 
with defective blood vessels with many sac-like formations and 
fenestrations. The extracellular matrix contains extra collagen fibres, 
fibroblasts and macrophages compared to normal tissue. Lymph vessels 
are absent139. 
The excessive production of vascular mediators, such as 
vascular endothelial growth factor (VEGF), bradykinin, 
fibroblast growth factor (bFGF), nitric oxide, peroxynitrite, 
prostaglandins, and matrix metalloproteinases, are responsible 
for the hyper-permeability in tumor tissues144, 145. VEGF, a 
protein excessively secreted by tumors, plays an important 
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role in the angiogenesis process which includes degradation of 
vascular basement membrane and surrounding extracellular 
matrix, as well as vascular endothelial cell division and 
migration118. This enhanced vascular permeability ensures the 
adequate supply of oxygen and nutrients for rapid growth of 
tumor tissues145, 146. Recently, reduction in vascular 
permeability in colon carcinomas when treated with anti-VEGF 
antibody confirmed the role of VEGF in enhanced permeability 
of tumor vasculature147.  
Furthermore, due to the defective lymphatic function in 
tumors, continuous draining and renewal of interstitial fluid is 
minimal148. As a result, high retention time of a 
macromolecule has been observed in tumor tissues compared 
to normal tissues140,149. These two factors (i.e. Enhanced 
Permeation and Retention) comprise the EPR effect, due to 
which selective extravasation and accumulation of 
macromolecules in tumor tissues were observed142, 143, 145. 
Indeed several polymeric micelle formulations have been 
reported which accumulate at the tumor sites via the EPR 
effect142. For instance, PEG-poly(g-benzyl L-glutamate) block 
copolymer micelles loaded with cisplatin,  demonstrated  high 
accumulation in solid tumor in Lewis lung carcinoma bearing 
mice, compared to free drug. The high accumulation at the 
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tumor site was suggested to occur via the EPR effect due to 
the prolonged blood circulation and small size ( approx. 30 nm 
in diameter) of micelles150. This formulation is now in Phase II 
clinical trials with the trade name ³NC-6004´127.   
Polymer Drug Size of micelles 
PEG2000-PE/Vitamin E
152
 Paclitaxel,  
Curcumin 
15-20 nm 
Pluronic® L61 and F127 
(SP1049C)
153
 
Doxorubicin 30 nm 
mPEG-b-poly(D,L-
lactide)
154
 
Docetexal 16.62±0.31 nm 
mPEG-b-poly(D,L-
lactide) (Genexol-PM)
155
 
Paclitaxel <50 nm 
Table 1-2 Examples of micelles formulations, which demonstrated 
enhanced tumor uptake by EPR effect. (mPEG- monomethoxyl PEG) 
NK105, PEG-poly(aspartic acid) micelles loaded with paclitaxel 
is another formulation which is in clinical trials. Approximately 
50% of carboxylic acid groups of poly(aspartic acid) have been 
modified with 4-phenyl-1-butanol in the NK105 formulation, 
which increased the hydrophobicity of polymer and eventually 
paclitaxel loading (23% w/w approx.). The average size of 85 
nm was observed with this formulation after redispersion in 
aqueous solvent. Approximately, 90-fold increase in the 
plasma area under curve (AUC), 25-fold increase in tumor 
AUC in Colon-26 tumors bearing CDF1 mice was observed, 
when compared with free drug. This high tumor uptake 
efficiency was attributed to the EPR effect of long circulatory 
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NK105 micelles. Phase II clinical trials of NK105 were 
conducted in Japan, which was successfully completed in 2010 
with positive results. Phase III Studies are on-going on 
patients with breast cancer and due to end by September 
2016151. Some more examples of polymeric micelles studied 
for tumor targeting via EPR effect are listed in table 1-2. 
Actively Targeted Micelles for Cancer Therapy 
Tumor targeting potential of polymeric micelles can be further 
enhanced by attaching the targeting ligands on to the micelle 
surface (actively targeted micelles). The concept of active 
targeting is based on the ligand±receptor interactions at the 
target site i. e. tumor. After reaching the target site, ligand 
decorated micelles should interact with certain specific 
receptors present on the tumor cell and then be internalised 
by receptor-mediated endocytosis (figure 1-13 and 1-15)120, 
131, 132, 139, 140.  
Increase in the cellular concentration of anticancer agents via 
receptor mediated endocytosis leads to superior therapeutic 
efficacy of the drugs. This in turn reduces the dose size and 
side effects of cytotoxic drugs156. The selection of ligands is 
usually based on any receptor, which is overexpressed by 
tumor cells or tumor vasculature but have minimal or no 
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Figure 1-15 Receptor mediated endocytosis mechanism of a ligand after 
being attached to the specific receptor (source - 
http://droualb.faculty.mjc.edu). 
Commonly used targeting ligands include antibodies, peptides, 
proteins, carbohydrates, small organic molecules and 
aptamers. The attachment of a ligand on to the surface of 
micelles is generally achieved either by the post-modification 
of a block copolymer with bifunctional spacer molecules or by 
the direct synthesis of hetero-bifunctional blocks115. Several 
polymeric micellar formulations based on ligand mediated 
targeting have been reported in literatures and were reviewed 
recently120, 131, 132, 157.  
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For instance, monoclonal antinucleosomal antibody (2C5) 
conjugated poly(ethylene glycol)-block-phosphatidyl 
ethanolamine (PEG-b-PE) micelles loaded with Doxorubicin 
(DOX) have been tested in a DOX-resistant ovarian cancer cell 
spheroid model. The 2C5 conjugated micelles demonstrated 
higher uptake (two fold) and penetration with greater cell 
death in spheroids compared to free DOX and non-targeted 
DOX micelles. The mean size observed for PEG±PE targeted 
micelles was 15 nm158. In another study Herceptin conjugated 
to d-Į-tocopheryl polyethylene glycol succinate (vitamin E 
TPGS) micelles have been developed for targeted co-delivery 
of docetaxel and siRNA159. Antibodies are very popular as 
targeting ligands, but only limited conjugation of these 
moieties on micelle surface is possible due to their large size 
(~150 kDa). Furthermore, rapid clearance of antibody 
conjugated micelles might be observed due to their potential 
immunogenicity160.  
Transferrin (Tf) (protein) conjugation is another widely studied 
approach to fabricate targeted carriers for the specific delivery 
of cytotoxic drugs to the cancer cells161. For instance, Yue et. 
al. developed the transferrin conjugated mPEG-b-PLA 
polymeric micelles for their enhanced uptake in cancer cells162. 
The size range of the micelles was between 85-110 nm. They 
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were tested on three human cell lines, SGC-7901 (gastric 
carcinoma), SKOV-3 (ovarian carcinoma), and MCF-7 (breast 
carcinoma) for uptake studies. Higher uptake of Tf- 
conjugated micelles (TfM-RhB) was evident by confocal laser 
scanning microscopy (CLSM) (using Rhodamine as marker) on 
MCF-7 and SGC-7901 cell lines compared to Tf-free micelles 
(M-RhB). SKOV-3 cells expressed a low level of transferrin and 
hence little difference in uptake was observed between TfM-
RhB and M-RhB (figure 1-16). This study suggested that the 
high uptake was due to transferrin receptor mediated 
endocytosis162.  
 
Figure 1-16 CLSM images of human MCF-$DQG$Ļ6*&-7901 (B and 
%ĻDQG6.29&DQG&ĻFHOOVLQFXEDWHGZLWK7I0-RhB (A, B, and C) or 
M-RhB $Ļ%ĻDQG&Ļ162. 
High cellular uptake and effective tumor growth inhibition have 
been also demonstrated by using arginylglycylaspartic 
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acid (RGD) (peptide)163, lactose164 and galactose165 
(carbohydrates) and A10-aptamer166 as targeting ligand. 
Due to the higher expression level of folate receptors in 
tumors (100 to 300 times) compared to normal tissue, folic 
acid as targeting ligand has been widely studied for cancer 
chemotherapy167, 168. Folic acid is a commercially available 
small molecule that can be easily conjugated on to micelles 
surfaces168, 169.  
 
Figure 1-17 CLSM images of HeLa (a), KB (b), A549 (c) and MCF7/ADR 
cells (d), after incubation with different DOX formulations for 3 h. For each 
images, the columns from left to right correspond to Hoechst, DOX and 
merge, respectively170 
Recently, Qiu et. al. reported the fabrication of targeted 
micelles using folate-modified poly (2-ethyl-2-oxazoline)-b-
SRO\İ-caprolactone) (FA-PEOz-PCL) block copolymer170. DOX 
loaded FA-PEOz-PCL micelles with the size range of 157-191 
nm were tested for cellular uptake using folate receptor 
positive (FR+) Human HeLa cervical carcinoma cell lines 
(HeLa), human KB nasopharyngeal epidermal carcinoma cell 
lines (KB), Multidrug-resistant human breast cancer MCF-
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7/ADR cell lines and folate receptor negative (FR-) human 
A549 lung adenocarcinoma cell lines. 
As shown in figure 1-17, higher cellular uptake of folate 
conjugated micelles (FA4) was observed with FR+ cell lines 
compared to non-folate micelles (FA0) and DOX. Further, 
folate receptor mediated endocytosis was confirmed by 
addition of free folic acid in cell culture media (FA4 + Folate). 
Addition of free folic acid competes with folate receptors for 
binding and thus reduced uptake of FA4 as evident by CLSM 
images (figure 1-17). Moreover FA4 demonstrated lower 
IC50 values in FR+ cell lines compared to FA0
170.    
 
Figure 1-18 Tumor volume growth for various formulations of free DOX, 
DOX micelles, and DOX/FOL micelles as a function of time172. 
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Kim et.al. demonstrated the effectiveness of folate mediated 
targeting in multi-drug resistant (MDR) tumors using PLLA-b-
PEG-folate micelles171. In another study, a significant 
reduction in tumor size was observed using PLGA±b-PEG±FA 
micelles containing DOX as cytotoxic agent (DOX/FOL 
micelles) compared to free drug (doxorubicin) and non-folate 
micelles (DOX micelles) (figure 1-18)172. 
1.5 Summary 
Polymeric drug-delivery systems have been investigated to 
address the problems associated with drugs such as poor 
aqueous solubility, stability and significant side effects. 
Indeed, polymeric micelles as a drug delivery carrier have 
demonstrated their potential to address some of the above 
mentioned problems as discussed earlier. Polymeric micelles 
can be easily prepared by conjugating a hydrophilic and 
hydrophobic polymer followed by its dispersion in aqueous 
solvent. Further, the unique core-corona structure of 
polymeric micelles provides satisfactory stability to this 
formulation. Due to these advantages, several polymeric 
micelles have been studied for the effective treatment of 
cancer and some of them are in clinical trials.   
Apparently, biodegradable polymers because of their low 
toxicity and biodegradability are the polymers of choice to 
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fabricate micelles for in vivo applications. Undoubtedly, 
polyesters are the front-runner biodegradable polymers used 
to generate the micelles. Polyesters derived from renewable 
feedstocks recently have attracted more attention due to the 
depletion of fossil fuel reserves and their increased prices. As 
discussed earlier, several new polyesters, which have been 
derived from renewable feedstocks are in a development 
stage. However, new sustainable materials are produced 
frequently; their applications in drug delivery have been rather 
less investigated. 
1.6 Aim and Objectives 
Based on the published research, the aim of this project has 
been designed. By considering the advantages of polymeric 
micelles and polyesters, it was decided to fabricate micelles 
using polyesters synthesised from renewable feedstock. 
Further, the investigation of prepared micelles in drug delivery 
applications was proposed. To synthesise amphiphilic block 
copolymer, PEG as a hydrophilic polymer was chosen due to 
its extensive use in pharmaceutical formulations (see section 
1.4). Synthesis of hydrophobic polyester polymer was 
proposed via ROP route because of its advantages over 
polycondensation reaction (see section 1.2.2). Lactone 
monomer obtained from renewable resources (i.e. į-
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decalacWRQH DQG ǔ-pentadecalactone) were chosen to 
synthesise polymers using mild reaction conditions. 
Additionally, the preparation of ligand tethered polymeric 
micelles for tumor targeted delivery was also suggested. Folic 
acid was selected as the targeting ligand due to its extensive 
reported use (see section 1.4.2).  
All materials were picked on the basis of their commercial 
availability and a cheap price in order to reduce the cost of 
formulation. A general overview of proposed work is shown in 
figure 1-19. 
 
Figure 1-19 Pictorial representation of general overview of proposed work 
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2.1 Materials 
General chemicals 
All chemicals used in this project were purchased from Sigma-
Aldrich unless specifically stated. The detailed list of chemicals 
with their purity as stated by the manufacturer was described 
below.  
11Ļ-dicyclo hexylcarbodiimide (99%), 4-(dimethylamino) 
pyridine (99%), sodium trifluoroacetate (98%), poly(ethylene 
glycol) monomethyl ether (Mn~550), pyrene  į-
dHFDODFWRQH  -triazabicyclo[4.4.0]dec-5-ene 
(TBD) (98%), poly(ethylene glycol) (Mn-4000), poly(ethylene 
glycol) monomethyl ether (Mn-5000), propargyl alcohol 
(99%), cis-1,3-O-benzylideneglycerol (97%), benzoic acid 
 pyrene  İ-caprolactone (97%), ǔ-
pHQWDGHFDODFWRQH  novozymes-  8J
recombinant, expressed in Aspergillus niger), nile red 
(technical grade), Curcumin (99.5%), Amphotericin B 
(~80%), Tween 80, Ļ-bipyridyl , p-toluenesulfonyl 
chloride , sodium azide (99.5%), anhydrous pyridine 
(99.8 %), folic acid 7%), rhodamine B isothiocyanate 
(mixed isomer), N-hydroxysuccinimide (98%), triethylamine 
9%), copper (I) bromide (99.9%). Sodium ascorbate and 
ortho phosphoric acid (85%) was purchased from Fluka. N3-
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PEG-NH2.TFA salt was purchased from JenKemUSA which has 
95 % of amine substitution and >90 % of azide substitution. 
į-decalactone was passed through basic alumina before use. 
PEG4K, mPEG5K, į-decalactone and İ-caprolactone were 
dehydrated by azeotropic distillation using anhydrous toluene. 
Novozymes-435 was dried under vacuum at 50°C for 24 hours 
before use.  All other materials were used as received unless 
otherwise stated. 
All other solvents were purchased from Fischer Scientific UK 
except deuterated solvents and dimethylacetamide, which 
were purchased from Sigma Aldrich. 
Cells and Cell Culture reagents 
Opti-MEM®, reduced serum media and Alamar Blue® were 
purchased from Life Technologies, UK. RPMI-1640 Medium 
was procured from Sigma Aldrich. A549, MCF-7 and HCT116 
cell lines were obtained from the ATCC and the media used for 
general maintenance was RPMI-1640 supplement with 2 mM 
L-glutamine and 10% fetal bovine serum.   
2.2 Instruments and Methods 
Fourier Transform Infrared (FTIR) Spectroscopy 
FTIR analysis of polymers was performed on Cary 630 Agilent 
FTIR spectroscopy. A small quantity of sample was directly 
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SODFHGRQFOHDQFU\VWDOSUHVHQW LQWKHVDPSOHKROGHU$ µUHDO-
WLPH¶ VSHFWUXP ZLOO DSSHDU RQ WKH VFUHHQ ZKLFK ZDV WKHQ
analysed using MicroLab software. A background spectra was 
also collected before placing sample. 
Nuclear Magnetic Resonance (NMR) 
NMR analysis was performed on a Bruker NMR spectrometer at 
400 MHz (1H) and 101 MHz (13C) in deuterated solvent. 
Spectra were analysed using MestReNova 6.0.2 copyright© 
2009 Mestrelab Research S.L. All chemical shifts were 
recorded in ppm using residual solvent as an internal standard 
(CDCl3į+į&, DMSO-d6: į+2.50į&39.52). 
MALDI-TOF Mass Spectrometry (MALDI-MASS) 
Matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectroscopy was performed on an 
Ultraflex III MALDI-TOF spectrometer with N2 laser of 337 nm 
and pulses of 3 ns. Trans-2-[3-(4-tert-Butylphenyl)-2-methyl-
2-propenylidene] malononitrile (DCTB) was used as the matrix 
and Sodium trifluoroacetate was used as dopant. Samples 
were prepared by mixing 5mg/mL of sample in 10mg/mL of 
matrix in a suitable solvent (acetone or acetonitrile). 
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Size Exclusion Chromatography (SEC) 
The number-average molecular weight (Mn), weight average 
molecular weight (Mw) and molecular weight distribution 
(polydispersity, Mw/Mn) were measured by SEC. Molecular 
weight analysis was performed on a Polymer Laboratories GPC 
50 spectrometer fitted with a differential refractive index 
detector. The eluent was HPLC grade CHCl3 at 30 °C with a 
flow rate of 1 mL min-1. The instrument was fitted with a 
Polymer Labs PLgel guard column (50 × 7.5 mm, 8 µm) 
followed by a pair of PLgel Mixed-D columns (300 × 7.5 mm, 8 
µm). Column calibration was achieved using narrow 
polystyrene standards of known Mp in the range of 100 Da-
500 kDa. Molecular weight and polydispersity were calculated 
using Polymer Labs Cirrus 3.0 software. 
Some samples were also run on a SEC having HPLC grade 
tetrahydrofuran as eluent. The instrument used was Polymer 
Laboratories (PL-120) spectrometer equipped with RI detector 
and calibrated with linear polymethylmethacrylate (PMMA) 
standards. The columns used were PLgel Mixed-C (30 cm, 2 in 
series) with a guard column of PL Gel M and analysis was 
performed at 40°C, with flow rate of 1ml/min. 
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Differential Scanning colorimeter (DSC) 
A TA-Q2000 DSC (TA instruments), was used to determine the 
melting temperature (Tm) and glass transition temperature 
(Tg) of polymers. Typically, the sample (5±15 mg) was 
weighed into a Tzero DSC pan and capped with a Tzero DSC 
lid which was than sealed with a Tzero press (TA instruments) 
using a %ODFN7]HURORZHUGLHDQGDÀDWXSSHUGLH,QDW\SLFDO
run, two cycles of experiment were run and the temperature 
was increased from ±90 to 200 ° C at a rate of 10 ° C/min and 
the results obtained from the second cycle were reported. 
Dynamic light scattering (DLS) and Zeta Potential 
DLS is a well-established technique for measuring the size and 
size distribution of samples of nano-materials. It measures the 
scattered laser light at different intensities caused by the 
Brownian motion of particles in a diluted suspension. Analysis 
of these intensity fluctuations gives the velocity of the 
Brownian motion, which can be converted into particle size 
using the Stokes-Einstein relationship.  
The z-average diameter and the Polydispersity Index (PdI) of 
micelles were measured by DLS using a NanoZS instrument 
(Malvern, UK). The measurements were carried out at 25° C 
using 633 nm (4mW) wavelength laser. The scattered light 
ZDVGHWHFWHGDWDQDQJOHRIÛ 
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Zeta Potential was measured using a NanoZS instrument 
(Malvern, UK) via a Laser Doppler Micro-electrophoresis 
technique. An electric field was applied to the dispersion of 
particles, which induced movement at a certain velocity. This 
velocity was measured using phase analysis light scattering to 
give the value of electrophoretic mobility from which zeta 
potential and zeta potential distribution were calculated. Data 
analysis was carried out using zetasizer software version 7.03 
and mean values were obtained from three measurements. 
Transmission Electron Microscopy (TEM)  
TEM was used to determine the size and morphology of the 
micelles. Samples were imaged using a FEI Tecnai G2 electron 
microscope. One drop of sample in water, typically 25-50 
µg/mL was dropped onto a copper grid and allow to dry in air. 
Samples were then imaged on TEM in bright field at high 
tension of 100 Kv using TIA imaging software without staining.  
Rotary Evaporator 
A Buchi rotavapor R-200 equipped with a B490 heating bath 
was used to remove organic solvent under reduced pressure. 
Freeze Drier  
An Edwards Modulyo freeze drier equipped with an Edwards 
high vacuum pump was used to remove water from samples. 
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All samples were frozen with liquid nitrogen before placing in 
drier. 
Fluorescence Spectroscopy 
Fluorescence spectra were recorded using a Cary Eclipse 
Fluorescence spectrophotometer (Varian). The intensity was 
measured against appropriate blank solutions at room 
temperature with the excitation and emission slit widths of 5 
nm. 
Ultraviolet-visible Spectroscopy (uv/vis)  
Samples for UV-vis absorbance were analysed on a Beckman 
Coulter DU 800 UV spectrophotometer using capped quartz 
cuvettes. A sample volume of 700µl was used for all 
measurements after appropriate dilutions. 
Critical Micelle Concentration (CMC) determination  
The CMC values of amphiphilic block copolymers were 
determined using the pyrene 1:3 ratio method1. Pyrene 
showed five different peaks in its fluorescence spectra (figure 
2-1) whose intensities are totally dependent on the 
surrounding environment (i.e. polarity) experienced by the 
pyrene molecule. Consequently, when pyrene moves from a 
polar region to a nonpolar region the intensity of first peak (I1) 
at 373 nm is observed to reduce, while that of the third peak 
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intensity (I3) at 384 nm rises and thus gives an idea of the 
environment facing by the pyrene in experimental solutions2. 
This difference in the peak intensity was used to determine 
the CMC of surfactants. When micelles start forming in 
experimental solution, they provide a hydrophobic region to 
the pyrene, which leads to decrease in the intensity of peak 1 
or the ratio of peak 1st to 3rd. 
 
 
 
Figure 2-1 Pyrene fluorescence spectra in (A) solvents with different 
polarity and (B) in different concentration of amphiphilic block copolymer 
in water 
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Briefly, a stock solution of pyrene was made in acetone and a 
pre-calculated quantity contains 6x10-7 M of pyrene was 
transferred into 22 vials followed by evaporation of acetone 
under a slow stream of nitrogen. Different concentrations 
(from 0.001 to 50 µg/mL) of polymer solutions in water were 
then added in each vial and left overnight (in the dark) with 
agitation to equilibrate. Fluorescence spectra of solutions were 
then recorded in the range of 350 to 420 nm at an excitation 
wavelength of 335 nm. The intensities of emitted light at 373 
nm (I1) and 384 nm (I3) were used to calculate the pyrene 1:3 
ratio and plotted against the concentration of polymer used 
(log scale).  All measurements were carried out in triplicate at 
25.0 ± 1°C and mean value with error was reported.  
Drug Content and Encapsulation Efficiency 
Drug content weight percent (DC wt%) and percent 
encapsulation efficiency (EE %) in the samples were calculated 
using the formula below: 
DC wt%= 
Amount of drug loaded 
x 100 
Amount of polymer 
used 
EE% = 
Weight of loaded drug 
x 100 
Weight of drug in feed 
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3.1 Introduction 
Ring opening polymerisation (ROP) is a widely used, 
industrially important synthesis methodology to obtain 
polyesters with high molecular weight. Unlike 
polycondensation, ROP does not always require high 
temperature or long reaction time. The conversion rate 
observed in ROP is generally high without the need to remove 
any side products or the use of exactly stoichiometric amount 
of monomers1. Lactides and lactones are the most important 
and investigated category of monomers used to make 
polyesters by ROP. Polymers and copolymers of lactides are 
well established materials, which are currently marketed for 
various applications2 3RO\FDSURODFWRQH V\QWKHVLVHG IURP İ-
caprolactone is another class of extensively studied 
biodegradable and less-toxic polymer which is cheap and 
commercially available3.   
Poly(caprolactone) and its copolymers are amongst the most 
studied polymers in biomedical applications but the long 
degradation time and non-renewable monomer source restrict 
their extensive use4,5. Hence, monomers and polymers from 
natural/renewable resources are of increasing importance. 
However, many polymers derived directly from natural 
resources have limitations; for example, batch to batch 
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variability in terms of molecular weight, lack of addressable 
chemical functionalities and limited scope to alter the physical 
and chemical properties. Consequently, polymers synthesised 
in the laboratory using monomers obtained from renewable 
resources are attractive materials, which can address the 
problems of unsustainable feedstocks and unfavourable 
application properties.  
Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) 
are Food and Drug Administration (FDA) approved polymers, 
obtained from renewable monomers, however their 
applicability has been limited by certain disadvantages. For 
instance, the use of PLGA in medical implants can cause local 
irritation by releasing excessive acid upon degradation. In the 
case of PLGA-derived drug delivery materials, the production 
of excessive acid from PLGA degradation can cause deleterious 
effects on loaded acid sensitive drugs6,7. In addition, the 
loading of hydrophobic drugs into PLA or PLGA matrices has 
been reported to be low, which was suggested due to the 
lower hydrophobicity of these polymers compared to long 
chain polyesters8, 9. Therefore, more hydrophobic derivatives 
of lactide and resulting copolymer have been prepared8, 9 
however, the synthesis procedure is tedious and expensive in 
terms of monomer cost. Considering these limitations there is 
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an urgent need to develop a polymeric system, which can be 
produced from cheap renewable monomers via easy synthesis 
methodologies. 
į-Decalactone is a FDA approved flavouring agent10 (FDA 21 
CFR -172.515) but its applicability in biomedical fields has not 
yet been demonstrated. This commercially available 
compound is obtained from the plant Cryptocarya massoy11 
and therefore can be considered as a renewable monomer. We 
selected this monomer to explore its potential in drug delivery 
applications due to its renewable source; commercial 
availability and the presence of an alkyl side chain. The 
presence of an alkyl chain in monomer structure could 
generate a highly hydrophobic polymer, which may be useful 
to achieve better drug loading than other currently-used 
polymers9, 127KHILUVW523RIį-decalactone was reported by 
Dong et. al in 1999 using lipase PSL (Pseudomonas sp.) as a 
catalyst with 87% conversion (Mn - 9,000) after 480 hrs
13. 
Additionally, despite the high efficiency of enzymes in ROP for 
polymer preparation, some drawbacks remain. For instance: 
a) Enzymes are expensive compared to other ROP catalysts 
and therefore use of enzymes is limited for large scale 
synthesis14. 
b) Required in high concentration to initiate ROP15. 
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c) Dilution of polymers with solvent is desirable when 
removing enzyme at the end of the reaction, leading to an 
additional step in purification15. 
d) Limited use at high temperatures (melt polymerization)16. 
e) Poor control of molecular weight due to trans-esterification 
reactions16. 
Considering these limitations, a highly efficient organic 
catalyst named 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) has 
been reported as an alternative for ROP of macrolactones and 
hindered lactones which addresses many of the problems 
associated with enzyme catalysts17, 18. TBD is a bicyclic 
guanidine base, first synthesised by McKay and Kreling in 
1957. It is reported to be a very efficient catalyst for various 
reactions like acyl transfer19, aldol reaction20, Michael 
reactions21, ring opening polymerization22 etc. TBD can be 
recovered by CO2 treatment reported by Cota et. al. and 
therefore could be used in more batches to catalyse 
reactions20. In addition, an active organic catalyst like TBD for 
ROP is preferable compared to metal catalysts due to reported 
higher catalytic efficiency and easier purification22, 23.  
More recently, Martello et. al UHSRUWHG WKH 523 RI į-
decalactone to synthesise high molecular weight 
poly(decalactone) (PDL) under mild conditions using TBD18. 
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Following the work of Martello et. al., it was postulated to 
synthesise block copolymers of PDL, using TBD as catalyst, 
and then to evaluate the potential of these block copolymers 
for drug delivery applications.  
In this chapter, the synthesis of novel amphiphilic block 
copolymers has been reported via 523 RI į-decalactone 
initiated by poly(ethylene glycol) (Mn-4000) (PEG) and mono 
methoxy poly(ethylene glycol) (Mn -5000) (mPEG). The 
reaction was performed under mild conditions in the absence 
RI VROYHQW DV D VWHS WRZDUGV D PHWDO IUHH ³JUHHQ´ V\QWKHVLV
approach24. The PEG initiators were chosen to provide 
hydrophilic blocks, which, when combined with the 
hydrophobic decalactone blocks, would generate amphiphilic 
copolymers. In turn, self-assembly of these copolymers was 
expected to occur in water providing micelle-like structures 
with hydrophobic cores for drug incorporation and hydrophilic 
shells to provide colloidal stability and resistance to protein 
attachment in biological media. This design provided a 
framework for materials intended for use in various 
pharmaceutical applications25.  
HomopRO\PHUV RI į-decalactone were also synthesised using 
initiators like glycerol, propargyl alcohol and cis-1,3-O-
benzylideneglycerol (BZD) to compare the properties with 
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novel block copolymers of PDL. Initiators such as BZD and or 
propargyl alcohol are of further interest due to the presence of 
end functional groups, which could be later used to introduce 
desirable properties by post polymerisation functionalization. A 
EORFNFRSRO\PHURIİ-caprolactone using mPEG as initiator was 
also synthesised for comparative studies.  
/DFWRQH ULQJV RI ODUJHU VL]H WKDQ İ-caprolactone have been 
rather less investigated for the preparation of more 
hydrophobic polyesters and only a few reports have been 
published for ROP of macrolactones. Therefore, a 
macrolactone (i.e. ǔ-pentadecalactone) was explored in the 
FXUUHQWVWXG\WRPDNHEORFNFRSRO\PHUVǔ-pentadecalactone 
is a FDA approved flavouring agent/food additive (FDA 21 CFR 
-172.515), found naturally in angelica root oil26 and 
commercial quantities of the monomer are produced 
V\QWKHWLFDOO\ 7KH DSSOLFDWLRQV RI KRPRSRO\PHUV RI ǔ-
pentadecalactone i.e. poly(pentadecalactone) (PPDL) have 
previously been limited due to poor solubility in non-
chlorinated organic solvents and high crystallinity27523RIǔ-
pentadecalactone has been well studied and therefore it was 
K\SRWKHVLVHG WKDW PDNLQJ FRSRO\PHUV RI ǔ-pentadecalactone 
with į-decalactone could produce materials of better solubility 
and intermediate crystallinity, thus enhancing its applicability 
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for biomedical use28. In addition, it has been reported that 
ROP of macrolactones has been successful using enzyme 
catalysts, despite the above-mentioned limitations29. 
Therefore, to provide comparison with other catalytic routes, a 
FRSRO\PHU RI ǔ-pentadecalactone was synthesised using 
Novozyme-435 as a catalyst and diblock copolymer of PDL as 
initiator. The resulting polymer was expected to contain a soft 
part (amorphous PDL) and a hard part (crystalline PPDL) thus 
was anticipated to have mixed physicochemical properties30 
which could be tunable by changing the molar ratio of starting 
materials.  
*HQHUDO6\QWKHVLV0HWKRGIRUį-Decalactone 
Polymers 
6\QWKHVLVRIį-Decalactone Homopolymers 
3RO\GHFDODFWRQHZDVV\QWKHVLVHGYLD523RIį-decalactone in 
bulk according to the reported procedure18 %ULHIO\ į-
decalactone (10 g, 58.73 mmol) was transferred into a flask 
containing an initiating alcohol i.e. either BZD (0.10 g, 0.58 
mmol) or propargyl alcohol (0.03 g, 0.58 mmol) or glycerol 
(Gly) (0.05 g, 0.58 mmol). The mixture was stirred for 10-15 
minutes to make a homogeneous mixture. TBD (0.20 g, 1.45 
mmol) was then added under a nitrogen atmosphere and the 
mixture was allowed to react for 11 hrs at desired 
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temperature (See table 3-1). The obtained viscous liquid was 
than quenched by adding benzoic acid (0.35g, 2.90 mmol) 
solution in acetone, precipitated in cold methanol and the 
residual solvent was evaporated under vacuum. Polymer BZD-
PDL propargyl-PDL and Gly-PDL were recovered as colourless 
viscous liquid with the percentage yield of 78.21% (7.90 g) 
76.07% (7.63 g) and 80.39 (8.08 g) respectively.  
BZD-PDL -: 1H NMR (400 MHz, CDCl3 į  ± 7.42 
(aromatic-CH, m, 2H), 7.38 ± 7.30 (aromatic-CH, m, 3H), 
5.52 (aromatic-C-CH-O, s, 1H), 4.94 ± 4.78 (CH-O-CO, m, 
89H), 4.68 (CH2-CH-O-CO, dd, 1H), 4.31 ± 4.09 (O-CH2-CH, 
m, 4H), 3.64 ± 3.48 (CH2-CH-OH, m, 4H), 2.37 ± 2.18 (O-CO-
CH2, m, 178H), 1.76 ± 1.38 (CH2-CH2-CH-CH2, m, 535H), 1.27 
(CH2-CH2-CH2-CH3, m, 546H), 0.96 ± 0.76 (CH3, t, 282H).  
13C NMR (101 MHz, CDCl3 į  &+-O-CO, CH2-CH-O-
CO), 137.25 (aromatic-C-CH-O) 128.98 (aromatic-CH), 
128.19 (aromatic-CH), 125.97 (aromatic-CH), 101.15 
(aromatic-C-CH-O), 73.62 (CH2-CH-O-CO, CH2-CH-OH), 71.21 
(O-CH2-CH), 69.04 (CH2-CH-O-CO), 34.14 (CH-CH2-CH2), 
33.91 (CH2-CH-O-CO, CH2-CH-OH), 33.43 (O-CO-CH2), 31.60 
(CH2-CH2-CH3), 24.89 (CH-CH2-CH2), 22.48 (O-CO-CH2-CH2), 
20.77 (CH2-CH3), 13.94 (CH2-CH3) 
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Propargyl-PDL -: 1H NMR (400 MHz, CDCl3į± 4.78 (CH-
O-CO, m, 87H), 4.67 (C-CH2-O, s, 2H), 3.64-3.48 (CH2-CH-
OH, m, 4H), 2.48 (CH-C, s, 1H), 2.37 ± 2.18 (O-CO-CH2, m, 
174H), 1.76 ± 1.38 (CH2-CH2-CH-CH2, m, 522H), 1.38 ± 1.14 
(CH2-CH2-CH2-CH3, m, 526H), 0.96-0.76 (CH2-CH3, t, 270H). 
13C NMR (101 MHz, CDCl3) į  &+-O-CO, CH2-O-CO), 
77.23 (CH-C-CH2), 75.86 (CH-C-CH2), 73.69 (CH2-CH-O-CO, 
CH2-CH-OH), 34.19 (CH-CH2-CH2), 33.94 (CH2-CH-O-CO, CH2-
CH-OH), 33.46 (O-CO-CH2), 31.64 (CH2-CH2-CH3), 24.93 (CH-
CH2-CH2), 22.52 (O-CO-CH2-CH2), 20.79 (CH2-CH3), 13.98 
(CH2-CH3) 
Gly-PDL -:  1H NMR (400 MHz, CDCl3į± 5.15 (CH-O-
CO, m, 1H), 4.86 (CH-O-CO, m, 88H), 4.26 (CH-CH2-O-CO, 
m, 2H), 4.19 ± 4.00 (CH-CH2-O-CO, m, 2H), 3.54 (CH2-CH-
OH, m, 4H), 2.29 (O-CO-CH2, m, 176H), 1.73 ± 1.38 (CH2-
CH2-CH-CH2, m, 528H), 1.37 ± 1.15 (CH2-CH2-CH2-CH3, m, 
532H), 0.97 ± 0.74 (CH2-CH3, t, 277H). 
13C NMR (101 MHz, CDCl3 į  &+-O-CO, CH2-O-CO), 
73.67 (CH2-CH-O-CO, CH2-CH-OH), 71.27 (CH-CH2-O-CO), 
59.52 (CH-OH), 34.18 (CH-CH2-CH2), 33.94 (CH2-CH-O-CO, 
CH2-CH-OH), 33.46 (O-CO-CH2), 31.76 (CH2-CH2-CH3), 24.9 
(CH-CH2-CH2), 22.51 (O-CO-CH2-CH2), 20.39 (CH2-CH3), 
13.88 (CH2-CH3). 
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6\QWKHVLVRI%ORFN&RSRO\PHUVRIį-Decalactone 
A di-EORFN $% W\SH FRSRO\PHU RI į-decalactone was 
synthesised using mPEG (Mn~5000) as initiator. Briefly, mPEG 
 J  PPRO ZDV DGGHG LQ D IODVN FRQWDLQLQJ į-
decalactone (57.2 g, 336 mmol) and the content was heated 
to 50°C and stirred for 10 min to make a homogeneous 
mixture. TBD (1.17 g, 8.4 mmol) was then added and the 
mixture was allowed to react for 7 hrs at 50°C. The reaction 
mixture was then cooled, quenched by adding benzoic acid 
(2.05 g, 16.8 mmol) solution in acetone and polymer was 
precipitated in cold methanol followed by removal of residual 
solvent in vacuo. The obtained dry material was again 
precipitated in petroleum ether and any residual solvent was 
evaporated under vacuum to yield a wax-like material (mPEG-
b-PDL). The ratio of monomer to initiator was changed to 
obtain copolymers with different molar masses. A similar 
procedure was followed to synthesise tri-block (PDL-b-PEG-b-
3'/ $%$ W\SH FRSRO\PHU RI į-decalactone (4.25 g, 25.0 
mmol) using PEG (1 g, 0.25 mmol) as initiator (see table 3-1). 
Copolymer mPEG-b-PDL and PDL-b-PEG-b-PDL were 
recovered as a wax-like material with the percentage yield of 
67.60% (46.24 g) and 69.71% (3.66 g) respectively. 
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mPEG-b-PDL -:   1H NMR (400 MHz, CDCl3į-4.84 (CH-
O-CO, m, 37H), 4.27 ± 4.17 (CH2-O-CO, t, 2H), 3.65 (O-CH2-
CH2-O, s, 497H), 3.38 (O-CH3, s, 3H), 2.32 (O-CO-CH2, m, 
75H), 1.75 ± 1.40 (CH2-CH2-CH-CH2, m, 222H), 1.39 ± 1.18 
(CH2-CH2-CH2-CH3, m, 227H), 0.95 ± 0.77 (CH2-CH3, t, 138H).  
13C NMR (101 MHz, CDCl3 į  &+-O-CO, CH2-O-CO), 
73.67 (CH2-CH-O-CO, CH2-CH-OH), 70.57 (CH2-CH2-O), 65.96 
(CH2-O-CO)  57.86 (O-CH3), 34.19 (CH-CH2-CH2), 33.94 (CH2-
CH-O-CO, CH2-CH-OH), 33.47 (O-CO-CH2), 31.64 (CH2-CH2-
CH3), 24.93 (CH-CH2-CH2), 22.52 (O-CO-CH2-CH2), 20.80 
(CH2-CH3), 13.99 (CH2-CH3) 
FTIR wavenumber (cm-1): 2858 (C-H, stretching), 1729 (C=O, 
stretching), 1341 (C-H, bending), 1106 (C-O, Stretching).  
PDL-b-PEG-b-PDL -: 1H NMR (400 MHz, CDCl3į± 4.80 
(CH-O-CO, m, 37H), 4.24 (CH2-O-CO, t, 4H), 3.66 (O-CH2-
CH2-O, s, 409H), 2.41 ± 2.18 (O-CO-CH2, m, 78H), 1.75 ± 
1.39 (CH2-CH2-CH-CH2, m, 218H), 1.37 ± 1.12 (CH2-CH2-CH2-
CH3, m, 226H), 0.97 ± 0.77 (CH2-CH3, t, 140H). 
13C NMR (101 MHz, CDCl3) į  &+-O-CO, CH2-O-CO), 
73.70 (CH2-CH-O-CO, CH2-CH-OH), 70.56 (CH2-CH2-O), 64.11 
(CH2-O-CO),  34.20 (CH-CH2-CH2), 33.94 (CH2-CH-O-CO, CH2-
CH-OH), 33.47 (O-CO-CH2), 31.65 (CH2-CH2-CH3), 24.95 (CH-
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CH2-CH2), 22.52 (O-CO-CH2-CH2), 20.79 (CH2-CH3), 13.99 
(CH2-CH3) 
6\QWKHVLVRI%ORFN&RSRO\PHURIİ-Caprolactone 
A di-EORFN $% W\SH FRSRO\PHU RI İ-caprolactone was 
synthesised  using mPEG as initiator and TBD as catalyst17. 
Briefly, mPEG (6 g, 1.2 mmol) was added in a flask containing 
İ-caprolactone (7 g, 61.3 mmol), heated to 110°C and stirred 
for 10 min to make a uniform mixture under a nitrogen 
atmosphere. TBD (0.17 g, 1.2 mmol) was dissolved in 
anhydrous acetone (500µl) and added to the mixture via a 
syringe and reaction was continued for 10 minutes under 
nitrogen atmosphere. The reaction mixture was cooled, 
quenched by adding benzoic acid (0.29 g, 2.4 mmol) solution 
in acetone and the resultant polymer was precipitated in cold 
methanol followed by precipitation in diethyl ether. The 
residual solvent was evaporated under vacuum to obtain 
purified material. Copolymer mPEG-b-PCL was recovered as 
an off-white powder with the percentage yield of 93.84% 
(12.20 g).  
1H NMR (400 MHz, CDCl3 į  &+2-O-CO, t, 2H), 4.07 
(CH2-O-CO, t, 100H), 3.66 (O-CH2-CH2-O, s, 522H), 3.40 (O-
CH3, s, 3H), 2.33 (O-CO-CH2, t, 100H), 1.74 ± 1.58 (CH2-CH2-
CH2, m, 200H), 1.46 ± 1.32 (CH2-CH2-CH2,m, 100H). 
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13C NMR (101 MHz, CDCl3į&+2-O-CO), 70.57 (CH2-
CH2-O), 64.13 (CH2-O-CO), 57.69 (O-CH3), 34.11 (O-CO-
CH2,), 28.35 (CH2-CH2-CH2), 25.52 (CH2-CH2-CH2), 24.57 
(CH2-CH2-CH2) 
&RSRO\PHU 6\QWKHVLVRIǔ-Pentadecalactone with 
mPEG-b-PDL (ABC Type) 
$ FRSRO\PHU RI ǔ-pentadecalactone was synthesised using 
mPEG-b-PDL as initiator via a reported procedure31. Briefly, 
mPEG-b-3'/  J  PPRO DQG ǔ-pentadecalactone 
(0.75 g, 3.12 mmol) were dissolved in anhydrous toluene 
(10mL) and transferred into a flask containing Novozyme-435 
(0.075 g, 10% weight of pentadecalactone). The reaction 
mixture was than heated to 70°C and allowed to react for 3 
hrs, then cooled and an excess of cold acetone was added. 
The reaction mixture was then filtered to remove the catalyst, 
and concentrate up to the volume of 30mL. The solution was 
again filtered to remove insoluble copolymer and 
homopolymer, if any. The filtrate was then concentrated and 
precipitated in cold methanol to remove any unconverted 
monomer followed by drying in vacuum. Copolymer mPEG-b-
PDL-b-PPDL was recovered as a white sticky solid with the 
percentage yield of 61.37% (2.24 g).   
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mPEG-b-PDL-b-PPDL-:1H NMR (400 MHz, CDCl3į &+-
O-CO, m, 38H), 4.28 ± 4.17 (CH2-O-CO, t, 2H), 4.08 (CH2-O-
CO, m, 14H), 3.66 (O-CH2-CH2-O, s, 505H), 3.39 (O-CH3, s, 
3H), 2.32 (O-CO-CH2, m, 92H), 1.77 ± 1.42 (CH2-CH2-CH-CH2, 
O-CO-CH2-CH2, m, 243H), 1.28 (CH2-CH2-CH2-CH3, CH2-CH2, 
m, 374H), 0.88 (CH2-CH3,t, 121H). 
13C NMR (101 MHz, CDCl3į&+-O-CO-CH2), 173.03 
(CH-O-CO), 73.68 (CH2-CH-O-CO), 70.56 (CH2-CH2-O), 64.38 
(CH2-O-CO), 58.58 (O-CH3),  34.40 (O-CO-CH2), 34.19 (CH-
CH2-CH2), 33.94 (CH2-CH-O-CO), 33.46 (O-CO-CH2), 31.64 
(CH2-CH2-CH3), 29.77 ± 29.00 (pentadecalactone-CH2), 28.65 
(pentadecalactone-CH2), 25.93 (pentadecalactone-CH2), 24.98 
(CH-CH2-CH2, pentadecalactone-CH2 ), 22.51 (O-CO-CH2-
CH2), 20.81 (CH2-CH3), 13.98 (CH2-CH3). 
3.3 Results  
3.3.1 Synthesis and Characterisation of Homopolymers 
of į-Decalactone 
The synthetic route for synthesis of poly(decalactone) (PDL)  
homopolymer is shown in scheme 3-523RIį-decalactone 
was performed at either 5°C or at room temperature to 
generate homopolymers with end-terminal functionality. 
Conversion was monitored using 1HNMR by integrating the 
peak at 4.3 ppm corresponding to the proton adjacent to the 
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cyclic ester in monomer (figure 3-1, position 1) and 4.9 ppm 
which was corresponds to the proton adjacent to the ester 
bond in polymer (figure 3-3, position 8). Characterisation data 
was obtained after precipitating the quenched reaction 
mixture in cold methanol, which removed the unconverted 
monomer and inactive catalyst (figure 3-2).  
(I) 
 
(II) 
 
Scheme 3-1 5LQJ RSHQLQJ SRO\PHUL]DWLRQ RI į-decalactone catalysed by 
TBD using different initiators. (RT ± room temperature) 
The pure polymer was separated from methanol by 
centrifugation and any solvent residue was removed under 
vacuum. 7KH REWDLQHG SRO\PHU RI į-decalactone was 
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amorphous and therefore no melting point was observed in 
DSC analysis, while Tg of the polymer was ~ -54°C (table 3-1, 
figure 3-4). 
 
Figure 3-1 1+105 RI į-decalactone acquired in chloroform-d. Inset 
showing zoomed spectra between 3.3 and 5.0 ppm. 
 
Figure 3-2 1HNMR spectra of propargyl PDL before and after purification of 
polymer. Purification was done by precipitating the quenched reaction 
mixture in cold methanol 
1 
1 
2 
2 
3 
4 5 
6 
6 
6 
7 
3 
4 
7 
6 
5,6 
4 
2 
8 9 
8 
9 
1 
9 8 
4.9 4.7 4.5 4.3 4.1 3.9 3.7 3.5 3.3 
Propargyl -PDL 
Before Purification 
After Purification 
Catalyst 
Unconverted  
Monomer 
Unconverted  
Monomer 
After conversion 
After conversion 
CHAPTER 3 
Page | 96  
 
 
 
 
Figure 3-3 1HNMR spectra of propargyl-PDL, BZD-PDL and Gly-PDL 
acquired in CDCl3. 
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Figure 3-4 DSC plot of propargyl PDL. The presented trace was acquired 
from second cycle. 
1HNMR of the synthesised polymers with assigned peaks are 
shown in figure 3-3. Proton integration of peaks at 4.9 ppm 
and 4.67 ppm (for propargyl-PDL), or 5.52 and 4.68 ppm (for 
BZD-PDL) were used to calculate the molecular weight of 
polymer. Carbon NMR was also acquired to characterise the 
structure and to check the purity however; the peaks of 
carbons present in the initiators were not prominent compared 
to the signals of the carbons of PDL backbone (figure 3-5). 
The peak positions in NMR for poly(decalactone) were 
matched with the previously reported values suggesting the 
successful synthesis of polymer18. 
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Figure 3-5 13Carbon NMR of BZD-PDL, propargyl-PDL and Gly-PDL acquired 
in CDCl3. 
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Size exclusion chromatography (SEC) using chloroform as 
eluent and polystyrene as reference polymer gave a unimodal 
size distribution with narrow polydispersity for all polymers. 
However, the Mn observed by SEC was almost half compared 
to the molecular weight calculated by proton NMR (table 3-1, 
figure 3-6). Additionally, the integral of the end group proton 
resonance at 3.5 ppm in 1HNMR was observed to be double 
that of the expected integrals. These data indicates either 
presence of an additional initiator or chain cleavage due to 
back biting (transesterification) obstructing the synthesis of 
polymer up to target molecular weight.   However, SEC traces 
obtained (THF as eluent) using PMMA as reference polymer 
gave the Mn values, which matched with the calculated 
molecular weight by NMR (figure 3-7). 
Syntheses of polymers were also tried in the presence of 
solvents (chloroform, toluene, and acetonitrile) in attempts to 
improve polymerisation control. However, it was found that 
TBD was not an effective catalyst while used in the above 
PHQWLRQHG VROYHQWV IRU 523 RI į-decalactone. A decrease in 
the catalytic efficiency of TBD for the ROP of lactide in some 
solvents has also been reported earlier22. 
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Figure 3-6 SEC traces of (A) BZD-PDL, (B) propargyl-PDL and (C) Gly-PDL,  
which were acquired using chloroform as eluent and molecular weight was 
calculated against polystyrene as internal standard. 
A 
B 
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Figure 3-7 SEC traces of (A) BZD-PDL and (B) propargyl-PDL using THF as 
eluent. Molecular weight was calculated against PMMA as internal standard. 
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Run Initiator 
M/I 
ratio 
Temp. 
(°C) 
Time 
(hrs) 
Catalyst 
(Mole%) 
Conversion 
by NMR 
(%) 
Mn by 
NMR 
(KDa) 
Mn by SEC 
(Chloroform) 
(KDa) 
Mw/Mn Tg (°C) Tm (°C) 
1 
Cis-1,3-O- 
Benzylidene 
Glycerol 
100 5 11 2.5 89 15.3 8.8 1.21 ND ND 
2 
Propargyl 
Alcohol 
100 RT 11 2.5 87 14.8 7.5 1.18 -54.2 ND 
3 Glycerol 100 RT 11 2.0 88 15.1 8.5 1.15 ND ND 
4 
Poly(Ethylene 
Glycol) 
150 40 8 2.5 89 10.3 16.2 1.15 -53.3 47.0 
5 
Poly(Ethylene 
Glycol) 
methyl ether 
150 50 7 2.5 91 11.3 19.5 1.17 -54.6 54.6 
6* 
Poly(Ethylene 
Glycol) 
methyl ether 
52 110 
10 
min 
2.0 99 10.7 19.3 1.31 ND ND 
7$ mPEG-b-PDL 12 70 3 
10.0 
(% wt) 
98 12.9 21.8 1.25 -52.7 
54.7, 
88.0 
Table 3-1 Summary of experimental details and molecular weight obtained after ROP of į-GHFDODFWRQHİ-caprolactone and 
$ǔ-pentadecalactone. (ND- not determined, M/I - monomer/initiator, Tg - glass transition temperature, Tm - melting 
temperature). 
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3.3.2 Synthesis and Characterisation of Block 
Copolymers of į-Decalactone 
Block copolymers RI į-decalactone were synthesised at a 
temperature above the melting point of polyethylene glycol to 
avoid the use of added solvents in reaction (scheme 3-1). The 
target molecular weight of PDL chain for both copolymers was 
5 KDa. It was observed that increases in the catalyst loading 
accelerate the conversion rate. Reaction kinetics was 
monitored by 1HNMR and SEC, and the acquired data 
suggested that the reaction followed first order kinetics. No 
back-biting/transesterification reaction was observed 
regardless of the time and concentration of catalyst (up to 5 
mol% to monomer) (figure 3-8, 3-9 and table 3-2). Onset of 
homopolymer formation was observed from the very 
beginning of the reaction (figure 3-8). These data suggested 
that the homo-polymerisation was because of a competing 
ROP initiated by an unknown initiator and not by a 
transesterification reaction (chain cleavage via backbiting 
during polymerisation).  
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Figure 3-8 1HNMR spectrum and SEC trace of mPEG-b-PDL (during kinetic 
study) after 9 hrs containing 5% of TBD as catalyst. SEC trace was 
obtained using chloroform as eluent and polystyrene as internal standard 
whereas 1HNMR was acquired in CDCl3. 
 
Time Conversion 
by NMR 
(%) 
Mn by 
SEC 
Peak 1 
PD  
Peak1 
Mn by 
SEC 
Peak 2 
PD  
Peak 2 
15 min 14.88 12596 1.02 1172 1.36 
30 min 20.97 13700 1.02 1662 1.37 
1 hr 34.78 15214 1.02 2814 1.23 
1.5 hr 45.02 15847 1.02 3312 1.21 
2 hr 52.28 16384 1.02 3878 1.16 
3 hr 61.60 17232 1.02 4451 1.14 
4 hr 68.60 17315 1.02 4576 1.13 
5.5 hr 69.77 17647 1.02 4659 1.13 
9hr 69.84 17624 1.02 4735 1.12 
Table 3-2 Data obtained from the kinetic study of mPEG-b-PDL synthesis. 
As shown in figure 3-8, peak 1 and 2 are corresponds to copolymer and 
homopolymer respectively. SEC traces were obtained using chloroform as 
eluent and polystyrene as internal standard (PD ± Polydispersity).  
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Figure 3-9 Reaction kinetics for ROP of į-decalactone using mPEG as 
initiator and TBD (5 mole%) as catalyst. Maximum 70% conversion was 
observed in this reaction. 
 
 
Figure 3-10 2YHUODSSHG)7,5VSHFWUDRIP3(*į-decalactone and mPEG-b-
PDL copolymer. 
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Figure 3-11 1HNMR of mPEG-b-PDL and PDL-b-PEG-b-PDL copolymer 
acquired in CDCl3 
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Figure 3-12 Carbon13 NMR of mPEG-b-PDL and PDL-b-PEG-b-PDL 
copolymer acquired in CDCl3.   
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Figure 3-13 SEC traces of initiators and different block copolymers of į-
decalactone, which were obtained using chloroform as eluent and 
polystyrene as internal standard. 
The PDL homopolymer was separated from block copolymers 
by washing the reaction mixture with excess of petroleum 
ether (2-3 times). PDL is freely soluble in petroleum ether 
whereas PEG is insoluble, and hence PDL block copolymers 
were precipitated leaving homopolymer PDL in ether. FTIR, 
1HNMR and 13CNMR of the synthesised block copolymers with 
assigned peaks are shown in figure 3-10, 3-11 and 3-12. 
Molecular weights were calculated through 1HNMR by 
comparing the number of protons adjacent to the PDL ester 
link at 4.9 ppm with respect to protons of initiator (PEG) at 
3.6 (3.3 ppm with mPEG) and the protons adjacent to the 
ester bond created after ring opening of decalactone by PEG-
OH at 4.2 ppm. 
 
10 11 12 13 14 15 16 17
Retention Time (Min.) 
PEG4K mPEG5K PDL-b-PEG-b-PDL mPEG-b-PDL mPEG-b-PDL-b-PPDL
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Figure 3-14 DSC plot of (A) mPEG-b-PDL and (B) PDL-b-PEG-b-PDL, 
obtained from second cycle. 
Both copolymer showed unimodel distribution in SEC traces 
however, tailing was detected for mPEG-b-PDL (figure 3-13), 
which might be due to the presence of some free mPEG. 
Number average molecular weight (Mn) determined by SEC for 
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copolymers were almost twice those of the molecular weight 
calculated by 1HNMR (table 3-1). Synthesised copolymers 
were also characterised by DSC to determine the change in 
thermal properties. The block copolymers showed the melting 
points corresponding to PEG, as well as a low glass transition 
temperatures (Tg) attributed to amorphous PDL, thus 
suggesting the formation of a semicrystalline polymer (figure 
3-14). The number average molecular weight (Mn) by SEC, 
molecular weight by NMR, Tg, melting temperature (Tm) and 
other experimental details are summarised in table 3-1. The 
molecular weight calculated by 1HNMR was used for the 
calculations in further experiments. 
3.3.3 Synthesis and Characterisation of block 
&RSRO\PHURIİ-Caprolactone 
 
Scheme 3-2 Ring opening polymerizatiRQ RI İ-caprolactone using TBD as 
catalyst 
The synthetic route to produce poly(caprolactone) is shown in 
scheme 3-2. Approximately 99% of monomer was converted 
to polymer in 10 minutes of reaction time at 110°C. The target 
molecular weight for mPEG-b-PCL was aimed to be similar to 
the mPEG-b-PDL (i.e. 10 KDa), in order to carry out the 
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appropriate comparison of this copolymer with novel block 
copolymers of į-decalactone.  
mPEG-b-PCL was characterised by NMR and by SEC to check 
the purity of obtained polymer and to determine the molecular 
weight (figure 3-15,3-16). Molecular weight was calculated by 
1HNMR through the integral of the protons of initiator, protons 
adjacent to the caprolactone ester bond and the protons 
adjacent to the ester bond created after ring opening of 
caprolactone by PEG-OH at 3.4, 4.0 and 4.2 ppm respectively. 
The peak positions in NMR were matched with the previously 
reported values17. The obtained characterisation results are 
reported in table 3-1. The characterisation data suggested the 
successful synthesis of pure mPEG-b-PCL copolymer having an 
approximate molecular weight of 10 KDa.  
 
Figure 3-15 SEC trace of mPEG-b-PCL obtained using chloroform as eluent 
and polystyrene as internal standard. 
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Figure 3-16 1HNMR and 13CNMR of mPEG-b-PCL in chloroform-d. 
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3.3.4 Synthesis and Characterisation of block 
&RSRO\PHURIǔ-Pentadecalactone 
7KH V\QWKHVLV RI EORFN FRSRO\PHUV RI ǔ-pentadecalactone 
using mPEG-b-PDL as initiator was performed by following a 
reported method31 (scheme 3-3). Novozyme 435 is a well-
established catalyst for the ring opening polymerization of ǔ-
pentadecalactone and hence gave successful conversion of 
monomer to polymer in this study32. Reaction was performed 
in anhydrous toluene at 70°C, which resulted in 98% 
conversion of monomer to polymer in 3 hrs. The reaction was 
conducted in an inert atmosphere to avoid any initiation from 
water. The conversion of monomer to copolymer (mPEG-b-
PDL-b-PPDL) was monitored by 1HNMR in which, appearance 
of at 4.08 ppm suggested the ring opening polymerisation of 
ǔ-pentadecalactone. No change in peak positions of mPEG-b-
PDL in 1HNMR spectrum was observed after addition of PPDL 
block.  
 
Scheme 3-3 5LQJ RSHQLQJ SRO\PHUL]DWLRQ RI ǔ-pentadecalactone using 
lipase as catalyst 
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Figure 3-17 1HNMR and 13CNMR spectra of mPEG-b-PDL-b-PPDL acquired in 
chloroform-d 
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Figure 3-18 DSC plot of mPEG-b-PDL-b-PPDL, which was obtained from 
second cycle. 
The physical state of polymer was changed from a waxy 
material (mPEG-b-PDL) to a sticky solid (mPEG-b-PDL-b-
PPDL) after incorporation of the poly(pentadecalactone) block. 
The 1HNMR of copolymer was obtained in chloroform-d and 
the peaks positions of PPDL block were matched with the 
previously reported results32 (figure 3-17). Integrals of 
methylene protons in 1HNMR at 4.0, 4.8 and 3.3 ppm were 
used to calculate the experimental molecular weight of 
copolymer, which was 12.9 KDa whereas Mn obtained by SEC 
was 21.8 KDa with Mw/Mn (PDI) of 1.25 (table 3-1, figure 3-
13). 
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This block copolymer was further characterized by 13CNMR and 
DSC to confirm the structure and to determine the effect on 
thermal properties due to the presence of poly(penta 
decalactone) (PPDL) block. Peak positions of the PPDL block in 
13C NMR spectra were also matched with the reported values32 
(figure 3-17).  The Tg of mPEG-b-PDL-b-PPDL copolymer did 
not change when compared to mPEG-b-PDL however the 
graph showed two distinct melting peaks which corresponded 
to the individual PEG and PPDL blocks (figure 3-18). The 
melting temperature observed for the PPDL block was ~88°C 
after polymerisation with mPEG-b-PDL while the Tg of this 
block (PPDL) was not detectable by DSC27. Characterisation 
data obtained for this copolymer confirmed the successful 
synthesis and purification of the desired triblock copolymer 
(ABC type). 
3.4 Discussion 
6\QWKHVLVRIKRPRSRO\PHUVDQGFRSRO\PHUVRIį-decalactone 
were performed under mild conditions using a procedure 
reported by Martello et. al. with slight modification in order to 
develop a green synthesis approach. In contrast to the 
synthesis procedure reported by Martello et. al., any 
conversion of monomer to polymer was not observed using 
catalyst quantities less than 1.5 mol% to the monomer. 
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Though, it was observed that reactions at low temperature 
gave higher conversion and no further reaction occurred after 
a certain conversion (maximum 91% after which 
thermodynamic equilibrium was achieved). This latter result 
was analogous to those reported by Martello et. al18.  
Poly(decalactone) homopolymers were prepared to understand 
the difference in physicochemical properties compared to 
FRSRO\PHUVRI3'/'XULQJ WKHV\QWKHVLVRIFRSRO\PHUVRIį-
decalactone, the formation of poly(decalactone) homopolymer 
suggested the presence of an initiator additional to the added 
PEG or alcohol in reaction mixture. The most probable reasons 
that can be associated with the additional polymer synthesis 
are: 
1. Impurities present in the commercial available monomer. 
7KHSXULW\RIį-decalactone was checked by 1HNMR and a 
peak at 3.5 ppm in spectrum suggested the existence of 
open form of the lactone ring with hydroxyl end group 
(figure 3-1 inset). This hydroxyl group could have acted as 
initiator, which could not be separated during the 
purification procedure for the monomer.  
2. Traces of water present. It may have been that the starting 
materials were not dried completely during the drying 
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procedure and hence residual water could have acted as 
initiator.  
3. Mechanism of TBD for ROP proposed by Pratt et al22. There 
is a reversible step in which an alcohol group is generated 
(shown in red in scheme 3-4) which can potentially act as 
initiator for other molecules activated by TBD. Jaffredo et. 
al. used TBD as catalyst as well as initiator for the ROP of 
ǃ-butyrolactone33 suggested that TBD has potential to act 
as a initiator.  
 
Scheme 3-4 Ring opening mechanism of TBD suggested by Pratt et. al.22 
Fortunately, the difference in solubility of co-polymers and 
homo-polymers in ether offered a route to separate the 
desired co-polymer from the homopolymer impurity. Due to 
the formation of undesired homopolymer during synthesis, the 
target molecular weight would not achieve based on degree of 
polymerisation. Representative molecular weight 
determination using 1HNMR was only feasible with pure 
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copolymers because of the absence of undesired homopolymer 
in samples. In case of propargyl-PDL, BZD-PDL and GLY-PDL, 
Mn observed by SEC was considered as the molecular weight 
of polymer which half to the molecular weight calculated by 
1HNMR. In contrast, Mn detected by SEC for copolymers were 
almost twice to the molecular weight calculated by 1HNMR. 
This may have been because of the interaction of PEG with 
SEC column (PLgel Mixed-D). The Mn of PEG itself detected by 
SEC was almost twice the molecular weight reported by 
supplier (PEG4000 Mn-7.7 KDa, mPEG5000 Mn- 10.8 KDa).    
The main objective of the project is to synthesise the 
DPSKLSKLOLFEORFNFRSRO\PHUVRIį-decalactone and to evaluate 
their ability as drug delivery carriers. Therefore, an extensive 
study of the chemistry behind the polymer formation from 
additional initiator was not pursued. Other catalysts such as 
stannous octanoate and scandium triflate were also 
investigated for ROP of į-decalactone. Nevertheless, TBD was 
proved to be the most effective catalyst for the ROP of į-
decalactone. All the obtained characterisation data suggested 
the successful synthesis and purification of block copolymers 
of į-decalactone.   
TBD was reported as a very efficient catalyst for the ROP of İ-
caprolactone17 and therefore it was used for the synthesis of 
CHAPTER 3 
Page | 120  
 
copolymer of İ-caprolactone. Compared to the ROP of į-
decalactone, no polymer synthesis from additional initiator 
ZDV REVHUYHG GXULQJ 523 RI İ-caprolactone with TBD as 
catalyst. This finding suggested that the impurity present in 
WKH PRQRPHU į-decalactone could be the probable initiator 
which caused the formation of the homopolymer of 
Poly(decalactone) during copolymer synthesis.  
$IWHUWKHVXFFHVVIXOV\QWKHVLVRIFRSRO\PHUVRIį-decalactone 
and İ-caprolactone, ROP of ǔ-pentadecalactone was 
investigated. The solubility of poly(pentadecalactone) (PPDL) 
in organic solvents (especially non-chlorinated) has been 
considered as a major issue limiting its applicability in drug 
delivery. Hence, the aim was to make a copolymer of 
pentadecalactone, which would be soluble in acetone and 
other similar solvents preferable in pharmaceutical 
industries34. To do this, ROP of ǔ-pentadecalactone using 
mPEG-b-PDL as initiator was tried with TBD (1 mole% to 
monomer) at 110°C in bulk17. During the reaction it was found 
that at higher temperature the chain of mPEG-b-PDL was 
cleaved and the ring of decalactone was regenerated as 
detected by 1HNMR (figure 3-19). Based on this result it was 
concluded that TBD was not a good catalyst in the selected 
conditions for copolymer synthesis. The depolymerisation 
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UHYHUVLEOH SURFHVV REVHUYHG ZLWK SRO\į-decalactone) could 
EH DVVRFLDWHG ZLWK WKH WKHUPRG\QDPLF HTXLOLEULXP RI į-
decalactone with TBD at high temperature18. 
 
Figure 3-19 1HNMR spectra of (A) at 0 hr and (B) after conversion of the 
reaction mixture obtained during the attempt of ROP of ǔ-
pentadecalactone using TBD as catalyst and mPEG-b-PDL as initiator.  
Tin (II) trifluoromethanesulfonate was another catalyst tried 
(1 mole% to monomer) for copolymer synthesis but no 
conversion was observed at 110°C. Stannous octanoate as 
catalyst (1 mole% to monomer) was also investigated for the 
same but only 10-15% of conversion (by 1HNMR) was 
observed in 2 days. Finally, the use of lipase as catalyst gave 
the desired product without any side reactions.  
A 
B 
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The molecular weight of poly(pentadecalactone) block was 
varied in attempt to modulate solubility of the final copolymer 
in acetone. It was found that increasing in the PPDL block 
molecular weight above 2 KDa in the mPEG-b-PDL-b-PPDL 
copolymer reduced its solubility in acetone. Therefore, a PPDL 
block of less than 2 KDa molecular weight was targeted to 
synthesise the subsequent copolymer. This copolymer was 
also characterised by NMR, SEC and DSC however, the 
synthesis confirmation of such triblock copolymer with NMR 
alone is difficult. Absence of substantial change in peak 
positions of poly(pentadecalactone) block after 
copolymerisation in NMR spectrum reduce the efficiency of this 
technique as a tool of synthesis confirmation. A physical 
mixture of mPEG-b-PDL and PPDL could generate a similar 
spectrum. Therefore, the synthesis confirmation is mainly 
relying on SEC and a clear shift in SEC trace of mPEG-b-PDL-
b-PPDL compared to mPEG-b-PDL confirmed the synthesis of 
desired copolymer. It was expected that the incorporation of 
crystalline block (PPDL) to mPEG-b-PDL could have increased 
the crystallinity of mPEG-b-PDL. However, the determination 
of exact change in percent crystallinity was not possible since 
two melting temperatures were observed.   
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3.5 Conclusion 
In this chapter, successful synthesis of homopolymers and 
novel block copolymers based on renewable monomers via 
ROP using organic (TBD) and enzyme (novozymes-435) 
catalysts has been reported. Small molecule initiators such as 
propargyl alcohol, cis-1,3-O-benzylideneglycerol were 
successfully initiaWHG WKH SRO\PHULVDWLRQ RI į-decalactone at 
room temperature in the absence of solvents. However, it was 
observed that polymers could also be obtained without using 
an added alcohol initiator under certain circumstances. The 
reason for this unexpected polymerisation was not fully 
investigated owing to time constraint.  
Block copolymers (mPEG-b-PDL and PDL-b-PEG-b-PDL) were 
synthesised at temperature above the melting point of PEG to 
avoid the use of solvents.  All block copolymers were 
successfully separated from homopolymer contamination by 
washing them with ether. Characterisation data of the 
resultant purified polymers were established by FTIR, NMR, 
SEC and DSC. The acquired data suggested the successful 
synthesis and purification of the desired products. Copolymers 
of PEG with PDL displayed both Tm and Tg in thermal analysis, 
indicated the presence of both crystalline and amorphous 
regions. A diblock copolymer (i.e. mPEG-b-PCL) of 
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poly(caprolactone) of similar molecular weight was also 
synthesised using TBD as catalyst and characterised fully. This 
copolymer will be used as a standard for comparison in future 
formulation studies. 
Novozymes-435 was found to be an effective catalyst for the 
523 RI ǔ- pentadecalactone to generate an ABC type of 
triblock copolymer (mPEG-b-PDL-b-PPDL). It was observed 
that increases in the molecular weight of poly 
(pentadecalactone) block above 2 KDa decreased the solubility 
of the resultant copolymer in acetone. The polydispersity 
index detected by SEC for all synthesised novel block 
copolymers was found to be less than 1.3.  
7KH V\QWKHVLV RI SRO\PHUV DQG FRSRO\PHUV RI į-decalactone 
was performed using organic catalysts under mild conditions 
without using any solvents except in the case of 
FRSRO\PHULVDWLRQ RI ǔ-pentadecalactone. The investigated 
procedure for the synthesis of novel amphiphilic copolymers of 
į-decalactone can thus be considered as a more sustainable 
and less environmentally-costly method compared to the 
standard routes to synthesise amphiphilic block copolymers.  
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4.1 Introduction 
Aqueous solubility of active pharmaceutical ingredients (API) 
is one of the important determining factors affecting their 
absorption in vivo. Poor absorption and therefore low 
bioavailability after oral administration is often attributed to 
the poor aqueous solubility of drugs. On average 
approximately 40% of drugs available in the market and 
around 75% of drugs currently in development stage are 
poorly soluble in water1. The approaches generally utilised to 
solubilise the drugs in water include the use of co-solvents, 
solid dispersions, surfactants, dendrimers etc1. 
Micelles/surfactants are widely used drug delivery vehicles 
used to enhance the bioavailability of pharmaceutically active 
ingredients1, 2. However, small surfactant molecules with 
generally high critical micelle concentration (CMC) values can 
dissociate upon dilution in the bloodstream and thus can 
release the loaded drug before reaching the target site3. To 
address this problem, polymeric micelles having low CMC 
values have been developed and some have been successfully 
utilised to solubilise hydrophobic drugs3. Many academic 
science papers have been published in this field, indicating the 
potential of polymeric micelles as effective drug delivery 
carriers4,5,6.    
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Figure 4-1 Proposed assembly of (A) low molecular weight surfactant and 
(B) amphiphilic block polymer after dispersion in water. 
Amphiphilic block copolymers with a hydrophobic and a 
hydrophilic block are readily self-assembled into micelles in 
aqueous media to generate core shell structures (figure 4-1) 
and can have low CMC values7. The use of PEG (hydrophilic 
polymer) WRJHQHUDWHDK\GURSKLOLFµFRURQD¶KDVEHHQUHSRUWHG
to hinder the uptake of micelles by the reticulo endothelial 
system (RES) thus improving the circulatory time of polymeric 
micelles in vivo4, 6. Long circulating drug delivery systems are 
useful in cancer therapy because of their accumulation in 
tumor by the Enhanced Permeability and Retention (EPR) 
effect8. Several core forming blocks (hydrophobic polymers) 
such as poly(caprolactone) (PCL), poly(lactide) PLA, 
poly(lactide-co-glycolide) (PLGA), poly(propylene oxide), 
poly(L-lysine), poly (styrene), poly(aspartic acid) etc. have 
been successfully utilised to synthesise amphiphilic block 
Hydrophilic Hydrophobic 
A B 
Hydrophilic Head 
Hydrophobic 
tail 
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copolymers3, 6, 7. However, hydrophobic polymer obtained 
from renewable/sustainable feedstocks offers advantages over 
those polymers which are synthesised from petrochemicals 
sources in terms of low-toxicity and source of origin9. 
The amphiphilic block copolymers derived from renewable 
lactic acid and glycolic acid with PEG has been the polymers of 
choice for various pharmaceutical applications to date. Micelles 
prepared from PLA and PLGA block copolymers with 
hydrophilic PEG-type shells have already shown their potential 
in solubility enhancement10, sustained release11, tumor 
targeting12, stimuli-responsive drug delivery13 etc. However, 
continuous efforts are in place to develop other sustainable 
polymers which can overcome certain problems associated 
with PLA and PLGA block copolymers such as sub-optimal 
degradation profile14 and poor drug loading15.    
The successful synthesis of novel amphiphilic block 
copolymers with alkyl side chains using renewable monomers 
were reported in chapter 3. The aim of the studies performed 
in this chapter is to evaluate the efficiency of those 
synthesised novel block copolymers to encapsulate 
hydrophobic drug-like molecules. The results obtained from 
these amphiphilic block copolymers micelles were compared 
with block copolymer micelles of mPEG-b-PCL in terms of size, 
CHAPTER 4 
Page | 132  
 
loading efficiency and release profile. Poly(caprolactone) block 
copolymer was selected for the comparative studies because 
of its source of origin (petroleum) and its prior investigation 
for drug delivery applications, against which the novel PDL 
block copolymers could be evaluated.  
Micelles of block copolymers were fabricated using a revised 
nano-precipitation method16 as this offers advantages over the 
other methods such as dialysis, emulsion and solvent 
evaporation6. For instance, with the solvent evaporation (film 
method) method, incomplete reconstitution of the polymeric 
film was observed in aqueous solvent resulting in polymer loss 
and consequently decreases in the micelles efficiency6. Hence, 
the solvent evaporation method was considered not suitable 
for the PDL block copolymers because of their expected high 
hydrophobicity. Emulsion methods for micelle preparation 
were not preferred because they generally require the use of 
volatile water immiscible solvents such as dichloromethane 
(DCM) and chloroform5, 6. In the dialysis method, use of 
organic solvents in dialysis bag is required to fabricate 
micelles. However, solvents other than DMSO are not 
recommended for use with the regenerated cellulose 
membrane and none of the solvents commonly used for the 
preparation of micelles using dialysis method were 
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recommended for use with the cellulose membrane. The 
commonly used non-volatile organic solvents in the dialysis 
method are DMF, DMSO and DMAc,17,18 which generally 
removed from the formulation by dialysis. Since these 
solvents are not compatible with dialysis membrane and thus 
could damage the membrane that can cause undesired loss of 
micelles formulation in release medium. 
To check the efficiency of poly(decalactone) micelles in 
encapsulation of hydrophobic molecules, Nile Red (NR) was 
chosen as a model hydrophobic compound. The aqueous 
solubility of NR is less than 1µg/mL19 and therefore it is a good 
candidate for the evaluation of polymeric micelles as 
encapsulate. Additionally, NR loaded micelles can be used for 
various imaging studies, if needed20.  
 
Curcumin was selected as a model drug to evaluate the 
encapsulation efficiency and release behaviour using novel 
PDL block copolymer micelles. Curcumin is a natural 
chemotherapeutic agent obtained from the rhizome of the 
Curcuma longa Linn. It has attracted much attention recently 
Curcumin Nile Red 
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due to its various claimed pharmacological properties 
combined with lack of systemic toxicity at high dose21. 
However, the therapeutic use of curcumin has been hampered 
due to its low aqueous solubility and poor in vivo stability. 
Numerous literature precedence is available discussing the 
applications and drawbacks associated with the use of 
curcumin as well as the approaches to overcome those 
drawbacks22,23. It was proposed that the encapsulation of 
curcumin in nano-sized drug delivery carriers could be a better 
approach to overcome the solubility and stability problems 
associated with curcumin24, 25. Several nano-sized 
formulations like nanoparticles, micelles, nanogels, liposomes 
were reported previously to enhance the solubility, stability 
and thus bioavailability of curcumin24,25.  
Recently mixed micelles formulation using Pluronic (PEO-PPO-
PEO) co-polymers was reported for the improved delivery of 
curcumin26, 27. It has been also demonstrated that mixed 
micelles prepared from two or more different block copolymers 
were able to enhance the formulation stability and drug 
loading efficiency compared to the micelles prepared from 
single block copolymer28. Therefore, curcumin loaded mixed 
micelle formulation was also prepared using mPEG-b-PDL and 
mPEG-b-PCL copolymer.  
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4. 2 Methods 
4.2.1 Determination of CMC of Poly(decalactone) and 
Poly(caprolactone) Block Copolymers Micelles 
The CMC of block copolymers of poly(decalactone) (i.e. mPEG-
b-PDL, PDL-b-PEG-b-PDL and mPEG-b-PDL-b-PPDL) and 
Poly(caprolactone) (mPEG-b-PCL) were determined by using 
the pyrene 1:3 fluorescence ratio method29. The results were 
analysed using GraphPad Prism software (version 6.4). 
Detailed procedures for CMC determination are described in 
chapter 2.  
4.2.2 Empty and Dye/Drug Loaded Micelles Preparation 
from PDL and PCL Block Copolymers  
Micelles of synthesised block copolymers were prepared by a 
single-step nano-precipitation method with minor 
modification30. Briefly, block copolymer (50 mg) of PDL or PCL 
was dissolved in 5 mL of acetone and this solution was added 
drop-wise into 10 mL of HPLC grade water under stirring 
(1000 rpm). The solution was then stirred for 3 hrs at room 
temperature and left overnight (open vial) to ensure the 
complete removal of acetone. The micellar solution was then 
filtered through a membrane syringe filter (pore size: 220 nm) 
(Millex-LG, Millipore Co., USA) and the filtrate was used for 
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the analysis of size and zeta potential after appropriate 
dilutions. 
Drug or dye-loaded micelles were prepared by a similar 
method used to prepare blank micelles. Briefly, curcumin (2 
mg) or nile red (NR) (1 mg) was dissolved along with the 
polymer (50 mg) in acetone (5 mL) and added drop wise in to 
HPLC grade water (10 mL). The micellar solution was stirred 
for 3 hrs and then stored overnight to remove the traces of 
acetone. Curcumin is light sensitive and hence the whole 
process was performed in the dark (vials covered using 
aluminium foil). Mixed micelles using mPEG-b-PDL and mPEG-
b-PCL copolymer were prepared to understand the effect on 
curcumin loading content and release pattern. Mixed micelles 
were fabricated by physical mixing31 of both copolymer (25 
mg each) in acetone (5mL) and the method described above 
was employed to obtain curcumin-loaded mixed micelles.  
The unencapsulated NR was removed by filtering the micellar 
solution through a membrane filter (pore size: 220 nm). 
Curcumin loaded micelles were purified by passing through 
PD10 Desalting Column (Sephadex G-25 Medium, GE 
Healthcare Life Sciences) in order to retain material of < 5K 
molecular weight and hence the collected solution was free 
from any unencapsulated drug. The curcumin-loaded micelles 
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were filtered through a membrane filter (pore size: 220 nm, 
Millex-LG, Millipore Co., USA). Purified micelle solutions were 
then used for further characterisation. A part of the micellar 
solution was freeze dried for the determination of drug 
content. A pictorial presentation of preparation, purification 
and characterisation of curcumin loaded micelles is shown in 
figure 4-2.  
 
Figure 4-2 Pictorial representation of preparation, purification and 
characterisation of curcumin loaded micelles 
4.2.3 Preparation of Nano-emulsion from homopolymer 
of Poly(decalactone)  
An end-functional homopolymer of poly(decalactone) i.e. 
propargyl-PDL was used to make an oil-in-water 
nanoemulsion32 for comparative studies with blank micelles. 
Briefly, a solution of propargyl-PDL (50 mg) in 5 mL of 
acetone was added drop-wise into 10 mL of HPLC grade water 
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under stirring (1000 rpm). This procedure formed dispersed 
droplets of poly(decalactone) due to its immiscibility with 
water. The solution was then stirred for 3 hrs at room 
temperature and then stored overnight to remove the traces 
of acetone. The nanoemulsion was then filtered through a 
membrane syringe filter (pore size: 220 nm) (Millex-LG, 
Millipore Co., USA) and the filtrate was used for size and zeta 
potential analysis after appropriate dilutions. No stabiliser was 
used during the preparation of nanoemulsion.  
4.2.4 Characterisation of micelles for size, zeta 
potential and surface morphology 
For the size and polydispersity index measurements, micelle 
samples (50µg/mL) in HPLC grade water were analysed using 
a Malvern NanoZS instrument. The Z-average size (d.nm) has 
been reported, which was calculated by the instrument using 
the formula below33. 
Z-average 
diameter (Dz)  
= 
ƶ6i 
ƶ6i/Di) 
Where, Si is the scattered intensity from particle i and Di is the 
diameter of particle i obtained using the Stokes-Einstein 
equation.  
Surface zeta potential was measured from same instrument in 
HEPES 10mM buffer (pH-7.4). TEM was performed to confirm 
CHAPTER 4 
Page | 139  
 
the size and to determine the surface morphology. Samples 
were imaged on TEM grids without staining.  
The full experimental procedures for these methods are 
reported in chapter 2. All the measurements were performed 
on three different batches and the mean values were reported.  
4.2.5 Determination of Drug Content, Curcumin Stability 
and in vitro Release behaviour from Micelles. 
Drug Content (DC) and Encapsulation Efficiency (EE) of 
drug/dye in micelles were determined by dissolving a known 
amount of freeze dried sample (5-10 mg) of micelles in 
acetone followed by quantification of the drug/dye 
concentration. For the determination of NR concentration, the 
UV absorption of sample solutions was recorded at Ǌmax of 541 
nm using a UV spectrophotometer. The amount of NR was 
calculated using a standard calibration curve of NR (figure 4-
3).  
 
Figure 4-3 Standard calibration curve of Nile red. The UV-Vis absorbance of 
Nile red solution (in acetone) was measured at wavelength of 541nm. 
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For curcumin analysis, samples were excited at a fixed 
ZDYHOHQJWK Ǌex = 420 nm) and emission spectra were 
recorded in a range of 450 to 650nm34 using a fluorescence 
spectrophotometer. The excitation and emission slit widths 
were selected at 5 nm and the emission intensity at 524 nm 
was selected for drug content calculations. Amounts of 
curcumin present in the samples were then calculated using a 
standard calibration curve of curcumin (figure 4-4).  
 
 
Figure 4-4  (A) Fluorescence emission spectra of curcumin at different 
concentraWLRQLQDFHWRQHǊex -420 nm) and (B) Standard calibration curve 
of curcumin. The fluorescence emission of curcumin solution (in acetone) 
was measured at wavelength of 524nm. 
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DC and EE were calculated using the formula reported in 
chapter 2 and the results were reported as mean ± standard 
deviation (SD) from three different batches. 
The ability of mPEG-b-PDL micelles to protect the curcumin 
from degradation at physiological pH was tested using a 
reported method35. Freeze dried micelles containing curcumin 
equivalent to 100ug, were redispersed in 2mL of PBS (pH 7.4) 
and incubated at 37°C. For the preparation of control samples, 
free curcumin (100 µg) was dissolved in 2mL of phosphate 
buffer saline (PBS) with the aid of methanol and incubated at 
37° C35. At predetermined time intervals, 100 µL of the 
sample was withdrawn and diluted with acetone up to 1 mL. 
The amount of remaining curcumin was then determined using 
a fluorescence spectrophotometer by following the similar 
parameters used to determine DC.  
The release profile of curcumin from micelles was determined 
by a dialysis method35. Briefly, a calculated quantity of 
curcumin-loaded freeze dried micelles equivalent to 350µg of 
curcumin was dissolved in PBS (2mL) (pH-7.4). The micelle 
solution in PBS was then placed in dialysis tubing (Float-A-
Lyzer) having the molecular weight cut off (mwco) of 3.5-5 
KDa. The samples were dialysed against 500 mL of PBS (pH 
7.4) at 37°C. The release media was replaced with fresh PBS 
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every 24 hrs. The volume of solution in the dialysis tubing was 
measured at appropriate time intervals (every 6-12 hrs), and 
restored to the original with PBS, if necessary. Samples (100 
µL) were withdrawn directly from the dialysis tubing at 
predetermined time intervals and the volume of solution in the 
dialysis tubing was restored with fresh solvent. Samples were 
analysed after diluting with acetone using a fluorescence 
spectrophotometer to calculate the amount of curcumin 
remaining in the micelles. 
4.3 Results 
4.3.1 Determination of CMC of Poly(decalactone) and 
Poly(caprolactone) Block Copolymer Micelles 
The CMC values of PDL-b-PEG-b-PDL, mPEG-b-PDL, mPEG-b-
PCL and mPEG-b-PDL-b-PPDL were determined by plotting the 
graph between polymer concentration versus I1 and I3 peak 
intensity ratio of pyrene. The data (mean values) used to plot 
the graph is presented in table 4-1. The obtained curve was 
fitted using nonlinear regression (Sigmoidal, 4PL, X is on log 
scale) to determine the CMC value (figure 4-5).  The inflection 
point (IC50) of the sigmoidal curve suggesting the abrupt 
change in values was considered as the CMC value of the 
polymer. Further, 95%-confidence intervals of the CMCs were 
plotted to visualise any statistical difference in obtained CMC 
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values (figure 4-6). The CMC range detected for 
poly(decalactone) copolymers overlapped each other, 
suggested no statistical significant differences among them. 
The CMC value observed for mPEG-b-PCL was approximately 
2.5 times higher compared to the novel poly(decalactone) 
block copolymers micelles (table 4-2).  
Concentration 
 (µg/mL) 
I1/I3 mPEG-b-
PDL 
I1/I3 PDL-b-PEG-
b-PDL 
I1/I3 mPEG-b-
PDL-b-PPDL 
I1/I3 mPEG-b-
PCL 
0.001 1.5153 1.5269 1.5562 1.5469 
0.005 1.5145 1.5278 1.55331 1.5457 
0.01 1.5126 1.5249 1.5493 1.5379 
0.05 1.5019 1.5216 1.5391 1.5313 
0.1 1.4908 1.4995 1.5245 1.5211 
0.3 1.4562 1.4829 1.507 1.5179 
0.5 1.439 1.4709 1.4933 1.5084 
0.8 1.4331 1.4663 1.4708 1.4997 
1 1.4253 1.4434 1.4381 1.4757 
2 1.3801 1.4159 1.3596 1.4391 
4 1.3355 1.3746 1.3087 1.4061 
6 1.3185 1.3609 1.3021 1.3850 
8 1.3179 1.3467 1.2984 1.3618 
10 1.3105 1.3427 1.2976 1.3439 
15 1.3042 1.3384 1.2967 1.3347 
20 1.3009 1.3330 1.2955 1.3258 
25 1.297 1.3324 1.2934 1.3165 
30 1.2924 1.3328 1.2896 1.3131 
35 1.2916 1.3341 1.2877 1.3077 
40 1.2919 1.3316 1.2878 1.3073 
45 1.291 1.3307 1.2871 1.3070 
50 1.2927 1.3309 1.2873 1.3080 
Table 4-1 Intensity ratio of peak 1 and 3 of pyrene fluorescence spectrum 
acquired using different concentration of polymer in water. 
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Figure 4-5 CMC plot for (A) mPEG-b-PDL, (B) PDL-b-PEG-b-PDL, (C) 
mPEG-b-PDL-b-PPDL and (D) mPEG-b-PCL obtained by pyrene 1:3 peak 
ratio method. 
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Figure 4-6 Comparison of 95% confidence interval (IC50) of the CMC 
values of synthesised copolymers. IC50 value was obtained by non-linear 
curve fitting of CMC plot (sigmoidal, 4PL). 
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Sample 
CMC 
(µg/mL) 
Z-
average 
size 
(d/nm) 
(±SD) 
(Blank) 
PdI 
(Blank) 
Zeta 
Potential 
(mv) 
(±SD) 
Z-
average 
size 
(d/nm) 
(±SD) 
(NR 
Loaded)  
PdI  
(NR 
Loaded) 
Z-average 
size 
(d/nm) 
(±SD) 
(Curcumin 
Loaded)  
PdI  
(Curcumin 
Loaded) 
Zeta 
Potential 
(mv) 
(±SD) 
(Curcumin 
Loaded) 
aPropargyl 
PDL 
NA 149 ± 4 
0.04± 
0.02 
-70.5 ± 
3.0 
NA NA NA NA NA 
PDL-b-
PEG-b-PDL 
1.50  163 ± 7 
0.26± 
0.03 
-6.8 ± 
2.6 
58± 5 
0.32± 
0.02 
123± 7 
0.28± 
0.03 
-7.3 ± 0.9 
mPEG-b-
PDL 
1.33 34 ± 4 
0.12± 
0.02 
-3.1 ± 
0.8 
38± 3 
0.17±  
0.02 
40± 3 
0.14± 
0.02 
-2.8 ± 1.2 
mPEG-b-
PDL-b-
PPDL 
1.19 85 ± 5 
0.28± 
0.01 
-2.5 ± 
0.8 
83± 4 
0.38±  
0.02 
101± 9 
0.28± 
0.02 
-3.2 ± 1.8 
mPEG-b-
PCL 
3.34 36 ± 3 
0.14± 
0.02 
-1.2 ± 
1.2 
NA NA 40± 2 
0.12± 
0.02 
0.1 ± 1.3 
Table 4-2 Characterization data of polymeric micelles prepared from block copolymers of Poly(decalactone) and Poly(caprolactone). 
(CMC- critical micelles concentration, d/nm ± diameter in nanometer, NA - Not applicable, SD- Standard deviation, PdI ± polydispersity 
index, mv ± millivolt, NR- Nile Red). aNano-emulsion preparation of homopolymer. 
CHAPTER 4 
Page | 146  
 
4.3.2 Preparation and Characterisation of Empty 
Micelles.  
Nano-precipitation method was previously employed 
successfully for the incorporation of hydrophobic molecules 
inside micellar cores36, 37 and therefore this method is chosen 
for micelles preparation in the current study.    
Micelle solutions were filtered through a membrane filter in 
order to remove precipitates (if any) after complete removal 
of acetone. The recoveries of micellar suspension after 
filtration for mPEG-b-PDL, mPEG-b-PCL and PDL-b-PEG-b-PDL 
copolymer were ranged from 90 to 95%. However, the 
recovery of the micelle suspension of mPEG-b-PDL-b-PPDL 
was approximately 60% only. The Z-average size (in 
diameter) and polydispersity index obtained by DLS for empty 
amphiphilic block copolymers micelles are reported in table 4-
2. The mean particle size (Z-average size) produced by the 
DLS instrument was used here for the comparison. The Z-
average size is the intensity weighted harmonic mean size and 
the best value to report as defined by the International 
Organisation for Standardization in ISO 13321 and ISO 
2241238.  
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Sample Name 
Mean Size by Intensity 
(% intensity in bracket) 
Mean Size 
by Volume 
(± SD) 
 Peak 1 
(d/nm) 
Peak 2        
(d /nm) 
Peak 1 
(d/nm) 
PDL-b-PEG-b-PDL  
(Blank) 
32.7 
(47.2%) 
224.6 
(52.8%) 
29.0 ±3.0 
PDL-b-PEG-b-PDL  
(NR loaded) 
49.9 
(77.4%) 
365.4 
(22.6%) 
31.0 ±2.0 
PDL-b-PEG-b-PDL  
(Curcumin loaded) 
44.3 
(55.4%) 
143.7 
(44.6%) 
36.0 ±2.0 
Table 4-3 Average size by intensity and volume of PDL-b-PEG-b-PDL 
micelles in bimodal size distribution curve. (SD - standard deviation, d/nm 
± diameter of micelles in nanometer, NR ± Nile Red) 
Size detected for empty mPEG-b-PCL micelles was comparable 
to the size of mPEG-b-PDL micelles (table 4-2, figure 4-7). 
Intensity size distribution curve observed for mPEG-b-PDL and 
mPEG-b-PCL micelles was unimodal whereas micelles 
prepared from PDL-b-PEG-b-PDL gave bimodal distribution 
curve (figure 4-7). The average size by intensity detected for 
each peak along with the intensity percentage in bimodal 
distribution curve is shown in table 4-3. The bigger size 
micelles were expected in this sample due to the cloudy 
appearance of purified micellar solution (figure 4-8).  
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Figure 4-7 Size distributions by intensity (top) and by volume (bottom) of 
blank micelles determine by DLS method in water. 
 
Figure 4-8 Physical appearance of purified blank micelles in water obtained 
from different copolymers via nanoprecipitation method. 
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Figure 4-9 TEM images and size distribution histogram (analysed using 
ImageJ software) of empty (A) mPEG-b-PDL, (B) PDL-b-PEG-b-PDL, (C) 
mPEG-b-PDL-b-PPDL and (D) mPEG-b-PCL micelles. Arrow represents the 
presence of clusters in PDL-b-PEG-b-PDL micelles sample. Scale bar ± 
1000nm 
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Figure 4-10 TEM images of empty (A) mPEG-b-PDL, (B) PDL-b-PEG-b-PDL, 
(C) mPEG-b-PDL-b-PPDL and (D) mPEG-b-PCL micelles. Scale bar ± 
200nm. Arrow represents the presence of clusters in PDL-b-PEG-b-PDL 
sample. 
Micelles prepared from mPEG-b-PDL-b-PPDL copolymer gave 
the broadest size distribution determined by DLS with high 
polydispersity index when compared to the other PDL block 
copolymers (table 4-2, figure 4-7). However, the average size 
by volume detected for this sample was 41 ± 4 nm. The 
presence of small numbers of large size micelles increased the 
polydispersity and the Z-average size.  
All micelles samples were also imaged on TEM and were found 
that the micelles obtained from amphiphilic block copolymers 
were of roughly spherical in shape (figure 4-9, 4-10). TEM 
A B 
C D 
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image of mPEG-b-PDL-b-PPDL displayed the presence of a 
broad size range in the sample whereas mPEG-b-PDL and 
mPEG-b-PCL possessed narrower and more uniform size 
distribution (figure 4-9, 4-10). TEM image of the sample PDL-
b-PEG-b-PDL indicated the presence of some aggregates 
(clusters) of the micelles. Thus, it can be hypothesised that 
the bimodal distribution observed in the DLS analysis for this 
sample was due to the clusters formation (figure 4-10). Size 
histogram plotted using TEM images suggested that none of 
the micelles exhibits the size greater than 60 and 80 nm in 
mPEG-b-PDL and mPEG-b-PCL samples respectively. However, 
as expected PDL-b-PEG-b-PDL and mPEG-b-PDL-b-PPDL 
samples contains micelles of bigger size.  
Size detected for the nanoemulsion prepared from propargyl-
PDL homopolymer was found to be the biggest if the clusters 
of PDL-b-PEG-b-PDL micelles were ignored (table 4-2, figure 
4-11). This was might be due to the absence of any stabiliser 
(surfactant) in the nano-emulsion formulation39. 
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Figure 4-11 Size distribution spectrum (by volume) of propargyl-PDL nano 
emulsion. Nano-emulsion was prepared by dispersing oily propargyl-PDL 
polymer in water by following nanoprecipitation method. 
Surface charge is one of the fundamental parameters known 
to affect the stability of colloidal suspension and can be 
defined as the repulsion or attraction between particles based 
on the presence of surface charge. The zeta potential is the 
measure of the surface charge that exists on a particle. It is 
well established that particles with zeta potentials above ±30 
mV are generally considered as stable in aqueous 
suspension40. The zeta potential detected for nano-emulsion 
(globules) prepared from poly(decalactone) homopolymer in 
HEPES buffer (10mM, pH-7.4) was -70.5 ± 3.0 mv, which 
suggested an excellent stability of this formulation (table 4-2, 
figure 4-12). The zeta potential values measured for 
amphiphilic block copolymers micelles were close to neutral. 
However, PDL-b-PEG-b-PDL gave slight negative value 
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compared to the other block copolymer micelles (table 4-2, 
figure 4-13). 
 
Figure 4-12 Zeta potential spectrum of propargyl-PDL nano emulsion 
measured in 10mM HEPES (pH-7.4) buffer. 
 
 
Figure 4-13 Zeta potential curve of (A) mPEG-b-PDL, (B) PDL-b-PEG-b-
PDL, (C) mPEG-b-PCL and (D) mPEG-b-PDL-b-PPDL micelles acquired using 
Zeta sizer instrument in HEPES 10mM buffer (pH ± 7.4). 
 
CHAPTER 4 
Page | 154  
 
PEG as a hydrophilic block has been reported to mask the 
charge of the micelles core and hence the micelles with PEG as 
corona gave the neutral surface charge41. Thus, the difference 
in zeta potential value between micelles and nano-emulsion 
suggested the assembly of amphiphilic block copolymers with 
PDL as core and PEG as corona. PEGylated particles have been 
generally regarded as sterically stabilised rather than 
electrostatically (charge) stabilised42.  
4.3.3 Characterisation of Drug/Dye loaded Micelles.  
The self-assembly behaviour of novel poly(decalactone) block 
copolymer micelles and ability to act as a model drug carrier 
was evaluated by using Nile red dye (NR)43.  
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Figure 4-14 UV-Visible absorbance spectra of Nile red (NR) in acetone and 
micelles. Micelles sample contains encapsulated NR in mPEG-b-PDL 
micelles dispersed in water. 
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NR was extensively used to check the self-assembly behaviour 
of amphiphilic block copolymers44. The absorption maxima of 
NR strongly depend on the polarity of the surrounding 
environment. Generally the Ǌmax of NR shifts from a high value 
to low value with a decrease in the polarity of surrounding 
media44. A clear shift in Ǌmax (i.e. 531 nm) of NR (encapsulated 
in micelles) was observed when compared with the maximum 
absorption of dye in acetone solution (Ǌmax - 541 nm). This 
result suggested the localisation of NR inside the hydrophobic 
PDL core of the micelles43 (figure 4-14).  
Further, the amount of NR encapsulated in each micelle 
formulation was calculated using UV-visible spectroscopy. A 
control sample (water only) showed no solubilisation of NR 
suggesting the highly hydrophobic behaviour of this dye 
(figure 4-15). The micelles fabricated from PDL-b-PEG-b-PDL 
copolymer displayed the maximum dye content (0.81 ±0.01 
wt%) among the tested poly(decalactone) micelles (figure 4-
15). The loading percentages were compared using one-way 
$129$ ZLWK 7XNH\¶V FRUUHFWLRQ IRU PXOWLSOH FRPSDULVRQV 
Using P<0.05 as a statistical significance threshold, only PDL-
b-PEG-b-PDL indicated significantly higher loading compared 
to the other formulations. The rest of formulations did not 
significantly differ in their dye content (0.69 ±0.01 and 0.71 
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±0.01 wt% for mPEG-b-PDL and mPEG-b-PDL-b-PPDL 
respectively). 
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Figure 4-15 (Top) Appearance of micellar solutions and control 
(formulation without polymer) after Nile red loading and (Bottom) NR 
content in different polymeric micelles estimate by UV-Visible 
Spectroscopy. Dots represent separate individual values and bar 
represents the mean value (n=3). 
Control mPEG-b-PDL-b-PPDL mPEG-b-PDL PDL-b-PEG-b-PDL 
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No significant differences in Z-average sizes of the micelles 
were observed after NR loading except with PDL-b-PEG-b-PDL 
micelles (table 4-2). The Z-average size detected by DLS is 
very sensitive to small changes in the sample distribution, e.g. 
the presence of a small proportion of aggregates (clusters).  
Therefore, the reduction in Z-average size of PDL-b-PEG-b-
PDL micelles after loading was attributed to the reduction in 
the percentage of scattered intensity of second peak 
(observed due to clusters) (table 4-3, figure 4-16D). Due to 
this reason, the mean size by volume was compared for PDL-
b-PEG-b-PDL micelles and no significant difference in size was 
observed after NR loading (table 4-3, figure 4-16). 
 
Figure 4-16 Size distribution curve by volume of (A) mPEG-b-PDL, (B) PDL-
b-PEG-b-PDL, (C) mPEG-b-PDL-b-PPDL and by intensity of (D) PDL-b-PEG-
b-PDL copolymer micelles in water after NR loading. 
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To further check the surfactant properties of these 
copolymers, a curcumin loading and release study was 
performed. Due to the poor stability of curcumin in alkaline 
conditions and low aqueous solubility (0.6 µg/ml), it was 
chosen as a model drug to assess the encapsulation efficiency 
of the novel surfactants24. Curcumin was loaded into the 
polymeric micelle cores via hydrophobic interactions during 
the process of self-assembly of the polymer in water. The 
unencapsulated curcumin was separated from micelles by 
passing through a PD10 desalting (Sephadex) column. 
However, loss of curcumin loaded micelles was observed with 
this method when compared with the purification performed 
by filtration using syringe filter (0.22 µm). Therefore, all 
micelles purification were subsequently performed by filtration 
to avoid loss of material. Similar encapsulation study was 
performed with mPEG-b-PCL block copolymer micelles for 
comparison.    
The cloudy appearance of PDL-b-PEG-b-PDL micelles solution 
after purification indicates the presence of clusters in this 
sample. The loss in volume of mPEG-b-PDL-b-PPDL micelles 
solution was observed after filtration (reduced due to the filter 
blockage) (figure 4-17). Purified micelles were analysed using 
DLS and TEM to determine the size after curcumin loading. 
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Figure 4-17 Polymer micelles after curcumin loading (Top) and curcumin 
content in polymeric micelles (Bottom). Dots represent separate individual 
values and bar represents the mean value (n=3). 
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Figure 4-18 Size distribution by volume of the micelles in water after 
loading of Curcumin. The Z-average size detected for mPEG-b-PDL, PDL-b-
PEG-b-PDL, mPEG-b-PCL and mPEG-b-PDL-b-PPDL was 40±3 nm, 123±7 
nm, 40±2 nm, and 100±9 nm respectively 
Slight increases in the Z-average sizes (except with PDL-b-
PEG-b-PDL micelles) of the micelles were observed after 
curcumin loading when compared to the empty micelles. The 
increase in the size of the micelles after curcumin loading has 
also been reported previously30, 35, 45, 46. In contrast, reduction 
in Z-average size of PDL-b-PEG-b-PDL micelles was observed 
after curcumin loading (table 4-2). This behaviour was due to 
the reduction in the percent intensity of the second peak 
(figure 4-18, table 4-3).  
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Figure 4-19 TEM images of curcumin loaded micelles of (A) mPEG-b-PDL 
and (B) mPEG-b-PCL copolymer. Scale bar - 200nm 
A 
B 
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Figure 4-20 TEM images of curcumin loaded micelles of (A) PDL-b-PEG-b-
PDL and (B) mPEG-b-PDL-b-PPDL copolymer. Scale bar - 200nm. Arrows 
represents the aggregates. 
A 
B 
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TEM images further confirmed the size and suggested that the 
obtained micelles are spherical in shape with smooth surfaces 
(Figure 4-19 and 4-20). Again, the presence of clusters 
(aggregates) in PDL-b-PEG-b-PDL micelles was evident via 
TEM images (Figure 4-20A). No significant difference in 
surface charge compared to blank micelles confirms the 
presence of curcumin in the micellar core, which was shielded 
by the PEG corona (Table 4-2). 
The curcumin content and encapsulation efficiency in 
amphiphilic block copolymers micelles are shown in figure 4-
17 and 4-21. The micelles fabricated from mPEG-b-PCL 
copolymer demonstrated the drug content of 4.0 ± 0.4 weight 
%, with an encapsulation efficiency of 80.3 ± 8.9 %. The drug 
content found for mPEG-b-PDL micelles was 3.3 ± 0.5 weight 
%. Curcumin content in PDL-b-PEG-b-PDL micelles was found 
to be least (2.1 ± 0.1 weight %) when compared with other 
studied polymeric micelles. The micelles prepared from mPEG-
b-PDL-b-PPDL copolymer showed a drug content of 2.6 ± 0.1 
weight %.  
Mixed micelles of mPEG-b-PDL and mPEG-b-PCL (1:1) were 
also prepared to assess any advantage which could be gained 
by physical mixing of two different amphiphilic block 
copolymers on the loading and release of curcumin28. The 
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sizes observed for mixed micelles were almost identical to the 
sizes observed for mPEG-b-PDL and mPEG-b-PCL micelles. 
Curcumin content observed in the mixed micelles was 3.6 ± 
0.4 weight % (figure 4-17).  
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Figure 4-21 Percent encapsulation efficiency (EE%) observed for curcumin 
in different polymeric micelles 
The loading percentages were further compared using one-
ZD\$129$ZLWK7XNH\¶VFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQV 
Using P<0.05 as a statistical significance threshold, only PDL-
b-PEG-b-PDL micelles loading content showed significant 
differences when compared to the other formulations. The rest 
of formulations did not significantly differ in their drug 
content. Encapsulation efficiency followed the similar pattern 
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as loading content except for mPEG-b-PDL-b-PPDL micelles in 
which approximately 40% of loaded polymeric micelles were 
lost during purification by filtration (figure 4-21). 
4.3.4 Curcumin Stability Study and In vitro Release 
Behaviour from Block Copolymers Micelles 
It has been reported that curcumin undergoes hydrolytic 
degradation at alkaline pH47. The degradation mechanism of 
curcumin in PBS is presented in scheme 4-147, 48.  
 
Scheme 4-1 Degradation products of curcumin observed after its 
hydrolysis in 0.1 M phosphate buffer, (pH 7.2) at 37°C47, 49. 
Hence, evaluation of the degradation rate of curcumin 
encapsulated in nano-carriers is an important parameter, 
which needs to be established. mPEG-b-PDL performed better 
compared to other PDL block copolymers in terms of size and 
loading, and therefore it was selected for the curcumin 
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stability study. The stabilities of free curcumin and curcumin 
loaded in micelles were tested for 10 hrs. Free curcumin was 
degraded/ hydrolysed completely in 2 hrs whereas only 3% of 
encapsulated curcumin was degraded after 2 hrs (figure 4-
22). After 10 hrs, 10 % degradation of encapsulated curcumin 
was observed. 
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Figure 4-22 Plot representing the percentage of curcumin remains with 
respect to time of free curcumin and curcumin loaded in micelles incubated 
in PBS (pH-7.4) at 37°C. 
Determination of the release pattern of loaded drug from a 
drug delivery carrier is an important parameter, which needs 
to be assessed before performing any in vivo experiments. 
This experiment was intended to show how quickly a carrier 
system releases the encapsulated content to the surroundings.  
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Figure 4-23 In-vitro release pattern of curcumin from different block 
copolymer micelles (top) and zoomed graph showing the release pattern 
observed in first 50 hrs (bottom) using PBS as release media at 37°C 
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Generally a controlled release pattern from a polymeric 
system is desirable to justify its potential as a drug delivery 
carrier50. Curcumin showed rapid degradation in the chosen 
release medium and therefore samples were collected directly 
from the dialysis tube to avoid any error due to drug 
degradation35. The release patterns of curcumin from the 
different amphiphilic block copolymers micelles are presented 
in figure 4-23. 
Initial burst release of curcumin was observed in all samples 
where 43% of release was observed with mPEG-b-PDL-b-PPDL 
micelles and 19% of release was noticed with mPEG-b-PCL 
micelles in first 9 hrs. More than 95 % of curcumin was 
released from mPEG-b-PDL, mPEG-b-PCL and mPEG-b-PDL + 
mPEG-b-PCL micelles after 175 hrs however, mPEG-b-PDL-b-
PPDL micelles showed only 83% release. Micelles of PDL-b-
PEG-b-PDL copolymer displayed rapid release (96 % after 125 
hrs) compared to the release pattern observed with mPEG-b-
PDL-b-PPDL micelles (93 % after 270hrs). In summary, faster 
release was observed with micelles containing PDL block as 
core when compared to PCL or PPDL as core forming block. 
The rapid release from the mPEG-b-PDL could be useful in the 
cases where incomplete release of drug was observed51.   
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4.4 Discussions 
It is well established that the CMCs of amphiphilic block 
copolymers decrease with increase in the hydrophobicity5. As 
per the molecular weight calculated by 1HNMR, the 
hydrophobicity sequences of PDL block copolymers are mPEG-
b-PDL < PDL-b-PEG-b-PDL < mPEG-b-PDL-b-PPDL. However, 
no significant differences in CMCs were observed due to the 
minor difference in the hydrophobic chain molecular weight 
(figure 4-6) but, if mean values were compared, mPEG-b-PDL-
b-PPDL demonstrated the lowest CMC value as predicted 
based on hydrophobic block content. CMC value calculated for 
mPEG-b-PCL micelles was matched with the previously 
reported value where the hydrophobic to hydrophilic block 
ratio were similar52, 53. 
CMC values generated by the pyrene method for novel block 
copolymers of poly(decalactone) were lower compared to the 
well-established amphiphilic block copolymer of 
poly(caprolactone). The reason for significantly lower CMC 
values for PDL block copolymer micelles compared to the 
similar molecular weight poly (caprolactone) copolymer 
attributed to the presence of an additional hydrophobic alkyl 
side chain on PDL structure. A similar phenomenon was 
reported earlier in which copolymers of poly (lactide) 
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synthesised by using alkyl chain substituted lactide monomer 
displayed lower CMC compared to their un-substituted 
analogues43. It has been known that polymers with low CMC 
values are more stable in vivo thus preventing the premature 
release of loaded therapeutic agents before reaching the 
target sites2, 54. Therefore, it can be hypothesised that the 
novel poly(decalactone) block copolymers could perform 
better when compared to the poly(caprolactone) block 
copolymers. 
 
 
Figure 4-24 (A) Proposed assembly of synthesized di-block and tri-block 
copolymer in water and (B) the formation of cluster from triblock 
copolymer micelles. 
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The average sizes detected for the empty mPEG-b-PDL 
micelles were similar to the sizes of empty mPEG-b-PCL 
micelles. Similar sizes micelles were expected to generate 
from both AB type copolymer due to comparable hydrophobic 
to hydrophilic ratio.  The average sizes detected for mPEG-b-
PCL micelles were also matched with the sizes reported in 
literatures24, 37, 52, 55. 
A bimodal size distribution observed with ABA type copolymer 
(PDL-b-PEG-b-PDL) was probably due to the hydrophobic±
hydrophobic interaction between cores of the micelles which 
led in aggregation56 (figure 4-24). It has been proposed that 
an ABA type block copolymer can assemble in flowered shaped 
micelle57. This could lead to decrease in the length of PEG 
chain, which separates the core from surrounding 
environment. In addition, the PDL-b-PEG-b-PDL copolymer 
was synthesised using a small chain PEG (Mn ± 4000) and 
hence was expected to have a less dense corona. A slight 
negative zeta potential of PDL-b-PEG-b-PDL micelles also 
confirmed the presence of a less dense shell of PEG.  It was 
reported that PEG imparts steric stability to micelles by 
minimizing the interfacial free energy of the micellar core and 
by inhibiting hydrophobic inter-micellar attractions58. Thus, 
due to the presence of a less dense shell, some aggregation 
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was observed with triblock copolymers, which in turn gave 
bimodal size distribution3. 
Similar phenomena was reported earlier with PCL-b-PEG-b-
PCL micelles in which the presence of aggregates (clusters) 
was proposed59. Cluster formation was also reported with 
poly(t-butyl methacrylate) ABA block-copolymer micelles60 
and polystyrene-b-poly(ethylene oxide) block copolymer 
micelles61. Clusters of micelles may have different bio-
distribution and could be eliminated through the RES system 
from the body and thus would have impaired performance in 
vivo62. Hence, it could be possible that PDL-b-PEG-b-PDL 
micelles would not perform well in vivo compared to other PDL 
block copolymer micelles due to it tendency of clusters 
formation. 
The large size observed with mPEG-b-PDL-b-PPDL micelles 
may be attributed to the poor solubility of copolymer in 
acetone. Addition of crystalline PPDL block63 in mPEG-b-PDL 
copolymer reduced the overall solubility of the resultant 
copolymer (figure 4-25). Due to the high polydispersity of 
mPEG-b-PDL-b-PPDL copolymer (Mw/Mn by SEC ± 1.25), there 
is a possibility of existence of some copolymer chains with 
high molecular weight PPDL blocks. These particular 
copolymers chains with poor solubility in acetone could be 
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responsible for generating bigger size micelles.  Acetone is not 
a good solvent for poly(pentadecalactone) block and thus, this 
component of the copolymer would have been in a more 
collapsed state and possibly formed aggregates in acetone. 
During nano-precipitation, these collapsed chains present in 
the acetone (aggregates) produced larger size micelles64 and 
thus gave broad size distribution.   
Additionally, the presence of particles of diameter above the 
pore size of filter (i.e. 220 nm) in sample was responsible for 
the blockage of syringe filter. Therefore, 2-3 units of syringe 
filter were employed to filter the mPEG-b-PDL-b-PPDL micellar 
suspension, which potentially caused the loss of micellar 
suspension due to the retention/absorption of some material 
on each syringe filter thus gave low recovery. 
 
Figure 4-25 Physical appearance of (A) mPEG-b-PDL and (B) mPEG-b-PDL-
b-PPDL copolymer (50mg each) in 5mL acetone 
No significant differences in mean sizes of novel block 
copolymer micelles were observed after NR loading except 
with PDL-b-PEG-b-PDL micelles. This discrepancy was due to 
A B 
CHAPTER 4 
Page | 174  
 
the reduction in the intensity of clusters after NR loading, 
which reduced the overall mean size. NR loading study 
proposed that these novel micelles are able to encapsulate 
hydrophobic moieties inside their core and can act as 
solubilisation tool. Based on this result, curcumin 
encapsulation study was also performed to further evaluate 
the drug incorporation efficiency of the polymer micelles. In 
contrast to NR loading results, PDL-b-PEG-b-PDL micelles 
demonstrated lower loading of curcumin compared to other 
block copolymers. This behaviour could be attributed to the 
core compatibility with a particular drug. The ability of a 
hydrophobic core to encapsulate a drug mainly depends upon 
its compatibility with the drug molecule3, 65. It was assumed 
that curcumin could be less compatible with PDL polymer and 
therefore micelles with PDL core forming block demonstrated 
low loading compared to micelles with PCL core. 
Curcumin content observed with mPEG-b-PCL micelles in this 
study was significantly less when compared with previously 
reported results. In most of the reported studies, curcumin 
loadings with amphiphilic block copolymers of 
poly(caprolactone) of similar hydrophobic to hydrophilic block 
ratios were found to be more than 7.0 weight %45, 66-68. 
However, there were some studies, in which the curcumin 
CHAPTER 4 
Page | 175  
 
loading using poly(caprolactone) block copolymer was 
reported to be less than 5.0 weight %30, 35, 68.  
The variation in the results of curcumin loading with mPEG-b-
PCL micelles might have been due to the different parameters 
used for loading in the various individual studies. 
Encapsulation procedure, drug to polymer ratio, molecular 
weight of polymer, solvent used etc. can significantly influence 
the loading content30, 35, 66, 68. Since, the objective of current 
study was to compare the loading results obtained from novel 
and well established block copolymers rather than maximise 
specific drug loading. Thus, the optimisation of the formulation 
parameters was not performed to achieve the maximum drug 
loading.   
Curcumin loading observed with mixed micelles suggested 
that mixing of the novel renewable copolymer (mPEG-b-PDL) 
with a copolymer synthesised from non-renewable feedstock 
(mPEG-b-PCL) could produce similar results when compared 
with the results obtained from poly(caprolactone) copolymer 
alone. Thus, mixed micelle approach might be useful to reduce 
the amount of non-renewable copolymer in the overall 
formulation. Further optimisation of loading parameters could 
produce better results but was not studied in current work due 
to time constraints. 
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The degradation rate of curcumin encapsulated in mPEG-b-
PDL micelles was slower compared to free drug, suggesting 
that the curcumin was located inside the highly hydrophobic 
PDL core. Due to this reason, the direct contact of curcumin 
with PBS was hampered thus, the hydrolytic degradation rate 
was reduced. The mPEG-b-3'/PLFHOOH¶VDELOLW\WRSURWHFWWKH
degradation of curcumin was similar to the mPEG-b-PCL 
micelles reported by Ma et.al.35 
In release experiment, Burst release observed from all 
micelles could be attributed to the presence of some amount 
of curcumin on the exterior part (surface) of the PDL block. 
The initial burst release of curcumin from polymeric micelles 
was also reported earlier in which 30-40 % of drug was 
released within 10 hrs26, 45, 69. On the basis of the release 
results, it can be proposed that the diffusion mechanism was 
mainly responsible for the release of curcumin from the 
studied micelles. It has been reported that polymers with low 
Tm, Tg value and low crystallinity release their loaded content 
rapidly70, 71.  Therefore, the drug permeated faster from the 
amorphous PDL core compared to semicrystalline (PCL) or 
crystalline (PPDL) core polymeric micelles72. A similar release 
pattern has been reported with PLGA nano carriers where 
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increase in the composition of D, L-PLA (amorphous polymer) 
increased the release rate of loaded drug12, 73. 
Delayed release observed from mPEG-b-PDL-b-PPDL micelles 
was most likely due to the restricted diffusion of drug from the 
more crystalline poly(pentadecalactone) core74. Similar 
phenomena were observed earlier with poly(propylene 
succinate-co-caprolactone) copolymer nanoparticles where 
mixing of crystalline polymer with amorphous polymer 
decreased the release rate compared to the release observed 
from the amorphous polymer only71.  
 
Figure 4-26 Proposed encapsulation of curcumin in mPEG-b-PDL-b-PPDL 
copolymer micelles. Due to the layered hydrophobic core, curcumin can be 
localised at PDL and PPDL core. 
A significant percentage of burst release observed with mPEG-
b-PDL-b-PPDL micelles might have been associated with the 
presence of some larger size micelles. In this formulation, the 
drug molecules that were located in the PDL core, from the big 
micelles permeated (diffused) faster due to the large surface 
area when compared to the small size micelles (figure 4-26).  
Self Assembly 
- Curcumin 
PEG PDL PPDL 
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The release rate observed for mPEG-b-PCL micelles in this 
study was more sustained than previously reported release 
pattern for mPEG-b-PCL micelles of similar molecular weight35. 
This difference in release pattern can be attributed to the 
concentration of curcumin, sample withdrawal method and 
release media used for the study. It was reported that when 
higher drug concentration was used for the release study, a 
more sustained release pattern was observed75. Additionally, 
the release pattern could be different in the different release 
media, based on the partition coefficient of the drug at 
different pH.  
4.5 Conclusion  
In this chapter, the self-assembly and encapsulation behaviour 
of novel poly(decalactone) block copolymer micelles was 
demonstrated. These novel amphiphilic block copolymers 
possesses low CMC values compared to the similar molecular 
weight mPEG-b-PCL copolymer. The CMC values of novel 
amphiphilic block copolymers ranges between 1.07-1.77 
µg/mL in water, calculated from pyrene fluorescence method. 
Micelles of amphiphilic block copolymers were prepared by 
nano-precipitation method and no significant difference in size 
of mPEG-b-PDL and mPEG-b-PCL micelles were observed. 
Micelles obtained from PDL-b-PEG-b-PDL copolymer gave a 
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bimodal size distribution, in which the second peak was due to 
the formation of clusters. The Z-average size detected for 
mPEG-b-PDL-b-PPDL copolymer micelles were significantly 
higher when compared with mPEG-b-PDL micelles. The 
difference in size of these micelles was attributed to the 
change in solubility of mPEG-b-PDL-b-PPDL copolymer in 
acetone, which in turn produced some large size micelles. 
Micelles fabricated from all block copolymers were of roughly 
spherical in shape as evident by TEM images. The zeta 
potential obtained in HEPES buffer (10mM, pH-7.4) for block 
copolymer micelles was almost neutral except for PDL-b-PEG-
b-PDL micelles, which was slightly negative due to the less 
dense PEG corona. It was hypothesised that due to the less 
dense corona, the micelles obtained from PDL-b-PEG-b-PDL 
block copolymer were prone to aggregates thus gave large 
size micelles. 
All novel block copolymers were successfully encapsulated nile 
red and curcumin. A shift in UV-Vis absorbance maxima of NR 
suggested the self-assembly of block copolymer in water with 
PDL core. NR and curcumin loading did not significantly 
change the diameter of micelles except in case of PDL-b-PEG-
b-PDL where reduction in clusters volume led to decrease in 
average diameter. No significant difference in curcumin 
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loading content was observed with mPEG-b-PDL and mPEG-b-
PDL-b-PPDL micelles when compared to the well-established 
mPEG-b-PCL copolymer micelles. Micelles of mPEG-b-PDL 
were also demonstrated its ability to reduce degradation of 
curcumin at physiological pH. In vitro release studies of 
curcumin loaded micelles suggested that micelles having the 
more amorphous poly(decalactone) core gave the faster 
release compared to semicrystalline poly(caprolactone) and 
poly(pentadecalactone) core.  
From the results obtained in different studies, it was 
concluded that the overall performance of novel mPEG-b-PDL 
copolymer micelles was better (in terms of size, loading and 
release) when compared with the other PDL block copolymers 
studied in this work. Additionally, the performance of mPEG-b-
PDL micelles was almost equivalent to the mPEG-b-PCL 
micelles. Therefore, mPEG-b-PDL copolymer was selected for 
further evaluation of its drug delivery capability. 
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5.1 Introduction 
Amphotericin B (AmpB) is a polyene antibiotic from 
Streptomyces nodosus, a filamentous bacterium, and the 
compound was first isolated in 1955 at the Squibb Institute for 
Medical Research. AmpB is a reliable broad spectrum 
antifungal and antiprotozoal drug which is widely used against 
life threatening systemic infection such as visceral 
leishmaniasis1. AmpB is insoluble in water and therefore the 
conventional intravenous formulation of AmpB contains 
sodium deoxycholate (surfactant) to enhance its aqueous 
solubility. However, sodium deoxycholate, used for the 
solubilisation of amphotericin B has been known to be 
haemolytic2. Additionally, this conventional formulation is 
known to cause nephrotoxicity3,1. Therefore, to increase the 
efficacy and to reduce the systemic toxicity of AmpB, various 
lipid formulations of AmpB has been developed and a few of 
them are commercially available1,4. However, numerous other 
nano-sized carriers such as micelles2, nanospheres5, carbon 
nanotubes6, nanosuspensions7, nanoparticles8 etc. have also 
been evaluated for the delivery of AmpB.  
It has been reported that micellar formulations of AmpB 
performHG EHWWHU WKDQ LW¶V FRPPHUFLDOO\ DYDLODEOH DQDORJXH
For instance, micelles of poly(ethylene oxide)-block-poly(L-
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aspartate) and its derivatives2,9,10 have been extensively 
studied for the delivery of AmpB and found to be more 
effective (in vitro and in vivo) compared to the commercially 
available Fungizone® (a formulation of amphotericin B 
containing sodium deoxycholate)2,9,10. In addition to the 
poly(L-aspartate), micelles fabricated using other hydrophobic 
blocks such as PLGA11, PCL12, phospholipid13 etc. has also 
been tested for the delivery of AmpB. Considering the 
advantages of micellar formulations over the conventional 
formulations of AmpB, it was decided to evaluate the potential 
of novel poly(decalactone) block copolymer micelles for AmpB 
delivery. 
Good solubility of drug and polymer in common water miscible 
volatile organic solvent (preferably acetone and 
tetrahydrofuran) is must for the effective loading via 
nanoprecipitation. Encapsulation of AmpB using a 
nanoprecipitation method is generally a complex procedure, 
which always requires a co-solvent. The commonly used co-
solvents are dimethyl sulfoxide (DMSO) and methanol. 
However, the mixture of acetone and methanol required an 
additional step of pH adjustment to dissolve the AmpB 
completely14. Similarly, when non-volatile DMSO has been 
used as a co-solvent, additional steps such as dialysis or 
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washing were required to remove the solvent from final 
formulation11. A polymer, which is soluble in methanol, could 
avoid the additional steps required to load AmpB via 
nanoprecipitation. In the view of this, a lipid formulation of 
AmpB has been reported, which was fabricated via 
nanoprecipitation using methanol as solvent15. The co-polymer 
mPEG-b-PDL is soluble in methanol and therefore it was 
proposed that the encapsulation of AmpB via nanoprecipitation 
using this copolymer might be possible. 
Polymers containing ester group in their backbone have the 
ability to perform a certain role for a specific period and be 
subsequently degraded into low molecular weight products, 
which can be easily eliminated from the body via metabolic 
pathways16,17. The hydrolytic degradation of a poly(esters) is 
also known to affect the release rate of the encapsulated 
material and can be tuned to control drug release18. Most of 
the poly(esters) used for in vivo drug delivery can be 
degraded in the human body by acid or base catalysed 
hydrolysis in the presence or absence of esterase enzymes19. 
Since mPEG-b-PDL is a novel but highly hydrophobic 
polyester, and therefore it was expected that it might undergo 
a very slow hydrolytic degradation. Hence, a preliminary in 
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vitro degradation study was performed to investigate the 
degradation profile of the mPEG-b-PDL polymeric micelles. 
Another important parameter that needs to be addressed 
before the use of a new material in vivo is its cytotoxicity.  
Primary toxicity evaluation of new polymers has been 
generally done on human cell lines to determine their 
suitability for in vivo use20. Being a new polymer, the mPEG-b-
PDL formulation was tested to evaluate its effects on human 
cell lines. Alamar Blue assay was selected for the evaluation of 
the effects of polymers on cells. This assay is a simple and 
rapid test in which commercially available Alamar Blue® 
reagent21, 22, which is a water soluble nontoxic dye, is used to 
assess metabolic activity of cells. The assay was chosen in 
place of the common 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) metabolic activity assay 
because, unlike the MTT test, re-use of cells is possible for 
further investigations which might be important for reasons of 
time in this study21. Previously reported mPEG-b-PCL co-
polymer was also tested using the same protocol for a 
comparative study23. 
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5.2 Methods 
5.2.1 Preparation and Characterisation of Blank and 
Amphotericin B loaded Micelles: 
Empty and drug loaded micelles of mPEG-b-PDL and mPEG-b-
PCL (50 mg each) were prepared and characterised by similar 
methods used for curcumin (see chapter 4). Methanol (5mL) 
was used as organic solvent instead of acetone to solubilise 
polymer and drug. The initial amount of AmpB used for the 
encapsulation study was 2 mg. The mPEG-b-PCL copolymer 
produced a hazy solution in methanol due to its poor solubility 
whereas mPEG-b-PDL gave transparent solution (figure 5-1). 
All micellar formulations were purified by filtration (0.22µm) in 
order to remove free drug and aggregates. Drug content (DC) 
in micelles was determined by dissolving the known amount of 
freeze dried sample in methanol followed by quantification of 
the AmpB using UV-Vis spectrophotometry. Freeze dried 
mPEG-b-PCL micelles formed precipitates after reconstitution 
in methanol and therefore, samples were sonicated for 2 
minutes and then centrifuged (2 min.) at 5000 rpm to remove 
precipitates. A similar method was followed for mPEG-b-PDL 
micelles samples for proper comparison. Supernatant 
(methanol) was collected from each sample and analysed at 
Ǌmax = 405 nm via UV-Vis spectrophotometry. The amount of 
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AmpB was then calculated using standard calibration curve, 
which was prepared from UV analysis of AmpB solutions in 
methanol (Dilutions ± 1 to 10 µg /mL).  DC and EE was 
calculated using the formula reported in chapter 2. 
 
Figure 5-1 Physical appearance of solution of mPEG-b-PDL and mPEG-b-
PCL copolymer (50 mg each) after being dissolved in 5mL of methanol. 
5.2.2 In vitro Release Study of Amphotericin B from 
Block Copolymers Micelles 
To facilitate the solubilisation of AmpB, a release study was 
performed in modified release media i.e. water containing 
Tween 80 (1% v/v )24,25. A calculated amount of AmpB loaded 
freeze dried micelles, equivalent to 200 µg of AmpB were 
redispersed in HPLC grade water (2 mL). The solution was 
then placed in a dialysis tubing (Slide-A-Lyzer, 3.5 KDa mwco, 
Thermo Scientific) and dialysed against 10 mL of release 
media at 37°C. The whole release media was replaced with 
fresh media at a predetermined time interval to maintain sink 
condition. Collected release media (samples) was freeze dried. 
The dried samples were then dissolved in methanol (1 mL) 
mPEG-b-PDL mPEG-b-PCL 
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and analysed on UV-Vis spectrophotomer (Ǌmax-405 nm). The 
amount of released AmpB was then calculated using a 
standard calibration curve of AmpB (figure 5-2). Control 
samples were prepared by dissolving 200 µg of AmpB in 2 mL 
of water (containing 2% v/v of Tween 80, Control A). An 
additional control experiment was also setup by adding 50 µl 
of mPEG-b-PDL copolymer solution in acetone (100 mg of 
mPEG-b-3'/ LQ P/ RI DFHWRQH WR WKH FRQWURO ³$´ 7KH
solution was then bubbled with nitrogen to remove acetone. 
7KLV VDPSOH ZDV DVVLJQHG DV FRQWURO ³%´ (figure 5-3). The 
AmpB release pattern from control samples was analysed by 
following the identical method used for mPEG-b-PDL micelles.  
 
Figure 5-2 Standard calibration curve of Amphotericin B. The UV 
absorbance of Amphotericin B solution (in methanol containing 10% v/v 
Tween 80) was measured at wavelength of 405 nm. 
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Figure 5-3 Sample distribution for release study. Control A contained AmpB 
in water having Tween 80 (2% v/v). Control B sample contained mPEG-b-
PDL co-polymer (5mg) in control A. mPEG-b-PDL sample contained AmpB 
loaded mPEG-b-PDL micelles in water. All samples contained 200 µg of 
AmpB. 
5.2.3 In vitro Degradation Study of mPEG-b-PDL 
Micelles 
The degradation profile of empty mPEG-b-PDL micelles was 
assessed in two different pH (i.e. pH ± 7.4 and 4.0) at 37° C. 
To perform this study, freeze dried empty micelles (8 mg) 
were redispersed in 1 mL of acetate buffer (pH ± 4.0, 10mM) 
and phosphate buffer (pH ± 7.4, 10mM) separately. The 
samples (6 each for both pH) were then incubated at 37°C 
using a water bath. At predetermined time intervals, one 
sample vial from each pH was collected and freeze dried. The 
freeze dried samples were then dissolved in chloroform, 
filtered and analysed by SEC to determine the change in 
molecular weight. 
Control A Control B mPEG-b-PDL 
Amphotericin B Tween 80 
Micelles 
mPEG-b-PDL 
Micelles 
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5.2.4 In vitro Cytotoxicity Study of mPEG-b-PDL and 
mPEG-b-PCL Micelles 
The Alamar Blue cell viability assay was performed to 
determine the toxicity of the empty micelles on HCT116 colon 
cancer cells. This study was kindly performed by Dr. Laura 
Purdie. Cells were seeded at 10,000 cells per well in a 96 well 
plate. After 48 hrs, the media (RPMI-1640, 10 % FBS, 2mM L-
Glutamine) was replaced with fresh 200µl of Opti-MEM®. The 
stock solution of micelles (mPEG-PDL and mPEG-b-PCL) (5 
mg/mL) was diluted in water as required to make the final 
concentration of 3.5, 7.0, 14.0 and 21.0 µg/µL. Micelle 
solutions (15 µL) were then added to the media (treated cells) 
and in three wells, only water (15 µL) was added as negative 
control (untreated cells). Three wells with no cells were also 
set up on the same plate containing Opti-MEM® only, as a 
background control. The plate was then incubated for 24 hrs in 
a humidified incubator at 37 °C (5% CO2). After 24 hrs, the 
media was replaced with 110 µL of 1:10 Alamar Blue reagent 
in OptiMEM. The plate was then incubated for 1 hr followed by 
fluorescence measurement at the excitation wavelength of 
594 nm and emission wavelength of 610 nm using a 
fluorescence plate reader (Molecular Devices Flexstation 3 
plate reader).  The background fluorescence was subtracted 
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from all of the cell readings. Considering the negative control 
as 100 % cell viability, calculations were performed to 
determine the percentage of cells which were actively 
metabolising (and thus viable) in each sample. 
Two-Way ANOVA analysis was performed for multiple 
comparison (Sidak test), to evaluate any significant 
differences in the samples.  
All experiments were done in triplicate and results were 
reported as mean with standard deviations. GraphPad Prism 6 
was used to analyse the data. 
5.3 Results 
5.3.1 Preparation and Characterisation of Blank and 
Amphotericin B loaded Micelles 
The appearance of micelle solutions before and after 
purification is shown in figure 5-4. The mPEG-b-PCL 
copolymer, due to its poor solubility in methanol, produced 
large size particles after nanoprecipitation method (figure 5-
4A). However, during purification of micellar suspension, 
particles above 220 nm sizes were removed (figure 5-4B). The 
recovery of micellar suspension after filtration was 
approximately 30-40% for mPEG-b-PCL copolymer whereas 
90-95% of mPEG-b-PDL micellar suspension was recovered.  
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Figure 5-4 Physical appearance of micellar suspension (obtained via 
nanoprecipitation method) in water (A) before and (B) after filtration 
through 0.22 µm syringe filter. 
 
Sample 
Z-average 
size (d/nm) 
(±SD) 
PdI 
Zeta Potential 
(mv) (±SD) 
mPEG-b-PDL 
(Blank) 
41 ± 2 0.15 ± 0.01 -2.4 ± 1.3 
mPEG-b-PDL 
(Loaded) 
44 ± 3 0.16 ± 0.02 -2.8 ± 1.1 
mPEG-b-PCL 
(Blank) 
36 ± 2 0.30 ± 0.03 -0.3 ± 1.7 
mPEG-b-PCL 
(Loaded) 
32 ± 3 0.26 ± 0.02 -1.2 ± 1.0 
Table 5-1 Characterisation data of micelles prepared by nanoprecipitation 
method using methanol as an organic solvent. (d/nm-diameter in 
nanometre, SD-standard deviation, PdI-polydispersity index, mv- millivolt). 
 
AmpB loaded 
mPEG-b-PDL 
AmpB loaded 
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Figure 5-5 Size distribution curve by intensity of (A) Blank mPEG-b-PDL, 
(B) AmpB loaded mPEG-b-PDL, (C) Blank mPEG-b-PCL and (D) AmpB 
loaded mPEG-b-PCL micelles. 
 
 
Figure 5-6 Size distribution curve by volume of (A) Blank mPEG-b-PDL, (B) 
AmpB loaded mPEG-b-PDL, (C) Blank mPEG-b-PCL and (D) AmpB loaded 
mPEG-b-PCL micelles. 
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Figure 5-7 TEM image of (A) blank mPEG-b-PDL and (B) AmpB loaded 
mPEG-b-PDL micelles. The images were taken without staining. Scale bar - 
500 nm 
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Figure 5-8 TEM image of (A) blank mPEG-b-PCL and (B) AmpB loaded 
mPEG-b-PCL micelles. The images were taken without staining. Scale bar 
500 nm 
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The mean sizes detected by DLS for empty and AmpB loaded 
micelles are reported in table 5-1. No significant differences in 
the size of empty micelles were observed when compared with 
micelles prepared using acetone as solvent (in chapter 4). 
Furthermore, AmpB loading did not significantly change the 
size of the micelles when compared with blank micelles (table 
5-1, figure 5-5 and 5-6). However, due to the broad size 
distribution, the polydispersity index observed for mPEG-b-PCL 
micelles was high.(figure 5-5). Interestingly, after loading of 
AmpB in mPEG-b-PCL micelles, a slight reduction in mean size 
and polydispersity index was observed. 
Zeta potential detected for all micelles formulation in 10mM 
HEPES was almost neutral and no significant change in zeta 
potential was observed after AmpB loading (table 5-1). The 
TEM images of blank and AmpB loaded micelles confirmed the 
size and suggested that the prepared micelles are of roughly 
spherical in shape (figure 5-7 and 5-8).  
The drug content and encapsulation efficiency observed for 
mPEG-b-PCL and mPEG-b-PDL micelles are presented in figure 
5-9. The AmpB content found in mPEG-b-PDL micelles (3.5± 
0.2 wt %) was 7.2 times higher than mPEG-b-PCL micelles 
(0.5± 0.1 wt %). The percentage encapsulation efficiency 
(EE%) found for mPEG-b-PDL micelles was 84.8 ± 4.7 % 
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whereas mPEG-b-PCL showed the EE% of 11.5 ± 1.7 % 
(figure 5-9 B). 
 
m P E G -b -P C L m P E G -b -P D L
0
1
2
3
4
P o ly m e ric  M ic e lle s
D
ru
g
 
C
o
n
te
n
t 
(w
t%
)
 
m P E G -b -P C L m P E G -b -P D L
0
2 0
4 0
6 0
8 0
1 0 0
E
E
 
%
 
Figure 5-9  Graph represents (A) Amphotericin B content (weight % to 
polymer) and (B) encapsulation efficiency (EE%) observed in micelles, 
which was determined by UV-9LVVSHFWURSKRWRPHWHUǊmax - 405 nm). Dots 
represent separate individual value and bar represents the mean value 
(n=3). 
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5.3.2 In Vitro Release Study of AmpB from Block 
Copolymer Micelles 
Amphotericin B is poorly soluble in water (< 0.5 µg/mL)2 and 
hence 1% v/v  of Tween 80 was added in release media to 
enhance its solubility. The concentration of Tween 80 used 
was well above its CMC and hence it was expected that the 
Tween 80 micelles (mol. wt. 76 KDa)26 were not diffused 
through the dialysis bag (mwco -3.5 to 5 KDa). Due to the 
poor loading of AmpB in mPEG-b-PCL micelles, this 
formulation was excluded from release study. Therefore, the 
release pattern of mPEG-b-PDL micelles was compared with 
the Tween 80 micelles formulation.  
 
Figure 5-10 Cumulative release (%) of AmpB from different test 
formulations in water containing Tween 80 (1% v/v) at 37°C. Release 
study was performed by dialysis method and AmpB concentration was 
estimated by UV-Vis spectrophotometer. 
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Initial burst release of AmpB (30% approx. within 6 hrs) was 
observed with mPEG-b-PDL micelles followed by a slow-
release phase, which continued for 8 days. In contrast, control 
³A´ (Tween 80 micelles) released 100 % of AmpB in 3 days 
out of which 53 % of drug was released in first 6 hrs. 
+RZHYHU LQ FRQWURO ³%´ IRUPXODWLRQ WKH UHOHDVH SDWWHUQ
REVHUYHGZDVPRUH VXVWDLQHGZKHQ FRPSDUHG WR FRQWURO ³$´
but was faster compared to mPEG-b-PDL micelles (figure 5-
10). In the first 6 hrs, no significant difference in the 
SHUFHQWDJHGUXJUHOHDVHGZDVREVHUYHGZLWKFRQWURO³%´ZKHQ
FRPSDUHG WR FRQWURO ³$´ +RZHYHU SUREDEO\ GXH WR WKH
partition of AmpB after a certain time in to empty mPEG-b-
PDL micelles, sustained release was observed with this 
control, which lasted for 5 days. If the percentage of burst 
release was ignored than all the three formulations 
demonstrated the similar pattern of drug release i.e. initial 
burst release followed by sustained release.  
5.3.3 In Vitro Degradation Study of mPEG-b-PDL 
Micelles 
Determination of the degradation time of a polyester is an 
important parameter to understand its fate inside the body 
and/or on long term storage in solution. A known degradation 
profile of a polymer could be useful to fabricate a drug 
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delivery carrier with predetermined release rate18. Therefore, 
in the current work, a preliminary study of hydrolytic 
degradation of mPEG-b-PDL micelles was performed for 4 
months. Samples were analysed by SEC to determine the 
change in molecular weight (Mn). Here, NMR spectroscopy was 
not useful for molar mass determination because of the 
absence of substantial change in peak positions of 
poly(decalactone) after chain cleavage. 
A SEC trace of mPEG-b-PDL micelles after 120 days and the 
loss of molecular weight (Mn) versus time are shown in figure 
5-11 and 5-12 respectively. The change in Mn of peak at 
position 1 (figure 5-11) was monitored and used to plot the 
graph against time. As the degradation of polymer chain 
continued, the reduction in the Mn value of peak at position 1 
was observed. Complete cleavage of the PDL block from mPEG 
block (Mn by SEC ± 10.8K) was observed in 53 days at pH 4.0. 
High degradation rate at this pH was attributable to the acid-
catalysed hydrolysis of ester bonds. However, at physiological 
pH (i.e. pH-7.4) only 16% drop in Mn was observed after 4 
months from the initial value.  
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Figure 5-11 SEC trace of mPEG-b-PDL after 120 days of storage at pH 7.4 
(temperature ± 37°C). SEC instrument was calibrated using polystyrene 
standards and chloroform was used as mobile phase. 
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Figure 5-12 Loss in molecular weight (Mn) of mPEG-b-PDL micelles with 
time at two different pH as determined by SEC. SEC instrument was 
calibrated using polystyrene standard and chloroform was used as mobile 
phase.  
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5.3.4 Effect of Micelles on Cells Metabolic Activity by 
Alamar Blue Assay 
The Alamar Blue assay is based on the measurement of the 
reduction of resazurin by viable cells due to their continuing 
metabolic activity27. The oxidised non fluorescent Alamar Blue 
dye undergoes chemical reduction in the cell culture medium 
by mitochondrial enzymes and is converted into a pink 
fluorescent dye, resorufin21,22. Fluorescence intensity of 
resorufin is directly related to the metabolic activity of cells. 
 
Figure 5-13 In vitro cytotoxicity of empty micelles formulations. The 
percent cell viability was calculated using Alamar Blue assay on HCT116 
cell lines for 24 hrs.   
The cytotoxicity of empty micelles was studied on HCT116 
colon cancer cell lines for 24 hrs. The percent viability of cells, 
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(after 24 hrs) is shown in figure 5-13. No significant 
differences in percent viability of cells were observed between 
mPEG-b-PCL and mPEG-b-PDL micelles at any used 
concentration of micelles. Furthermore, not more than 20% 
cell death was observed in any cell culture treated with empty 
micelles after 24 hrs in vitro. These results suggested that the 
empty micelles were of relatively low toxicity to this cell line 
up to the concentration of 300 µg/mL. 
5.4 Discussion 
Empty and AmpB loaded mPEG-b-PDL micelles demonstrated 
no significant change in size when compared to micelles 
prepared using acetone as solvent. These results suggested 
that the solubility of mPEG-b-PDL copolymer is almost similar 
in acetone and methanol. However, large size micelles were 
observed with mPEG-b-PCL micelles due to the poor solubility 
of this copolymer in methanol. Similar result was earlier 
observed with mPEG-b-PDL-b-PPDL copolymer when micelles 
were fabricated using acetone as solvent.  The presence of 
aggregates led to an increased polydispersity index for the 
mPEG-b-PCL micelles, but after AmpB loading, a reduction in 
size and polydispersity was observed. This behaviour might 
have been due to the hydrophobic interaction between PCL 
core and AmpB, which facilitated the assembly of mPEG-b-PCL 
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in water. Similar results have been reported with mPEG-b-PCL 
micelles when highly hydrophobic fenofibrate was loaded28. A 
similar phenomenon was also observed earlier with PDL-b-
PEG-b-PDL micelles, where loading of a hydrophobic drug 
decreased the size and polydispersity index (see chapter 4). 
The encapsulation study results suggested that the 
performance of mPEG-b-PDL copolymer using the reported 
encapsulation procedure was superior compared to mPEG-b-
PCL copolymer. Good solubility of mPEG-b-PDL in methanol 
and its higher hydrophobicity were the probable reasons, due 
to which a higher drug content in the novel polymeric micelles 
was observed. The EE observed with mPEG-b-PDL micelles for 
AmpB was higher than the previously reported micelles 
formulations having PLGA29, PLA30 or PCL31,12 as hydrophobic 
core. Although the drug content observed was low compared 
to the above mentioned polymers however, it can be improved 
by formulation optimisation. For instance, it has been reported 
that the loading content of AmpB in a polymeric drug delivery 
systems can be improved by increase in the initial quantity of 
drug used for loading11,2.  
An in vitro release experiment was performed using two 
control formulations to understand the role of drug partition 
between carrier and dispersed phase on release rate32. The 
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UHOHDVHUDWHREWDLQHGIRUFRQWURO³%´IRUPXODWLRQhypothesised 
that the partitioning of drug between the carrier and dispersed 
phase has an effect on the release rate determined by dialysis 
method.     
 
Figure 5-14 Pictorial presentation of control ³B´ VKRZLQJ WKH AmpB 
equilibration from Tween 80 micelles to mPEG-b-PDL micelles (step 1) and 
diffusion of AmpB in release media from dialysis membrane (step 2).  
As shown in figure 5-14, the loaded drug after releasing from 
the Tween 80 micelles into dispersed phase, could either 
encapsulated back in to mPEG-b-PDL blank micelles (step 1)  
or diffuse out to release media (step 2). Due to the higher 
hydrophobicity of mPEG-b-PDL micelles core, drug migration 
from Tween 80 micelles towards mPEG-b-PDL micelles was 
expected. Consequently, a more sustained release pattern was 
REVHUYHG ZLWK FRQWURO ³%´ ZKHQ FRPSDUHG ZLWK FRQWURO ³$´
This phenomena indicates that a reversible binding of drug 
towards carrier (micelles) is possible before permeating 
through dialysis membrane, based on the partition coefficient 
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of drug between carrier and dispersed phase33. Nevertheless, 
since the partition effect would have occurred in both 
formulations (i.e. LQFRQWURO³$´DQGP3(*-b-PDL micelles) and 
therefore it can be concluded that the mPEG-b-PDL micelles 
showed a more sustained release of AmpB compared to Tween 
80 micelles. The release pattern observed with novel mPEG-b-
PDL micelles was more controlled, compared to the earlier 
reported release pattern for AmpB in release media having 
Tween 80 as solubilising agent24,25. The obtained results 
suggested that the mPEG-b-PDL micelles have potential to 
improve delivery of AmpB. 
The preliminary in vitro degradation study suggested that the 
mPEG-b-PDL micelles were likely to undergo hydrolytic 
degradation. The degradation rate observed for mPEG-b-PDL 
copolymer at physiological pH (9 % after 30 days) was slower 
compared to two different reports on PEG-PLA block 
copolymers (27.6 %34, 16.3 %35 after 30 days). This might be 
due to the more pronounced steric effect (hindered ester 
groups) and higher hydrophobicity of the mPEG-b-PDL. 
However, it was found that the degradation rate of mPEG-b-
PDL was faster than with PEG-PCL copolymers (9.0 % after 
126 days36, 4.1% after 56 days37). It has been reported that 
amorphous polymers degrade faster than semicrystalline 
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polymers38,39. Therefore, a more rapid degradation of the 
amorphous PDL block when compared to semicrystalline PCL 
block could be attributed to this difference in crystallinity. 
The in vitro cell activity study results suggested that the 
mPEG-b-PDL micelles exhibited similar effects on a cancer cell 
line when compared to mPEG-b-PCL micelles. The similar cyto-
compatibility behaviour suggested that the PDL component 
was not different to PCL in its effects on cells, as in both cases 
the effects of PEG as corona were expected to be same. 
5.5 Conclusion 
In this study, the successful fabrication of mPEG-b-PDL 
micelles via a nanoprecipitation method using methanol as 
solvent was reported. No significant difference in average size 
was observed for mPEG-b-PDL micelles prepared using 
methanol as solvent when compared with the mPEG-b-PDL 
micelles fabricated using acetone. The encapsulation study of 
amphotericin B suggested that the mPEG-b-PDL micelles 
performed better in terms of drug loading than their 
counterpart mPEG-b-PCL micelles. The sustained release 
pattern was observed from mPEG-b-PDL micelles when 
compared with Tween 80 micelles as evident by in vitro 
release experiment. Additionally, with the help of an extra 
control (physically mixed copolymer) in release experiment, it 
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was demonstrated that the partition coefficient of a drug 
between carrier and dispersed phase was also a variable that 
influenced the release rate determined by the dialysis method. 
The investigated procedure for drug encapsulation proposed 
that these novel polymeric micelles could be useful for the 
encapsulation of highly hydrophobic drug molecules, which 
have good solubility in methanol (for ex. Paclitaxel) by 
nanoprecipitation method.  
The preliminary degradation study suggested that the ester 
bond of mPEG-b-PDL was susceptible to hydrolytic 
degradation. However, from the results, it can be 
hypothesised that the presence of long alkyl chain (steric 
effect) could be responsible for the slow degradation of mPEG-
b-PDL micelles. In vitro cell activity studies demonstrated that 
the novel mPEG-b-PDL and mPEG-b-PCL micelles were well 
tolerated by the studied HCT-116 human colon cancer cell. 
Based on the conclusions made above, further investigation of 
mPEG-b-PDL micelles as a drug delivery vehicle was proposed. 
Actively targeted micelles in chemotherapy have been 
reported to be an efficient approach for the treatment of 
cancer40. Therefore, in the subsequent study, preparation and 
evaluation of ligand tethered mPEG-b-PDL micelles for cancer 
therapy was proposed.  
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6.1 Introduction 
The delivery of an optimum concentration of a drug to the 
intended target site can minimise the systemic adverse 
reactions, reduce the dose, enhance its therapeutic efficiency 
and consequently improve patient compliance. Targeted drug 
delivery is crucial in cancer therapy and therefore extensive 
research is continuing to develop an effective treatment of 
cancer using targeted therapy. Although significant progress 
has been achieved for early stage cancer, the treatments are 
limited for advanced stage cancer1, 2. In conventional 
chemotherapy for late stage cancers, cytotoxic agents have 
been used to kill cancer cells, often on the assumption that 
these are more rapidly proliferating than normal cells and thus 
more prone to internalise drugs. However, due to the lack of 
selectivity and high toxicity associated with many anticancer 
drugs, severe side effects are often observed. Targeted 
delivery of an anticancer drug to a tumor has been suggested 
to increase the therapeutic efficacy and minimise the systemic 
toxic effects of anticancer agents1, 2. With the aid of drug 
targeting, selective killing of tumor cells is possible, leaving 
the normal cells unaffected and therefore fewer side effects 
are observed3. The strategy of drug targeting has been divided 
into ³DFWLYH´DQG ³SDVVLYH´categories. 
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Passive targeting is based on the Enhanced Permeation and 
Retention (EPR) effect4 in which drug-loaded polymeric nano-
carriers accumulate in solid tumors. It has been reported that 
effective retention of drugs in tumors through the EPR effect is 
generally observed with higher molecular weight drug loaded 
nano-carriers (typically > 40 kDa)5. Additionally, in passive 
targeting, the bulk (>95%) of administered drug-loaded nano-
carriers were found in other organs such as liver, lungs, and 
spleen6. Thus, it has been proposed that passive targeting is 
not very selective to tumors. Recently, Bae and Park 
suggested WKDW WKH WHUP ³SDVVLYH WDUJHWLQJ´ should be 
UHSODFHG ZLWK ³EORRG FLUFXODWLRQ DQG H[WUDYDVDWLRQ´ ZKLFK is 
not limited to tumors only6. 
Furthermore, it was reported that passive targeting is not very 
effective in multiple-drug resistance (MDR) tumors3. MDR is a 
condition in which cancer cells develop resistance towards one 
or more drugs. The overexpression of transporter proteins in 
cancer cells is responsible for MDR, as transporter protein 
frequently remove specific drugs from cancer cells. This leads 
to poor availability of the drug in tumors, which consequently 
reduces the effectiveness of treatment3. Moreover, variation in 
vascular permeability during tumor progression, tumor type 
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and in the anatomical location of tumors further limits the 
effectiveness of this approach for therapy in cancer2,7,6.  
Active targeting, also known as ligand-mediated targeting is 
another approach used for delivering cytotoxic agents to 
tumors. Active targeting has been suggested to be more 
effective when compared to passive targeting8. Superior 
antitumor activities of drug-loaded nano-carriers have been 
reported with active targeting due to their enhanced cellular 
internalisation via receptor-mediated endocytosis9,10. Active 
targeting of drug-loaded nano-carriers can be achieved by 
attaching a ligand, on the surface of the polymers, which 
binds with appropriate receptors expressed at the target site 
in vivo.  Commonly used ligands for tumor targeting are 
antibodies, proteins, peptides, nucleic acids, sugars, and small 
molecules such as vitamins10, 11.  
Among the different types of ligands utilised for the active 
targeting, folic acid (FA) as a ligand has been extensively 
studied in cancer therapy to deliver drug-loaded nano-carriers 
to tumor cells12. FA, a vitamin, and its reduced form are 
essential components for the biosynthesis of nucleotide bases 
via one-carbon transfer reactions. Therefore, cell proliferation 
and survival largely depends on their ability to uptake FA. 
Cells normally endocytose the FA either by reduced folate 
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carrier or via the folate receptor (FR)13. Reduced folate carrier 
is present in all cells and is able to provide a sufficient 
quantity of FA for cell growth. However, in many cancer cells, 
the FR is overexpressed, so that malignant cells can compete 
for the required FA with normal cells when the supply of this 
vitamin is limited12. Furthermore, the reduced folate carrier 
uptake mechanism is selective for the transportation of folate 
(reduced forms of folic acid) whereas FR favourably facilitates 
the uptake of folic acid (oxidised forms of folate)12. 
Therefore, a drug delivery carrier linked with folic acid has the 
ability to deliver its content specifically to cancer cells. Folic 
acid tipped carriers after binding to the FR present on to the 
cell surface have been shown to be taken up through receptor-
mediated endocytosis. The overexpressed FR is present in 
many human cancers which include breast, ovarian, colorectal, 
endometrial, brain, kidney, and lung14. 
In addition to the specific selectivity of folic acid to cancer cells 
its low immunogenicity, low molecular weight (mw ± 441.4), 
aqueous solubility, high stability, low cost, ready availability 
and facile conjugation chemistry make it an attractive ligand 
for use in drug targeting15, 16. Considering these advantages 
several folate-conjugated drug delivery carriers such as 
liposomes, nanoparticles, micelles, dendrimers, carbon 
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nanotubes have been investigated for targeted cancer therapy 
and has been reviewed recently16, 17. Based on the excellent in 
vitro and in vivo results, a few folic acid conjugated drug 
delivery systems have been entered in clinical trials18. 
Although liposomes, nanoparticles, and other drug delivery 
systems have been successfully used for the tumor targeting 
however, the use of polymeric micelles to deliver cytotoxic 
drug have their own advantages19 (refer chapter 1). Polymeric 
micelles have the ability to target tumor sites by active as well 
as passive mechanisms. Polymeric micelles after accumulation 
in tumors can selectively deliver the drugs to their subcellular 
targets by acting as intracellular ³7rojan horses´ thus; can 
overcome the drug resistance20, 21. The selective release of 
drugs can be achieved by pH sensitive micelles, which only 
release their content in the endosome and lysosome of cell 
(acidic pH), after internalisation by endocytosis22, 23. 
Furthermore, micelles have been shown to circumvent 
recognition by the drug efflux pump (such as P-glycoprotein) 
and thus can overcome multidrug resistance in cancer cells, 
which in turn enhanced the cellular concentration of drugs22, 
24. Attachment of a targeting ligand on the surface of 
polymeric micelles has been reported to enhance therapeutic 
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efficacy of a drug in cancer therapy by increasing its 
intracellular concentration23, 25. 
Folic acid-modified polymeric micelles have been widely 
studied for targeted therapy in cancer. Due to the functional 
group chemistry of FA, its conjugation with end-functionalised 
block copolymers is facile20. For instance, Yoo and Park 
reported the synthesis of folate conjugated PEG-b-PLGA block 
copolymers by amide chemistry. Folic acid was attached to the 
end-functionalised PLGA-b-PEG-NH2 YLD LWV Ǆ-carboxyl group. 
In vitro cytotoxicity studies in KB cells showed that these 
micelles displayed high uptake as well as cytotoxicity 
compared to non-targeted micelles26. In another study, FA 
was conjugated with a mPEG-b-PCL copolymer using similar 
chemistry but on the hydrophobic block (i.e. PCL). The 
obtained confocal images suggested that folate conjugated 
mPEG-b-PCL micelles were selectively taken up into MCF-7 
cells by folate-receptor mediated endocytosis27. Many reports 
have now been published proposing the effective treatment of 
cancer via folate conjugated polymeric micelles28-30. Therefore, 
it was hypothesised that FA conjugated PEG-b-PDL micelles 
could show their potential for targeted therapy in cancer. 
In this chapter, fabrication of PEG-b-PDL block copolymer 
micelles conjugated with FA is reported. Folic acid was 
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conjugated onto the N3-PEG-NH2 using a reported amidation 
reaction. Later this block was attached to the hydrophobic PDL 
block via click chemistry31. Rhodamine conjugated PEG-b-PDL 
copolymer was also synthesised for imaging purpose. A 
diblock copolymer (mPEG-b-PDL) was also synthesised using 
click chemistry for comparison studies. Mixed micelles of the 
functionalised and non-functionalised PEG-b-PDL copolymers 
were prepared and evaluated for the folate mediated targeting 
efficiency on human cancer cell lines in vitro.    
6.2 Methods 
6.2.1 Synthesis of Azide Terminated Poly(ethylene 
glycol) methyl ether 
Synthesis of methoxy-PEG-N3 using poly(ethylene glycol) 
methyl ether was accomplished in two steps via a reported 
procedure32. 
Step (I) ± Synthesis of tosylated poly(ethylene glycol) methyl 
ether: Poly(ethylene glycol) methyl ether (Mn=5.0 KDa, 2.00 
g, 0.40 mmol) was dissolved in anhydrous pyridine (10.0 mL) 
and toluene sulfonyl chloride (0.76 g, 4.00 mmol) was added 
to the solution. The reaction mixture was then stirred for 24 
hrs at room temperature under an inert atmosphere. The 
obtained solution was then precipitated four times in cold 
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diethyl ether and any solvent residue was removed under 
vacuum to obtain a white solid product (1.64 g, 82 %).  
mPEG-OTs -  1H NMR (400 MHz, CDCl3 į (ppm) 7.83 
(Aromatic-CH, d, 2H), 7.35 (Aromatic-CH, d, 2H), 4.23 ± 4.13 
(CH2-CH2-O-Tosyl, t, 2H), 3.66 (O-CH2-CH2-O, s, 508H), 3.40 
(O-CH3, s, 3H), 2.47 (Aromatic-CH3, s, 3H). 
Step (II) ± Synthesis of azide terminated poly(ethylene glycol) 
methyl ether: Tosylated poly(ethylene glycol) methyl ether 
(1.50 g, 0.25 mmol) was dissolved in DMSO (10.0 mL) and 
sodium azide (203.50 mg, 3.13 mmol) was added. The 
reaction mixture was then stirred for 24 hrs at room 
temperature under inert atmosphere. Dichloromethane (20.0 
mL) was then added to the reaction mixture and the organic 
layer was washed with cold distilled water (50.0 mL x 3), then 
with cold 6 M hydrochloric acid solution (50.0 mL x 2) and 
again with cold distilled water (50.0 mL x 2). The organic layer 
was dried with anhydrous MgSO4 and solvent was evaporated 
in vacuum. The obtained residue was then precipitated three 
times with cold diethyl ether. The solvent traces were then 
removed in vacuum to obtain an off white solid product (1.2 g, 
78 %). The conversion of tosyl to azide product as calculated 
by 1HNMR was 89%. 
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mPEG-N3 -
 1H NMR (400 MHz, CDCl3 į (ppm) 3.67 (O-CH2-
CH2-O, s, 508H), 3.43 ± 3.36 (O-CH3, CH2-CH2-N3, m, 4.9H) 
FTIR wavenumber (cm-1) - 2873 (C-H, stretching), 2079 
(N=N=N, stretching), 1464 (C-H, bending), 1091 (C-O, 
Stretching)  
6.2.2 Synthesis of Folate Conjugated Poly(ethylene 
glycol) 
Conjugation of folic acid on to the commercially available N3-
PEG-NH2.TFA salt was done in single step using a reported 
method33. Briefly, a solution of folic acid (0.055 g, 0.12 mmol) 
was prepared in anhydrous DMSO (2.0 mL) in the dark. 
Triethylamine (0.6 mL), N,NĻ-dicyclohexyl carbodiimide (DCC) 
(0.03 g, 0.15 mmol) and N-hydroxysuccinimide (NHS) (0.02 
g, 0.15 mmol) were then added to the above prepared 
solution. The reaction mixture was than stirred overnight at 
room temperature in the dark (covered flask) under a nitrogen 
atmosphere. Separately, N3-PEG-NH2.TFA salt (0.25 g, 0.05 
mmol) was dissolved in anhydrous DMSO (2.0 mL) 
contained triethylamine (0.1 mL) and stirred for 2 hrs. The 
solution of activated N3-PEG-NH2 was added to the solution of 
N-hydroxysuccinimidyl-ester of folic acid prepared above. The 
reaction mixture was then stirred for 24 hrs at room 
temperature in the dark. The obtained solution was then 
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precipitated several times in cold diethyl ether and any solvent 
residue was removed in vacuum. Recovered dry yellow solid 
was then dissolved in DCM (5.0 mL, a non-solvent for folic 
acid) and centrifuge in order to remove precipitate. 
Supernatant was collected after centrifugation and solvent was 
removed in vacuum. Further, the yielded product was 
dissolved in HPLC grade water (5.0 mL) and the pH was 
adjusted to 3.0 (approx.) using hydrochloric acid (1 M) to 
precipitate any remaining free folic acid. The solution was then 
filtered with 0.22µ syringe filter and dialysed (MWCO of 
dialysis bag ± 1000 Da)  against PBS (pH-7.4) for 3 days to 
ensure complete removal of any free folic acid and then for 2 
days against deionised (DI) water to remove salts (dialysis 
medium was changed in every 8 hrs). The final solution was 
then filtered and freeze dried to obtain the folate conjugate 
PEG-N3 which was light yellow in colour (251 mg, 92 %). To 
determine the amount of conjugated folic acid, folate±PEG5000-
N3 (FA-PEG-N3) was analysed on a UV-Vis spectrophotometer 
and the concentration of folic acid was calculated using a pre-
prepared standard calibration curve of folic acid (PBS was 
used as solvent to prepare different concentration of folic acid 
solution) DWǊmax of 280nm (figure 6-1 A). 
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Figure 6-1 Standard calibration curve of (A) folic acid and (B) rhodamine B 
isothiocyanate. The UV-Vis absorbance of folic acid and rhodamine B 
isothiocyanate solution (in PBS) was measured at wavelength of 280 and 
552 nm respectively. 
FA-PEG-N3 ± 1H NMR (400 MHz, DMSO-d6 contained few drops 
of D2O į (ppm) 8.65 (Ar-N-CH, d, 0.8H), 7.63 (Ar-CH, d, 
1.7H), 6.64 (Ar-CH, d, 1.7H), 4.50 (NH-CH2, d, 1.7H), 4.40 ± 
4.19 (CH2-CH-COOH, m, 0.8H), 3.49 (O-CH2-CH2-O, s, 498H), 
3.34 ± 3.26 (CH2-CH2-N3, m, 2H), 3.25 ± 3.10 (CH2-CH2-NH-
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COO, m, 1.6H), 2.43-2.10 (CH2-CH2-CH-COOH, m, 1.6H), 
2.10-1.75 (CH2-CH2-CH-COOH, m, 2.0H). 
MALDI-TOF MASS: N3-PEG-NH2.TFA - m/z Calculated ± 5000 
Found± 4706 [M]+  
FA-PEG-N3 ± m/z Calculated ± 5129, Found - 5176 [M + 
2Na]+.  
6.2.3 Synthesis of Rhodamine B Conjugated 
Poly(ethylene glycol) 
Conjugation of Rhodamine B isothiocyanate (RhB) on to 
commercially available N3-PEG-NH2.TFA salt was done via a 
reported method34. Briefly, N3-PEG-NH2.TFA salt (0.25 g, 0.05 
mmol) was dissolved in anhydrous DMSO (2.0 mL) that 
contained triethylamine (0.1 mL) and, the mixture stirred for 2 
hrs. Rhodamine B isothiocyanate (0.053 g, 0.10 mmol) was 
then added to the above solution and the reaction mixture was 
stirred for 24 hrs at room temperature. The obtained solution 
was precipitated four times in cold diethyl ether and any 
solvent residue was evaporated under vacuum. The dried red 
solid was then dissolved in HPLC grade water (5.0 mL) and 
dialysed (MWCO of dialysis bag ± 1000 Da) against DI water 
for 6 days (dialysis medium was changed in every 8 hrs) in 
order to remove free rhodamine B isothiocyanate. The 
obtained solution was then freeze dried to yield rhodamine 
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conjugated to PEG-N3, which was red in colour (231 mg, 84 
%). To determine the amount of rhodamine B, RhB±PEG5000-
N3 (RhB-PEG-N3) was analysed on UV-Vis spectrophotometer 
and concentration of rhodamine B was calculated using a pre-
prepared standard calibration curve of rhodamine DW Ǌmax of 
552nm (figure 6-1 B).  
1HNMR (400 MHz, CDCl3 į (ppm) 6.76 ± 6.25 (Ar-CH, m, 
5.3H), 3.66 (O-CH2-CH2-O, s, 509H), 3.45 ± 3.35 (CH2-CH2-
N3, m, 2H), 1.44 ± 1.01 (-N-CH2-CH3, m, 11.4H) 
1HNMR (400 MHz, DMSO-d6į (ppm) 10.57 (Ar-COOH, s, 0.5 
H), 8.01 (Ar-CH, m, 2.7H), 6.87 (Ar-CH, m, 5.4H), 3.52 (O-
CH2-CH2-O, s, 500H), 1.14 (-N-CH2-CH3, d, 11H) 
MALDI-TOF MASS: RhB-PEG-N3 ± m/z Calculated ± 5243, 
Found - 5361 [M +TFA] 
6.2.4 Synthesis of Propargyl-PDL 
Propargyl PDL was synthesised using a method reported in 
chapter 3. The degree of polymerisation selected for the 
synthesis of propargyl-PDL was 100. The Mn found by SEC was 
used for further calculations. 
6.2.5 Synthesis of Block Copolymers via Click Chemistry 
The block copolymers of PEG and PDL were synthesised using 
azide alkyne click chemistry35. The reaction between azide of 
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PEG and alkyne of PDL was performed at room temperature 
using copper as catalyst to yield mPEG-b-PDL, FA-PEG-b-PDL 
and RhB-PEG-b-PDL. Briefly, propargyl-PDL (1.82 g, 0.24 
mmol), mPEG-N3 (0.48 g, 0.10 mmol) and Ļ-Bipyridyl 
(0.02g, 0.10 mmol) were dissolved in 2.0 mL of 
dimethylacetamide (DMAc) under a nitrogen atmosphere. 
Copper (I) bromide (0.7 mg, 0.005 mmol) was then added to 
the above solution and the flask was sealed under nitrogen 
atmosphere. A saturated solution of sodium ascorbate (10 µl) 
in water was diluted to 100µl with DMAc and added to the 
reaction mixture. This is an additional precaution to prevent 
the oxidation of copper during the reaction. The reaction 
progress was monitored by 1HNMR and complete conversion 
was observed after 48 hrs of stirring. The obtained solution 
was then precipitated four times in petroleum ether to remove 
excess of propargyl-PDL and Ļ-bipyridyl. The precipitate 
was then dissolved in a minimum quantity of chloroform and 
centrifuged (15000 rpm, 2 min.) to remove copper and 
sodium ascorbate. The organic layer was collected and solvent 
was evaporated in vacuum to yield the product, which was a 
hard wax-like material (1.0 g, 87%). A similar procedure was 
followed to synthesise FA-PEG-b-PDL and RhB-PEG-b-PDL 
using FA-PEG-N3 (200 mg) and RhB-PEG-N3 (180 mg) 
respectively. The quantity of Ļ-bipyridyl (1 equivalent) and 
CHAPTER 6 
Page | 232  
 
copper (I) bromide (0.05 equivalent) was calculated based on 
the amount of PEG used. The percentage yield observed for 
FA-PEG-b-PDL was 81% (398 mg) while 79% (361mg) yield 
was observed for RhB-PEG-b-PDL. 
mPEG-b-PDL:  
1H NMR (400 MHz, CDCl3į (ppm) 7.80 (Triazole-CH, s, 1H), 
5.23 (COO-CH2-Triazole, s, 2H), 5.02 ± 4.78 (CH-O-CO, m, 
42H), 4.66 ± 4.46 (CH2-CH2-triazole, t, 2H), 3.93 ± 3.86 (CH2-
CH2-triazole, t, 2H), 3.66 (O-CH2-CH2-O, s, 507H), 3.39 (O-
CH3, s, 3H), 2.42 ± 2.21 (O-CO-CH2, m, 85H), 1.77 ± 1.40 
(CH2-CH2-CH-CH2, m, 254H), 1.40 ± 1.16 (CH2-CH2-CH2-CH3, 
m, 259H), 0.89 (CH3, t, 129H). 
FTIR wavenumber (cm-1): 2858 (C-H, stretching), 1729 (C=O, 
stretching), 1341 (C-H, bending), 1103 (C-O, Stretching).  
FA-PEG-b-PDL: 
1HNMR (400 MHz, CDCl3į (ppm) 7.80 (Triazole-CH, s, 1H), 
5.22 (COO-CH2-Triazole, s, 2H), 5.00 ± 4.80 (CH-O-CO, m, 
42H), 4.65 ± 4.49 (CH2-CH2-triazole, t, 2H), 3.96 ± 3.87 (CH2-
CH2-triazole, t, 2H), 3.65 (O-CH2-CH2-O, s, 500H), 2.48 ± 
2.19 (O-CO-CH2, m, 86H), 1.89 ± 1.40 (CH2-CH2-CH-CH2, m, 
253H), 1.40 ± 1.14 (CH2-CH2-CH2-CH3, m, 259H), 1.03 ± 0.76 
(CH3, t, 131H). 
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1HNMR (400 MHz, DMSO-d6į(ppm) 8.66 (Ar-N-CH, s, 1H), 
8.06 (Triazole-CH, s, 1H), 7.66 (Ar-CH, s, 1.7H), 6.66 (Ar-CH, 
s, 2H), 4.96 ± 4.60 (CH-O-CO, m, 42H), 4.54 (CH2-CH2-
triazole, NH-CH2, d, 4H), 3.89 ± 3.75 (CH2-CH2-triazole, m, 
2H), 3.51 (O-CH2-CH2-O, s, 546H), 1.45 (CH2-CH2-CH-CH2, m, 
247H), 1.20 (CH2-CH2-CH2-CH3, m, 246H), 0.80 (CH3, s, 
133H). 
RhB-PEG-b-PDL 
1HNMR (400 MHz, CDCl3į (ppm) 7.80 (Triazole-CH, s, 1H), 
5.22 (COO-CH2-Triazole, s, 2H), 4.89 (CH-O-CO, m, 42H), 
4.61 ± 4.51 (CH2-CH2-triazole, t, 2H), 3.95 ± 3.87 (CH2-CH2-
triazole, t, 2H), 3.66 (O-CH2-CH2-O, N-CH2-CH3 s, 500H), 2.45 
± 2.21 (O-CO-CH2, m, 85H), 1.78 ± 1.40 (CH2-CH2-CH-CH2, m, 
257H), 1.40 ± 1.16 (CH2-CH2-CH2-CH3, N-CH2-CH3 m, 270H), 
1.00 ± 0.78 (CH3, t, 133H). 
1HNMR (400 MHz, DMSO-d6 į (ppm) 8.24 (Ar-CH, s, 1H), 
8.06 (Triazole-CH, s, 1H), 7.66 (Ar-CH, m, 1H), 7.54 ± 7.38 
(Ar-CH, m, 1H), 6.54 (Ar-CH, m, 6H), 5.05 ± 4.60 (CH-O-CO, 
m, 43H), 4.54 (CH2-CH2-triazole, m, 2H). 
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6.2.6 Preparation and Characterisation of Mixed Micelles 
Mixed micelles of synthesised functional copolymers were 
prepared by nanoprecipitation method. Two formulations of 
micelles were prepared using an automated syringe pump. 
The details of the polymers quantities used were as follow: 
x PDL Formulation ± Contained mPEG-b-PDL (10 mg) 
and RhB-PEG-b-PDL (0.5 mg) 
x PDLFA Formulation ± Contained mPEG-b-PDL (8 mg), 
FA-PEG-b-PDL (2 mg) and RhB-PEG-b-PDL (0.5 mg) 
Briefly, calculated quantities (as above) of copolymers were 
dissolved in acetone (1.5 mL) and this solution was added 
drop-wise into PBS (3.0 mL) under stirring (1000rpm) using a 
syringe pump. The flow rate used was 0.25 mL/min. The 
samples were left under stirring for 3 hrs and then left aside 
for additional 2 hrs at room temperature to ensure complete 
removal of acetone. Both formulation was filtered through a 
0.22µ syringe filter and used for further analysis. 
Micelle size and surface charge was measured using a 
Zetasizer Nano ZS instrument. The concentration of samples 
used for the analysis was 70µg/mL. Micelle size was measured 
in PBS and in RPMI while the surface charge was measured in 
HEPES buffer (pH- 7.4, 10mM). Further, the samples were 
imaged using TEM to confirm the size and to determine the 
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surface morphology. TEM samples (70 µg/mL) were prepared 
in HPLC grade water. The concentration of folic acid Ǌmax ± 
280nm) and rhodamine B Ǌmax ± 552nm) present in the 
purified micelle solution was measured using UV-Vis 
spectroscopy. All UV-Vis absorbance were acquired in PBS and 
the concentration was calculated using a previously prepared 
standard calibration curve.  
6.2.7 Cellular Uptake Studies 
The cellular uptake studies was kindly performed by Dr. Laura 
Purdie and Lee Moir. Human cancer cell lines i.e. MCF-7 
(FR+ve, breast cancer cell line) and A549 (FR-ve, human lung 
adenocarcinoma epithelial cell line) were cultured in RPMI-
1640 (folate free) media containing 10% fetal bovine serum 
and 2 mM L-glutamine at 37° C with 5% CO2. Cells were 
seeded at 35,000 cells per chamber in an eight chamber 
borosilicate glass chamber slide. The whole media were 
removed after 24 hrs and cells were then incubated for 2.5 hrs 
ZLWK 3'/ DQG 3'/)$ PLFHOOHV  ǋJPL each) diluted in 
media with and without free folic acid (5 ǋJPL for 
competitive binding assay). After 2.5 hrs, media were 
removed from all chambers and cells were washed three times 
with PBS. To fix the cells, 4% paraformaldehyde (PFA) in 
PBS was added for 10 minutes at room temperature (RT). 
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After 10 minutes, PFA solution was removed and cells were 
washed three times with PBS and then treated with Hoechst 
(nuclear) stain for 5 minutes prior to imaging. Hoechst stain 
was removed after 5 minutes and the cells were washed with 
PBS. Control experiments were also performed at 4°C instead 
of 37°C to determine the energy-dependent uptake. The 
uptake of PDL and PDLFA micelles was then examined by Leica 
confocal microscope at emission wavelength of 580 nm.  
6.3 Results  
6.3.1 Synthesis and Characterisation of Block 
Copolymers 
Scheme 6-1 illustrates the synthesis methodology used to 
prepare the desired azide terminated PEG. Functionalised 
block copolymers were synthesised using commercially 
available N3-PEG-NH2.TFA while azide terminated mPEG was 
prepared in the laboratory to generate a non-targeted block 
copolymer. All block copolymers were synthesised in three 
steps i. e. (I) synthesis of desired azide terminated hydrophilic 
block (i.e. PEG), (II) synthesis of alkyne terminated 
hydrophobic block (i.e. PDL) and (III) linking of azide and 
alkyne terminated block by click chemistry.  
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(A) 
 
(B) 
 
(C) 
 
Scheme 6-1 Synthesis scheme of (A) PEG-azide, (B) FA-PEG-azide and (C) 
RhB-PEG-azide (RT= room temperature, NHS - N-hydroxysuccinimide, 
DCC- 11Ļ-dicyclohexylcarbodiimide). 
The conversion of the mPEG-OH into mPEG-azide was 
facilitated by preparing a more reactive mPEG-tosyl 
intermediate. The conversion of hydroxyl end group of mPEG-
OH into mPEG-tosyl was confirmed by 1HNMR (figure 6-2A). 
Appearance of a triplet peak at 4.2 ppm (corresponding to 
methylene protons next to the tosyl group, figure 6-2A, 
position 4) suggested the attachment of tosyl group to the 
PEG32.  Later, the tosyl group was replaced with azide by 
reacting the intermediate with sodium azide. Appearance of  
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Figure 6-2 1HNMR spectra of (A) mPEG-OTs and (B) mPEG-N3 acquired in 
chloroform-d. Inset in figure B showing the appearance of triplet peak at 
3.4 ppm.   
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Figure 6-3 Overlapped FTIR spectra of mPEG5000-OH before and after azide 
conversion of hydroxyl group. 
triplet at 3.3ppm (corresponding to the methylene proton next 
to azide, figure 6-2B, position 2) and disappearance of peak at 
4.2 ppm suggested the successful conversion of intermediate 
into product (figure 6-2B). mPEG-N3 was also characterised by 
FTIR and a peak detected at 2079 cm-1 suggested the 
presence of azide group in sample (figure 6-3). However, the 
peak is not distinguishable and hence the synthesis 
confirmation is basically rely on NMR. 
The conjugation of folic acid (FA) and rhodamine B 
isothiocyanate (RhB) to the amine group are well established 
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and facile reactions. FA and RhB were conjugated to the NH2-
PEG-N3 using reported mild reaction condition
33, 34 (scheme 6-
1 B, C).  
 
 
Figure 6-4 1HNMR of FA-PEG-N3 in DMSO-d6 that contained few drops of 
D2O. The water peak generally observed at 3.3ppm in DMSO which was 
shifted to 3.7 due to the presence of D2O. 
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Figure 6-5 1HNMR of RhB-PEG-N3 conjugate acquired in chloroform-d (top) 
and DMSO-d6 (bottom). 
1HNMR spectra in DMSO-d6 was acquired to 
visualise the peak of rhodamine B. 
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NH2-PEG-N3 was procured as a TFA salt and therefore it was 
treated with triethylamine before reaction to generate amine 
terminated PEG. Purified PEG conjugates (i.e. FA-PEG-N3 and 
RhB-PEG-N3) were characterised by 
1HNMR, MALDI-TOF MASS 
and SEC. Proton NMR spectrum of FA-PEG-N3 was acquired in 
DMSO-d6, which contained a few drops of D2O to shift the 
residual water (present in DMSO-d6) peak at 3.7 ppm. The 
methylene proton next to the azide group at 3.3 ppm was 
used as a standard for the comparative integration of other 
peaks (figure 6-4, position 7). The proton resonance and peak 
positions observed in the 1HNMR spectrum of FA conjugated 
PEG were matched with the values reported in literatures30, 36, 
which suggesting the successful conjugation of folic acid to 
PEG.  
The conjugation of rhodamine B isothiocyanate with PEG was 
confirmed with 1HNMR acquired in chloroform-d and DMSO-d6. 
The proton resonance of other peaks with respect to the 
methylene proton next to the azide group of PEG (figure 6-5, 
position 3, acquired in CDCl3) suggested the successful 
conjugation of RhB to PEG (figure 6-5). The peak positions 
observed for conjugated RhB were matched with the previous 
reported values37. Further, FA-PEG-N3 and RhB-PEG-N3 were 
characterised by MASS and SEC. Changes in the peak shape 
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and position further confirmed the conjugation of FA and RhB 
to PEG as evident by MALDI-TOF MASS spectra (figure 6-6). 
The molecular weight (m/z) demonstrated by the highest peak 
(100% intensity) detected in MASS spectra was selected to 
represent the product molecular weight. The molecular weight 
detected by MASS technique for the conjugates were matched 
with the calculated molecular weight.   
   
 
Figure 6-6 Overlapped MALDI-TOF MASS spectra of folic acid (FA), 
rhodamine B (RhB) conjugated PEG and non-conjugated PEG. 
The Mn observed in SEC analysis for N3-PEG-FA (Mn ~ 
16.3KDa, PD-1.02) and N3-PEG-RhB (Mn ~ 21.5KDa, PD-1.14) 
were more than the expected values but the change in 
retention time in SEC traces suggested the conjugation of FA 
and RhB on PEG (Mn ~ 7.1KDa, PD-1.05) (figure 6-7). 
However, SEC traces suggested the presence of free PEG in 
the final product, which indicates incomplete conversion. The 
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PEG conjugates were used in the next step without further 
purification, considering that any azide terminated PEG will be 
converted into block copolymer in subsequent stage.  
 
Figure 6-7 SEC trace of PEG conjugates and commercial PEG-azide. 
Chloroform was used as mobile phase and Mn was calculated against 
polystyrene polymer as reference 
PEG conjugates of FA and RhB were further analysed on UV-
Vis spectroscopy to determine the concentration of folic acid 
and Rhodamine B in samples. No change LQǊmax was observed 
after the conjugation of FA and RhB with PEG as evident by 
UV-Vis spectra. According to the results, each milligram of FA-
PEG-N3 contained 81.84 µg of folic acid while 101.65 µg of 
rhodamine B was present in each milligram of RhB-PEG-N3. 
The percentage conversion calculated based on UV-vis results 
suggested 88 and 89.2% of conjugation of folic acid and 
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rhodamine B to PEG respectively. Based on the overall 
characterisation results, it can be concluded that desired PEG 
blocks were synthesised successfully. However, the final 
products contained some free PEG. 
The hydrophobic block i.e. alkyne terminated PDL was 
synthesised by ROP of į-decalactone using propargyl alcohol 
as initiator. The characterisation data has been already 
reported in chapter 3 and hence was not reproduced here. 
The last step i.e. linking of PEG and PDL was done via a 
copper catalysed click reaction to fabricate the amphiphilic 
block copolymers (scheme 6-2). Excess of propargyl-PDL was 
used in the reactions to ensure complete consumption of azide 
terminated PEG.  Copper was separated from the product by a 
simple solvent extraction process (figure 6-8).  
 
Figure 6-8 Picture of separated copper at bottom of eppendorf after 
centrifugation at 15000 rpm for 2 minutes. Copolymer (FA-PEG-b-PDL) 
solution was made in chloroform at a concentration of 100 mg/mL. 
Copper 
FA-PEG-b-
PDL 
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Scheme 6-2 Synthesis scheme of block copolymers of į-decalactone via 
click chemistry 
Purified block copolymers were characterised by FTIR (figure 
6-9), NMR and by SEC to confirm synthesis and purity of 
products. Disappearance of peak in 1HNMR at 3.3 ppm 
(corresponds to CH2-N3) and appearance of new peak at 7.8 
(characteristic peak of triazole ring proton)35, 5.2, 4.5 and 3.9 
ppm suggested the successful conjugation of all azide 
terminated PEG to alkyne terminated PDL (figure 6-10 to 6-
12). All other peak positions were matched with values 
reported in chapter 3.  
 
PEG PDL 
PEG PDL Rhodamine 
PEG PDL Folic Acid 
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   Sample ID 
Mn by 
1HNMR 
(KDa) 
Mn by SEC 
(KDa) 
PD by 
SEC 
mPEG-b-PDL 12.2 21.0 1.06 
FA-PEG-b-PDL 12.6 43.1 1.15 
RhB-PEG-b-PDL 12.7 48.4  1.25 
Table 6-1 Mn of synthesised copolymers determined by 
1HNMR and by SEC 
using chloroform as solvent and polystyrene polymer as reference (PD- 
polydispersity). 
 
Figure 6-9 Overlapped FTIR spectra of mPEG-azide and mPEG-b-PDL 
synthesised by click reaction. 
The 1HNMR of copolymer FA-PEG-b-PDL and RhB-PEG-b-PDL 
were also acquired in DMSO to see the peaks of FA and RhB 
(figure 6-11 and 6-12). No change in peak positions of FA and 
RhB (conjugated with PEG) were observed after attachment of 
PEG onto PDL block.  Molecular weight of copolymers were 
calculated through 1HNMR by comparing the number of 
protons at 4.9 ppm (PDL chain, position 3) with respect to the 
proton resonance of PEG chain at 3.66 or 3.39 (for mPEG 
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only) ppm and the proton of the triazole ring at 7.8 ppm (table 
6-1, figure 6-10 to 6-12). 
 
 
Figure 6-10 (A) 1HNMR spectra of mPEG-b-PDL synthesised by click 
reaction and (B) overlapped 1HNMR spectra of mPEG-N3, mPEG-b-PDL,FA-
PEG-N3 and FA-PEG-b-PDL. Disappearance of peak at 3.42 ppm and 
appearance of peak at 3.90 ppm suggesting the conversion of azide in to 
triazole.  
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Figure 6-11 1HNMR spectra of FA-PEG-b-PDL acquired in chloroform-d and 
DMSO-d6. Due to poor solubility of folic acid in chloroform-d, 
1HNMR 
spectra of FA-PEG-b-PDL was also acquired in DMSO-d6 to visualise the 
folic acid peaks between 6.5-9.0 ppm. 
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Figure 6-12 1HNMR spectra of RhB-PEG-b-PDL acquired in chloroform-d 
and DMSO-d6. Due to poor solubility of rhodamine B in chloroform-d, 
1HNMR spectra of RhB-PEG-b-PDL was also acquired in DMSO-d6 to 
visualise the rhodamine peaks between 6.0-8.5 ppm  
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Further samples were analysed on size exclusion 
chromatography. The SEC chromatogram was acquired using 
chloroform as eluent and Mn was obtained using polystyrene 
as internal standard (figure 6-13, table 6-1). The retention 
time observed for each sample confirmed the conjugation of 
the PDL block to the PEG block. However, additional peaks 
were also observed in the SEC traces, which suggested the 
presence of free PEG and PEG conjugates (FA-PEG and RhB-
PEG) in the sample. 
 
Figure 6-13 Overlapped SEC traces of various PEG-b-PDL copolymers. 
Chloroform was used as mobile phase and Mn was calculated against 
polystyrene polymer as reference. 
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6.3.2 Preparation and Characterisation of Block 
Copolymer Micelles 
Micelles of synthesised block copolymers were prepared using 
an automated syringe pump via nanoprecipitation. The syringe 
pump was used to control the drop-rate of organic solvent in 
PBS, in order to obtain a consistent size in each batch. Due to 
the poor solubility of folic acid in water, PBS was used as a 
solvent during the fabrication of the micelles. The prepared 
micelle formulations is shown in figure 6-14. 
 
Figure 6-14 Pictorial presentation of different micelle formulations prepared 
in this study. PDL micelles were prepared by mixing mPEG-b-PDL (10 mg) 
and RhB-PEG-b-PDL (0.5 mg) block copolymers whereas PDLFA micelles 
were prepared by mixing mPEG-b-PDL (8 mg), FA-PEG-b-PDL (2 mg) and 
RhB-PEG-b-PDL (0.5 mg) block copolymers. 
 
PEG PDL PEG PDL Rhodamine PEG PDL Folic Acid 
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mPEG-b-PDL RhB-PEG-b-PDL FA-PEG-b-PDL 
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Both micelles preparations were characterised by DLS and the 
intensity and volume size distribution are shown in figure 6-
15, while the mean sizes are reported in table 6-2. No 
significant difference in Z-average size was observed for the 
both micelle formulations. However, due to the broad size 
distribution of the obtained micelles, the obtained Z-average 
size was almost double to the size observed in previous 
studies (see chapter 4 & 5).  
Sample 
Size by 
intensity 
(d/nm) (± 
SD) 
Size by 
volume 
(d/nm) (± 
SD) 
Z-average 
Size 
(d/nm) (± 
SD) 
PDI (± 
SD) 
Zeta 
Potential 
(mv) (± 
SD) 
PDL 
133 ± 5, 
24± 5 
33 ± 3 83 ± 3 0.34 ± 0.2 -2 ± 1 
PDLFA 118 ± 5 32 ± 3 76 ± 4 0.30 ± 0.1 -6 ± 1 
Table 6-2 Mean size and zeta potential  of PDL and PDLFA micelles. Size 
was measured in PBS (10mM, pH-7.4) whereas zeta potential was 
measured in HEPES buffer (10mM, pH-7.4). The concentration of samples 
used for analysis was 70 µg/mL. (SD - standard deviation, d/nm ± 
diameter in nanometre, PDI- polydispersity index, mv- millivolt). 
 
Figure 6-15 Size distribution by (A) Intensity and (B) volume of PDL and 
PDLFA micelles dispersed in PBS at room temperature. The concentration 
of samples used for analysis was 70 µg/mL. 
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The size distribution of the micelles was also determined in 
RPMI-1640 (cell culture media used in uptake study) to 
understand the effect of solvent on size. Due to the presence 
of proteins, the major size distribution peak (by volume) 
observed in RPMI-1640 was at approximately at 8nm. 
Therefore, only size distribution by intensity was considered 
for the comparison (figure 6-16). The mean size observed in 
RPMI was 58±3 nm for both samples. The size and size 
distribution detected for PDL and PDLFA micelles in RPMI-1640 
were comparable and hence the effect of size during uptake 
studies for both formulations would be negligible38. 
 
Figure 6-16 Size distribution by intensity of the micelles dispersed in RPMI 
media at room temperature. The concentration of samples used for 
analysis was 70 µg/mL. 
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The zeta potential observed for the PDL micelles was close to 
neutral. However, a slight negative charge was observed for 
PDLFA micelles when compared to PDL micelles due to the 
presence of folic acid on the micelles surface39 (table 6-2, 
figure 6-17). Both samples were further imaged using TEM to 
check the morphology and to confirm the size. Images 
acquired from TEM suggested that both micelle formulations 
were approximately spherical in shape with smooth surfaces. 
The size determined from TEM images was in the range of 20 
to 200nm, which spanned the size ranges detected by DLS 
(figure 6-18). 
 
Figure 6-17 Zeta potential distribution of (A) PDL and (B) PDLFA micelles in 
HEPES buffer (10mM, pH-7.4). The concentration of samples used for 
analysis was 70 µg/mL. 
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Figure 6-18 TEM image of (A) PDL and (B) PDLFA micelles. The samples 
were prepared in HPLC grade water with concentration of 70 µg/mL. 
Images were obtained without staining. Scale bar-200 nm. 
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The concentrations of rhodamine B and folic acid present in 
the final micelle formulations were determined by UV-vis 
spectroscopy. The overlaid UV-Vis spectrum of PDL and PDLFA 
micelles is presented in figure 6-19. The concentration of 
rhodamine B found in both micelle formulations was 
13.4µg/mL whereas 39.4 µg/mL of folic acid was present in 
PDLFA micelles. 
 
Figure 6-19 UV-Visible spectra of PDL and PDLFA micelles acquired using 
PBS as solvent. PDL and PDLFA micelles after purification were diluted by 
10 times using PBS before scanning.  
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6.3.3 Cellular Uptake Study of Block Copolymer Micelles 
Micelle formulations (PDL and PDLFA) were tested on two cell 
lines (i.e. A549 and MCF-7) to assess the effect of presence of 
folic acid on the micelles surface. The study was performed in 
the presence and absence of free folic acid in cell culture 
media to probe the folate receptor-mediated targeting 
(competitive assay). Interestingly, the uptake of both micellar 
formulations was observed in the tested cells regardless of the 
expected folate receptor expression level and 
presence/absence of free folic acid. As shown in figure 6-20 to 
6-23, both formulations were taken up by the A549 (FR-ve) 
and MCF-7 (FR+ve) cell lines as evident by confocal 
microscopy images. No specific cellular uptake was observed, 
which was contrary to the expected results. The uptake of 
micelles was reduced significantly at 4°C, which suggested 
that the uptake process was energy-dependent (figure 6-24 
and 6-25). These preliminary cell uptake studies thus 
suggested that the fabricated novel PEG-b-PDL copolymer 
micelles were taken up non-specifically by the human cancer 
cells (MCF-7 and A549) via endocytic pathways, which did not 
require folate-receptor recognition. 
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Figure 6-20 Confocal microscopy images of the A549 (FR-ve) cells treated 
with PDL micelles without (1A and 1B) and with added free folic acid (2A 
and 2B) present in the culture medium at 37°C for 2.5 hrs. Micelles were 
labeled with rhodamine (red) and nuclei of cells were stained with Hoechst 
(blue). The micelle concentration in the incubation medium was 100 µg/mL 
while the concentration of free folic acid used for the competitive assay 
was 500 µg/mL. PDL micelles were prepared by using mPEG-b-PDL (10 
mg) and RhB-PEG-b-PDL (0.5 mg) block copolymer. Scale bars = 20µm. 
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Figure 6-21 Confocal microscopy images of the A549 (FR-ve) cells treated 
with PDLFA micelles (folate conjugated) without (1A and 1B) and with 
added free folic acid (2A and 2B) present in the culture medium at 37°C 
for 2.5 hrs. Micelles were labeled with rhodamine (red) and nuclei of cells 
were stained with Hoechst (blue). The micelle concentration in the 
incubation medium was 100 µg/mL while the concentration of free folic 
acid used for the competitive assay was 500 µg/mL. PDLFA micelles were 
prepared by using mPEG-b-PDL (8 mg), FA-PEG-b-PDL (2 mg) and RhB-
PEG-b-PDL (0.5 mg) block copolymer. Scale bars = 20µm. 
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1A 
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Nucleus  Micelles Merged 
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Figure 6-22 Confocal microscopy images of the MCF-7 (FR+ve) cells 
treated with PDL micelles without (1A and 1B) and with added free folic 
acid (2A and 2B) present in the culture medium at 37°C for 2.5 hrs. 
Micelles were labeled with rhodamine (red) and nuclei of cells were stained 
with Hoechst (blue). The micelle concentration in the incubation medium 
was 100 µg/mL while the concentration of free folic acid used for the 
competitive assay was 500 µg/mL. PDL micelles were prepared by using 
mPEG-b-PDL (10 mg) and RhB-PEG-b-PDL (0.5 mg) block copolymer. 
Scale bars = 20µm. 
1A 
1B 
Nucleus  Micelles Merged 
2A 
2B 
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Figure 6-23 Confocal microscopy images of the MCF-7 (FR+ve) cells 
treated with PDLFA micelles (folate conjugated) without (1A and 1B) and 
with added free folic acid (2A and 2B) present in the culture medium at 
37°C for 2.5 hrs. Micelles were labeled with rhodamine (red) and nuclei of 
cells were stained with Hoechst (blue). The micelle concentration in the 
incubation medium was 100 µg/mL while the concentration of free folic 
acid used for the competitive assay was 500 µg/mL. PDLFA micelles were 
prepared by using mPEG-b-PDL (8 mg), FA-PEG-b-PDL (2 mg) and RhB-
PEG-b-PDL (0.5 mg) block copolymer. Scale bars = 20µm. 
1A 
1B 
Nucleus  Micelles Merged 
2A 
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Figure 6-24 Confocal microscopy images of the A549 (FR-ve) cells treated 
with PDL (1A and 1B) and PDLFA (folate conjugated) (2A and 2B) micelles 
at 4°C for 2.5 hrs in the absence of folic acid in the culture medium. 
Micelles were labeled with rhodamine (red) and nuclei of cells were stained 
with Hoechst (blue). The micelle concentration in the incubation medium 
was 100 µg/mL. PDL micelles were prepared by using mPEG-b-PDL (10 
mg) and RhB-PEG-b-PDL (0.5 mg) block copolymer. PDLFA micelles were 
prepared by using mPEG-b-PDL (8 mg), FA-PEG-b-PDL (2 mg) and RhB-
PEG-b-PDL (0.5 mg) block copolymer. Scale bars = 20µm. 
Nucleus  Micelles Merged 
1A 
1B 
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Figure 6-25 Confocal microscopy images of the MCF-7 (FR+ve) cells 
treated with PDL (1A and 1B) and PDLFA (folate conjugated) (2A and 2B) 
micelles at 4°C for 2.5 hrs in the absence of folic acid in the culture 
medium. Micelles were labeled with rhodamine (red) and nuclei of cells 
were stained with Hoechst (blue). The micelle concentration in the 
incubation medium was 100 µg/mL. PDL micelles were prepared by using 
mPEG-b-PDL (10 mg) and RhB-PEG-b-PDL (0.5 mg) block copolymer. 
PDLFA micelles were prepared by using mPEG-b-PDL (8 mg), FA-PEG-b-
PDL (2 mg) and RhB-PEG-b-PDL (0.5 mg) block copolymer. Scale bars = 
20µm. 
Nucleus  Micelles Merged 
1A 
1B 
Nucleus  Micelles Merged 
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6.4 Discussion 
In chapter 3, the formation of undesired free homopolymer 
was noted during the ROP of į-decalactone. Therefore, it was 
postulated that repetition of reactions to achieve the similar 
molecular weight polymer was not the best approach.  Thus, 
to keep the same molecular weight of hydrophobic block (i.e. 
PDL) in all block copolymers, click chemistry was selected for 
the synthesis to generate amphiphilic block copolymers. The 
1,3-dipolar cycloaddition of alkyne and azide often termed as 
"Click Chemistry" is a method of choice to couple a molecule 
containing an azide group with a molecule having alkyne 
groups, quickly and efficiently40. Copper catalysed click 
chemistries usually promote efficient reactions at room 
temperature and are very robust processes to generate 
regioselective products41.  
The azide-terminated methoxy-PEG was synthesised via a 
reported procedure with approximately 90 % of azide 
functionality present in the final product. The percent azide 
content observed with mPEG-N3 synthesised in laboratory was 
almost identical to the commercialised PEG (NH2-PEG-N3), 
which was procured to synthesise the functionalised PEG-
azide. Folic acid was conjugated to amine-terminated PEG via 
amide bond while rhodamine B was conjugated to the polymer 
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through a thiourea bond. The Mn observed by SEC for PEG 
conjugates (FA-PEG-N3 and RhB-PEG-N3) were higher than the 
expected values. This difference in the Mn detected by SEC 
was probably due to poor solubility of FA and RhB in 
chloroform (mobile phase used in SEC). Since the separation 
of product in SEC column is based on the solvo-dynamic 
radius and not on the molecular weight, the solubility of a 
given sample in the mobile phase markedly affects the 
measured molar mass. It is very likely that the PEG 
conjugates, due to the poor solubility of attached molecules 
(FA and RhB) could exist as aggregates in chloroform thus 
increasing the radius of polymeric species in solution. Any 
aggregates would have been eluted quickly, giving an 
apparent high Mn value compared to the polystyrene polymer 
standards used as calibrants. The poor solubility of folic acid 
and rhodamine in chloroform was clearly apparent in 1HNMR 
spectra of FA-PEG-N3 and RhB-PEG-N3. The proton peaks of FA 
and RhB were not visible in CDCl3 (poor solvent for these 
compounds), probably due to the formation of micelle like 
structure of conjugates with PEG as corona and RhB or FA as 
core28, 42. 
The coupling of PEG-azide with alkyne PDL was evident by 
1HNMR in which a proton peak of a newly formed triazole ring 
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was clearly noticeable. The proton NMR spectra of FA-PEG-b-
PDL and RhB-PEG-b-PDL were also acquired in DMSO-d6 to 
observe the peaks of FA and RhB. The SEC traces obtained for 
the block copolymers suggested the presence of free mPEG 
and PEG conjugates (FA-PEG and RhB-PEG) in the final 
purified products. Although as per the 1HNMR, 100% of azide 
was converted into triazole but due to the presence of 
approximately 10% of non azide PEG, free mPEG and PEG 
conjugates (FA-PEG and RhB-PEG) were detected in SEC 
analysis. The amount of free PEG and/or PEG conjugates in 
final polymer was expected to be 10% (based on azide 
functionalities). PEG itself is fully water soluble and it was 
reported that presence of PEG5k on the surface of 
nanoparticles reduced cellular uptake by minimizing protein 
adsorption43. Hence, it is very unlikely that free PEGs would 
internalize in cells and therefore were not separated from 
block copolymers. 
The Z-average size of the PDL and PDLFA micelles observed in 
PBS was almost double the size observed for mPEG-b-PDL 
micelles prepared in water. It should be noted that the 
presence of electrolytes in aqueous media during micelle 
fabrication does exert an effect on the aggregation number 
and ultimately size44. It has been reported that the presence 
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of salts in the dispersion medium increase the aggregation 
number of micelles45. A rise in aggregation number leads to an 
increased number of copolymers chains in the micellar 
structure which in turn gave large size micelles. This explains 
the difference in size, which was observed when micelles were 
prepared in PBS when compared with micelles fabricated in 
water.        
The preliminary in vitro cellular uptake studies suggested the 
non-specific uptake of novel PEG-b-PDL micelles in MCF-7 and 
A549 cells lines. The PEG-b-PDL micelles might have been 
taken up by the cells via pinocytosis pathways based on their 
size and/or slightly negative charge46, 47. Pinocytosis is a 
mechanism used by cells to internalise fluid surrounding them 
and it has been proposed that all substances present in the 
fluid phase are taken up simultaneously by cells48. Recently, 
the uptake of pegylated liposomal doxorubicin formulation 
(DOXIL) was reported via caveolae-mediated endocytosis in 
MDCK epithelial cancer cells49. The diameter of tested DOXIL
nanoparticles was 85.8 nm with a zeta potential of í 2.6 mV 
at pH 7.4, which was comparable to the PEG-b-PDL micelles49.  
Hence, it has been hypothesised that the PEG-b-PDL micelles 
might be taken up by caveolae-mediated endocytosis (a class 
of clathrin independent endocytosis under pinocytosis). The 
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endocytosis of PEG-b-PDL micelles in cancer cells could be 
beneficial, after the accumulation of these micelles in a 
tumour via the EPR effect, in order to deliver the cytotoxic 
drugs within the cells without the use of any ligand. Recently, 
the uptake of mPEG-b-PLA micelles in the absence of any 
targeting ligand was also reported in A54950 and MCF-751 
cells.  
One reason that might explain the similar uptake (based on 
the observed fluorescence of rhodamine B) of PDL and PDLFA 
micelle formulations in both tested cell lines could be the 
amount of expressed folate receptors. It has been reported 
that MCF-7 expressed low, but measurable, levels of folate 
receptor52 while A549 cells were generally considered as folate 
deficient cell lines53. Based on these reports, it was 
hypothesised that MCF-7 cells could behave as FR+ve cell 
lines whereas A549 cells might function as FR-ve cell lines 
(FR-ve).  However, Yuan et.al. revealed that the A549 
contains some level of folate receptor by demonstrating the 
higher uptake of folate decorated solid lipid nanoparticles in 
this cells54. In another study, it has been suggested that A549 
and MCF-7 cells have similar amounts of folate receptors by 
demonstrating the similar uptake of folic acid modified 
quantum dots in both cell lines55.  Considering these reports, it 
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was hypothesised that this might be because of very small 
differences in folate receptor expression in both cell lines, a 
difference in uptake would not be noticeable in folate-
conjugated micelles compared to non-folate micelles. 
However, further experiments to evaluate the effect of 
parameters such as dose, incubation time, cell lines, amount 
of folic acid conjugated polymer used etc. are still needed 
before concluding the uptake mechanism of PEG-b-PDL 
micelles46, 48, 56.  
6.5 Conclusion 
In this chapter, the syntheses of amphiphilic diblock 
copolymers of poly(decalactone) (PEG-b-PDL) via click 
chemistry has been reported. The azide derivative of PEG i.e. 
methoxy-PEG (mPEG-N3), folic acid conjugated PEG (FA-PEG-
N3) and rhodamine B conjugated PEG (RhB-PEG-N3) were used 
as hydrophilic blocks while propargyl-PDL was used as the 
hydrophobic block. The obtained co-polymers were 
characterised by 1HNMR and SEC, which suggested the 
successful conjugation of both blocks via triazole ring 
formation. Two mixed micelle formulations of the copolymers 
were fabricated using a nanoprecipitation method in which one 
was targeted (FA-PEG-b-PDL + RhB-PEG-b-PDL) and another 
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was non-targeted (mPEG-b-PDL + RhB-PEG-b-PDL) 
formulation.  
The size range observed for both micelle formulations was 20-
200 nm with zeta potentials close to neutral. These micelle 
formulations were then tested for the folate-mediated targeted 
delivery to MCF-7 (FR+) and A549 (FR-) cell lines. The non-
specific uptake of PEG-b-PDL micelles (targeted and non-
targeted) in both cell lines was observed.  This non-specific 
uptake was postulate to be taken place via an energy-
dependent route but not specifically by the folate receptor 
pathway. It was proposed that the micelles were taken up by 
cells through caveolae-mediated endocytosis. However, 
extensive studies are still needed to characterise the 
endocytosis mechanism(s) for novel PEG-b-PDL micelles.    
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7.1 Conclusion 
The work in the thesis is concluded below in two sections. The 
first section covers the work reported in chapter 3, 4 and 5. 
The second section synopsis the work reported in chapter 6, 
which was based on a possible targeted therapy in cancer.   
7.1.1 Synthesis, Characterisation and Evaluation of 
Polymers and Block Copolymers generated from  
Renewable į-Decalactone 
The synthesis of homopolymers and novel block copolymers 
based on renewable monomers (į-decalactone and ǔ-
pentadecalactone) was carried out successfully via ROP using 
organic (TBD) and enzyme (novozymes-435) catalysts. Small 
molecule initiators such as propargyl alcohol, cis-1,3-O-
EHQ]\OLGHQHJO\FHURO LQLWLDWHG WKH SRO\PHULVDWLRQ RI į-
decalactone at room temperature in the absence of solvents to 
obtain poly(decalactone) as an amorphous polymer. However, 
it was observed that polymers could also be obtained without 
an added alcohol initiator under certain circumstances. The 
reason for this unexpected polymerisation was not fully 
investigated owing to time constraints. 
Block copolymers of į-decalactone ( i.e. mPEG-b-PDL and 
PDL-b-PEG-b-PDL) were synthesised using PEG as initiator at 
temperatures above the melting point of PEG to avoid the use 
CHAPTER 7 
Page | 278  
 
of solvents. Both block copolymers were successfully 
separated from homopolymer contamination by washing with 
ether. Characterisation data of the resultant polymers 
suggested the successful synthesis and purification of the 
desired products. Further, the synthesis of a triblock 
FRSRO\PHURIǔ-pentadecalactone was attempted using mPEG-
b-PDL as initiator and TBD as catalyst but this approach did 
not produced the desired copolymer. Hence, Novozymes-435 
was used IRUWKH523RIǔ- pentadecalactone, to generate an 
ABC type of triblock copolymer (i.e. mPEG-b-PDL-b-PPDL). It 
was observed that increases in the molecular weight of 
poly(pentadecalactone) block above 2 KDa decreased the 
solubility of the resultant block copolymer in acetone. Hence, 
poly(pentadecalactone) block of less than 2KDa was targeted 
to generate an ABC type copolymer. The polydispersity index 
detected by SEC for all synthesised novel block copolymers 
was found to be less than 1.3. A diblock copolymer (i.e. 
mPEG-b-PCL) of poly(caprolactone) of similar molecular 
weight was also synthesised for comparative studies with 
mPEG-b-PDL. 
The CMC values of these novel amphiphilic block copolymers 
in water were calculated using the pyrene fluorescence 
method, which were ranges between 1.07-1.77 µg/mL. The 
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CMC values detected for PDL block copolymers were 
approximately half the CMC value observed for mPEG-b-PCL. 
Micelles of amphiphilic block copolymers were prepared by 
nano-precipitation method and the Z-average sizes observed 
for these micelles was <200 nm. No significant difference in 
sizes of mPEG-b-PDL and mPEG-b-PCL micelles was observed. 
Micelles obtained from PDL-b-PEG-b-PDL copolymer gave a 
bimodal size distribution, in which the second peak was due to 
the formation of clusters, which was evident by TEM images. 
The size detected for mPEG-b-PDL-b-PPDL copolymer micelles 
was significantly higher when compared with mPEG-b-PDL 
micelles. The large size of these micelles was attributed to the 
change in solubility of mPEG-b-PDL-b-PPDL copolymer in 
acetone compared to mPEG-b-PDL, which in turn generates 
some big micelles and hence, enhance the Z-average size. 
Micelles fabricated from all block copolymers were roughly 
spherical in shape as evident by TEM images. The zeta 
potential obtained in HEPES buffer (10mM, pH-7.4) for block 
copolymer micelles was almost neutral except for PDL-b-PEG-
b-PDL micelles, which was slightly negative due to the less 
dense PEG corona. It was hypothesised that due to the less 
dense corona, micelles obtained from PDL-b-PEG-b-PDL block 
copolymer were prone to make clusters. 
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All novel block copolymers of poly(decalactone) were 
successfully encapsulated Nile Red (NR) and Curcumin during 
a micelle fabrication process. A shift in UV-Vis absorbance 
maxima of NR suggested the self-assembly of block copolymer 
in water with PDL core. NR and curcumin loading did not 
significantly change the diameter of micelles except in case of 
PDL-b-PEG-b-PDL where reduction in clusters volume led to 
decrease in average diameter. No significant difference in 
curcumin loading content was observed for mPEG-b-PDL and 
mPEG-b-PDL-b-PPDL micelles when compared to the well-
established mPEG-b-PCL copolymer micelles. In curcumin 
stability study, it was found that micelles of mPEG-b-PDL 
copolymer were able to reduce degradation of curcumin at 
physiological pH. In vitro release studies of curcumin loaded 
micelles suggested that micelles having the amorphous 
poly(decalactone) core gave a faster release compared to 
semicrystalline poly(caprolactone) and poly(pentadecalactone) 
cores.  
In a subsequent study, effective loading of amphotericin B was 
demonstrated by utilising mPEG-b-PDL micelles via a 
nanoprecipitation method using methanol as an organic 
solvent. No significant difference in average size was observed 
for mPEG-b-PDL micelles prepared using methanol when 
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compared with the mPEG-b-PDL micelles fabricated using 
acetone. The loading results suggested that the mPEG-b-PDL 
micelles were able to encapsulate AmpB with high efficiency 
compared to their counterpart mPEG-b-PCL micelles. The in 
vitro release study suggested that mPEG-b-PDL micelles 
showed prolonged release of AmpB when compared with 
Tween 80 micelles. Additionally, with the help of an extra 
control (physically mixed copolymer) in release experiment, it 
was demonstrated that the partition coefficient of drug 
between carrier (micelles) and release phase is also a variable 
that influence the release rate determined by the dialysis 
method. Preliminary in vitro degradation study of mPEG-b-PDL 
micelles suggested that the ester bonds of PDL chain were 
susceptible to hydrolytic degradation. In vitro cell metabolic 
activity studies demonstrated that the novel mPEG-b-PDL and 
mPEG-b-PCL micelles were well tolerated by the studied HCT-
116 human colon cancer cell line. 
7.1.2 Synthesis, Characterisation and Evaluation of 
Ligand Mediated Targeting Efficiency of Amphiphilic 
Block Copolymers generated from Poly(decalactone) 
In this study, the synthesis of amphiphilic diblock copolymers 
of poly(decalactone) (PEG-b-PDL) with different functionalities 
were reported via copper catalysed click chemistry. The azide 
CHAPTER 7 
Page | 282  
 
derivative of PEG i.e. methoxy-PEG (mPEG-N3), folic acid 
conjugated PEG (FA-PEG-N3) and rhodamine B conjugated 
PEG (RhB-PEG-N3) were used as the hydrophilic blocks while 
propargyl-PDL was used as the hydrophobic block. Azide-
alkyne click reaction between PDL and PEG blocks generate 
the desired amphiphilic block copolymer. The synthesised 
copolymers were characterised by 1HNMR and SEC and was 
found that final purified copolymers contained some free PEG. 
Two mixed micelle formulations of the copolymers were 
fabricated using a nanoprecipitation method in which one was 
intended as a targeted (FA-PEG-b-PDL + RhB-PEG-b-PDL) 
formulation and another was non-targeted (mPEG-b-PDL + 
RhB-PEG-b-PDL) formulation. Copolymer RhB-PEG-b-PDL was 
used as a tracker to visualise the distribution of micelles in 
cells. The size range observed for both micelles formulation 
was 20-200 nm with a zeta potential close to neutral. These 
micelle formulations were then tested for the folate mediated 
targeted delivery to MCF-7 (folate receptor +ve) and A549 
(folate receptor -ve) cell lines. A non-specific uptake of PEG-b-
PDL micelles (targeted and non-targeted) in both cell lines was 
observed as evident by confocal images. . Based on the 
previously reported studies, it was proposed that the PEG-b-
PDL micelles might be taken up by the cells through a 
caveolae-mediated endocytosis. 
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7.2 Future Work 
A few of the studies reported in this thesis were in their 
preliminary stage. Therefore, the future studies related to the 
work presented in this thesis are as follows:   
o The ROP of poly(decalactone) via TBD needs 
investigation to understand fully the reason for 
homopolymer formation. 
o An extensive polymer degradation study is needed to 
establish the complete degradation profile of the 
synthesised novel block copolymer micelles. 
o Comprehensive research needs to be done on a range of 
human cell lines to generate a polymer toxicity profile 
and to identify the uptake mechanism.  
o Finally, in vivo studies are needed to establish the 
potential of novel poly(decalactone) block copolymer 
micelles as a drug delivery carriers.  
 
 
 
 
 
 
